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ABSTRACT 
 
Natural products have historically been a rich source of “lead compounds” in drug 
discovery. The investigation of terrestrial plants and marine organisms aimed at 
searching new biologically active compounds is a central issue of this kind of 
studies, trough structure elucidation combined with biological tests. My research 
activity has been mainly devoted to the discovery and to the chemical and 
pharmacological investigation of new bioactive natural products as “lead 
compounds” in the area of antitumor, anti inflammatory and antimalarial activities. 
My research work, described in this PhD thesis, was organized in two different 
topics, i) isolation and structural characterization of bioactive secondary metabolites 
from marine invertebrates; ii) synthesis of quinones derivatives endowed with 
cytotoxic and antimalarial activities from natural lead compounds. The fulfilment of 
my research project required the use of different procedures of isolation and 
extraction. The chemical characterization of the isolated compounds has been 
performed through an extensive spectroscopic analysis (UV, IR, ECD, 1D and 2D 
NMR) together with mass spectrometry and computational methods. I have also used 
synthetic methods both for the chemical derivatization of the isolated molecules and 
for the preparation of analogues on the simplified model of natural molecules. 
During the course of research conducted during the PhD course and whose results are 
reported in the following thesis, I have dealt with the extraction and chemical 
analysis of different species of sea squirts (Aplidium conicum, Ciona edwarsii, 
Aplidium elegans, Phallusia fumigata and Sidnyum elegans) and of the sponge 
Axinella polypoides. This analysis led to the isolation of new molecules, which are 
structurally different, with interesting bioactivity. Among these, two new 
meroterpenes, conithiaquinones A and B, and three alkyl sulphates with cytotoxic 
properties. Three sulfated sterols, phallusiasterols A-C, one of them with agonist 
activity on the pregnane X receptor (PXR) in HepG2 cells. The phosphoeleganin, a 
potent inhibitor of protein tyrosine phosphatase 1B (PTP1B). An analysis of the 
metabolic content of the sponge Axinella polypoides has provided important chemo-
taxonomic information about the organism, in addition, led to the isolation of a new 
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betaine and a new cyclonucleoside. Within the study of compounds with antimalarial 
activity, in collaboration with the University of Rome La Sapienza and the 
Department of Public Health, Microbiology and Virology, University of Milan, I 
have performed the synthesis and evaluation of in vitro on strains of Plasmodium 
falciparum D10 (chloroquine-sensitive) and W2 (chloroquine-resistant) of synthetic 
analogues of natural quinones, prepared on the pattern of two natural molecules 
previously isolated from an ascidian. The synthetic derivatives showed significant 
antimalarial activity and were also highlighted some structural requirements that are 
critical for the activity. Finally, during the period of research at the Institute of 
Materia Medica (SIMM ) in Shanghai, I started to study lipid-soluble extract of a 
fungal strain Penicillium sp, isolated from the Chinese mangrove Bruguiera 
gymnorrhiza. The analysis showed that the main component of the extract is a 
cytotoxic alkaloid, 2-(1-hydroxyethyl)-4 (3H) quinazolinone, which is currently 
subject to a broader drug screening. 
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ITALIAN ABSTRACT 
 
Le sostanze naturali sono da sempre una ricca fonte di composti guida per la scoperta 
di nuovi farmaci. Lo studio chimico di piante terrestri e organismi marini attraverso 
la determinazione stereostrutturale di nuovi metaboliti in combinazione con la 
valutazione della loro attività biologica costituisce il fulcro della Chimica delle 
Sostanze Naturali. Durante il corso di Dottorato, la mia attività di ricerca si è 
sviluppata principalmente nel settore delle sostanze organiche naturali di origine 
marina. Lo scopo della ricerca è stato l'identificazione di nuovi potenziali "leads" per 
la terapia antitumorale, antinfiammatoria e antimalarica. L‟attività di ricerca si è 
articolata in due linee parallele, i) analisi chimica di invertebrati marini (tunicati, 
poriferi) finalizzata all‟isolamento ed alla caratterizzazione di nuove molecole 
bioattive; ii) sintesi di derivati chinonici con attività pro-apoptotica ed antimalarica a 
partire da lead compounds di origine naturale. 
La realizzazione del progetto di ricerca ha comportato l‟utilizzo di diverse metodiche 
di estrazione e di isolamento (es. tecniche cromatografiche quali MPLC o HPLC). La 
caratterizzazione chimica dei composti isolati è stata realizzata mediante analisi 
spettroscopica (UV, IR, ECD e, soprattutto, NMR mono- e bidimensionale) 
combinata con spettrometria di massa e metodi computazionali. Sono state utilizzate 
metodiche sintetiche sia per la derivatizzazione chimica delle molecole isolate che 
per la preparazione di analoghi semplificati sul modello di molecole naturali. 
Nel corso dell‟attività di ricerca condotta durante il corso di Dottorato e i cui risultati 
sono riportati nella seguente tesi, mi sono occupata dell‟estrazione e dell‟analisi 
chimica di diverse specie di ascidie (Aplidium conicum, Ciona edwarsii, Aplidium 
elegans, Phallusia fumigata e Sidnyum elegans) e della spugna Axinella polypoides. 
Tale analisi ha portato all‟isolamento di nuove molecole, strutturalmente diverse, con 
interessanti bioattività. Tra queste, due nuovi meroterpeni, i conitiachinoni A e B, e 
tre alchilsolfati con proprietà citotossiche. Tre steroli solfatati, i phallusiasteroli A-C, 
di cui uno con attività agonista sul recettore X del pregnano (PXR) in cellule HepG2. 
La fosfoeleganina, un fosfo-polichetide potente inibitore della proteina tirosin-
fosfatasi 1B (PTP1B). L'analisi del contenuto metabolico della spugna Axinella 
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polypoides ha fornito importanti informazioni di natura chemio-tassonomica 
sull'organismo; inoltre, ha portato all'isolamento di una nuova betaina e di un nuovo 
ciclonucleoside. 
Nell'ambito dello studio di composti ad attività antimalarica, in collaborazione con 
l‟Università di Roma La Sapienza e con il Dipartimento di Sanità pubblica, 
Microbiologia e Virologia dell‟Università di Milano, ho effettuato la sintesi e la 
valutazione dell'attività in vitro sui ceppi di Plasmodium falciparum D10 
(clorochina-sensibile) e W2 (clorochina-resistente) di analoghi sintetici di natura 
chinonica, preparati sul modello di due molecole naturali precedentemente isolate da 
un'ascidia. I derivati sintetici hanno mostrato una significativa attività antimalarica e 
sono stati messi in evidenza anche alcuni requisiti strutturali che sono critici per 
l‟attività. Infine, durante il periodo di ricerca presso l‟Istituto di Materia Medica 
(SIMM) di Shanghai, ho iniziato lo studio dell‟estratto liposolubile di un ceppo 
fungino Penicillium sp, isolato dalla mangrovia cinese Bruguiera gymnorrhiza. 
L'analisi ha evidenziato che il componente principale dell‟estratto è un alcaloide 
citotossico, il 2-(1-idrossietil)-4(3H)chinazolinone, che è attualmente sottoposto ad 
un più ampio screening farmacologico. 
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INTRODUCTION  
 
The use of natural products has been up to now the most successful way to the 
discovery of new medicines. Approximately one-third of the top-selling drugs in the 
world are natural products or their derivatives; well-known examples of valuable 
natural products widely used in medical and animal health industries include 
erythromycin (antibiotic), amphotericin B (fungicidal agent), cyclosporine A and 
FK506 (immunosuppressive agents), lovastatin (anticholesterolemic agent); as many 
as 25% of the currently used anticancer drugs are natural chemicals, with another 
25% coming from synthetic derivatives of natural products.
1,2
 
Today, with the continuing need for novel drug-like lead compounds against an 
increasing number of ever-more challenging molecular targets, the availability of 
rich libraries of chemically diverse molecules is an essential requirement. The 
remarkable chemical diversity encompassed by the natural products is still relevant 
in the field of the discovery of new and more effective drugs. In most of the cases the 
natural metabolite is mainly considered a suitable chemical platform useful to project 
new molecular entities able to modulate biological activity rather than a real 
therapeutic agent. 
Nowadays, drug discovery has entered a more highly competitive era in which the 
quality of chemical collections and the time taken from assay to drug development 
are crucial factors. Thus, although the chemical novelty associated with natural 
products is higher than that of any other source, this diversity must be accessed more 
efficiently and effectively. Currently, most of the new drugs are discovered on the 
basis of a molecular approach, which can be performed not only through the rational 
drug design aided by computer based techniques or through the manipulation of 
genetic targets (antisense approach), but also through the pragmatic approach of 
random screening. This last approach to drug discovery, which is also called 
combinatorial biology, has been updated by the recent developments in molecular 
biology, instrumentation technology and information, so that it can now be carried 
out at high throughputs that could not have been imagined, even a few years ago.
3-6 
The increasing availability of new molecular targets, the potential to transform them 
by genetic engineering, such as the simplification of the de-replication processes 
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through the use of clones, make random screening a very promising tool to the 
discovery of novel bioactive compounds; a further not marginal improvement comes 
from the use of robotics to conduct the assays. Currently, wide-ranging assays can be 
quickly carried out by using micro plates equipped with numerous wells. Recent 
advances in random screenings enabled enormous increases in throughput to be 
achieved, but, on the other hand, they posed some problems in order to be 
conveniently applied. A high-throughput screening program requires the availability 
of large numbers of compounds for testing which have to be structurally different in 
order to increase the chance of finding activity at the molecular target. This 
requirement cannot be supplied by traditional organic synthesis and so, over the past 
few years, new approaches, such as combinatorial chemistry and computer-based 
molecular modelling design have become the source of new levels of chemical 
diversity. Initially, they seemed to lower the natural products value in drug 
discovery; however, as the use of these techniques has matured, it became clear that 
they achieved significant importance mainly in the generation of focused libraries for 
specific discovery programs.
3
 Indeed, combinatorial chemistry has failed to supplant 
natural products programs as the primary source of broad chemical diversity and it is 
now clear that combinatorial chemistry practiced by Nature is much more 
sophisticated than that in the laboratory, yielding elaborate structures rich in 
stereochemistry, concatenated rings and reactive functional groups. As a result, an 
amazing number of products have been found in nature, with peculiar structures and 
biological activities. 
The present thesis aims to illustrate the results obtained from of my PhD research 
program, which indeed is grounded in the natural product chemistry field. My 
research activity has been mainly devoted to the discovery of new bioactive natural 
products as “lead compounds” in the area of antiviral, antitumor, anti inflammatory 
and antimalarial activities.  
The road map for reaching this goal has been to follow a two-way course. The first 
one was the isolation and pharmacological characterization of new molecules with 
biological activity from terrestrial and marine organisms, which have been selected 
on the basis of their presumed content in bioactive metabolites. The second way was 
the optimization of natural leads under study through de novo synthesis and/or 
structural modifications. Our efforts have been directed towards both the total 
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synthesis, and the design of new simplified analogues obtained through the 
implementation of innovative synthetic procedures and parallel synthesis approaches. 
Selected collections of both natural and synthetic compounds have been submitted to 
pharmacological tests. The synthetic work, the analysis of the structure-activity 
relationship and the pharmacological evaluation of the new natural compounds and 
of their synthetic derivatives have been obtained through the active collaborations 
with selected national or foreign research groups from both industries and academia. 
This research activity led to the isolation of several bioactive molecules, some of 
them being new compouds. Their different structures, ranging from simple linear 
polyfunctionalized alkyl chains to complex polycyclic frameworks, contributed to 
enlarge the chemical diversity generated into natural products of marine origin. 
On the other hand, the synthetic studies performe using previously isolted marine 
natural compounds led to the identification of molecules with significant antimalarial 
activity and also highlighted some structural requirements critical for this activity. 
The research exemplified the potential of a natural product to qualify as lead 
structure for medicinal chemistry campaigns, affording simplified analogues with 
better bioactivity and easier to synthesize. 
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CHAPTER 1 
 
THE MARINE ENVIRONMENT. 
 
That nature represents an endless arsenal of new bioactive molecules has been 
recognized since ancient times and the study of these metabolites has historically 
proven of immense benefit in the drug discovery process. Some of these bioactive 
molecules have become life-saving drugs or biomedical tools. The history of 
terrestrial natural products chemistry can readily be traced back to the beginning of 
the XIX century with the first investigation of terrestrial plants aimed at finding the 
molecules responsible of the biological activities of the extracts. This is in distinct 
contrast to the natural products chemistry associated with marine species which has 
emerged only over the past 65 years mainly as a result in the improvement of 
collection techniques, as SCUBA diving. The marine environment contains a number 
of plants, animals and microorganisms, which, due to the unique adaptations to their 
habitat, elaborate a wide diversity of natural products with specific bioactivities. 
These products provide a rich source of chemical diversity that can be used to design 
and develop new potentially useful therapeutic agents. The exceptional marine 
reservoir represents a vast chemical and biological diversity of molecules, some 
without terrestrial counterpart or analogy, and often showing unique biological 
activities at extremely low concentration.  
Assessment of the chemical diversity contained in the oceans thus began in the fifties 
but now is an established field with a great deal of research focused on extraction of 
chemicals from sessile invertebrates, such as sponges, molluscs and ascidians. These 
organisms live in a complex and highly competitive environment and produce a wide 
variety of toxic chemicals in order to mediate spatial competition as a well as to 
prevent parasitism and predation. All marine organisms have provided a seemingly 
endless parade of very unusual novel structures; biogenetically, they can be included 
in the major biosynthetic pathways proposed for terrestrial secondary metabolites 
whereas, structurally, they often possess functional groups appearing uniquely or 
predominantly marine. Particularly, ascidians‟ chemistry is dominated by the 
presence of nitrogenous metabolites. Through the combined efforts of marine natural 
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product chemists and pharmacologists, a number of promising compounds have been 
identified and some of them are either already at advanced stages of clinical trials or 
have been selected as promising candidates for extended pre-clinical evaluation. 
Most of these products fall within the area of cancer therapy; the case of the marine 
alkaloid ecteinascidin 743 (ET-743), an anti-tumour compound especially effective 
against solid tumours, is an illustrative example.
1
 
On the other hand, research on molecules of marine origin has evolved relatively 
slowly, mainly due to the small quantities of the living material which generally 
could be obtained by collecting the marine species by hand. It is very common to 
isolate less than one milligram of a bioactive substance from one kilogram of the 
marine organism. However, more sensitive methods of NMR spectroscopy and mass 
spectrometry combined with advanced liquid chromatography techniques are 
currently routinely used for identification and characterization of natural products 
and, so, also complex molecular structures can be now solved with much less that 
one milligram of compounds. Chemical identification of the molecules present in 
biological extracts is just one step of their full investigation; particularly an 
interesting aspect is the individuation of their real producers. The extremely rich 
secondary metabolism of some marine invertebrates can be explained in the light of 
the evidence that marine invertebrates harbour microorganisms, such as bacteria, 
cyanobacteria and fungi, in their tissues, where they reside in the extra- and intra-
cellular spaces. In some cases, associated micro organisms may constitute up to a 
40% of the biomass, as it has been evidenced for the Mediterranean sponge Aplysina 
aerophoba.
2-5 
In fact,
 
sponges possess amoeboid cells that phagocytose bacteria and, 
at the same time, are efficient filter feeders; as a result of such a continuous 
functional activity, a certain amount of transient microorganisms (one ml of seawater 
contains an estimated one million microbes) are trapped within the vascular system 
or remain attached to sponge surface. In A. aerophoba, the bacterial concentration 
exceeds that of the surrounding seawater by two or three orders of magnitude. The 
relations between marine invertebrates and microorganisms living either permanently 
or temporarily inside have been currently understood to a very limited extent. Recent 
studies based on feeding experiments with different species of sponge bacteria 
suggest that the organism can differentiate between commensal bacteria and those 
permanently associated with the host. Interestingly, 16S rDNA diversity studies 
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revealed that sponges belonging to the same species but collected from different seas 
and at different depth showed a significantly uniform microbial community. Several 
roles are believed to be played by the retained microorganisms: they serve as food 
and enrich the diet of their hosts through nitrogen and carbon fixation. In addition, 
quite likely they are involved in the biosynthesis of natural products recovered from 
the sponges.
6
 Consequently, the permanent bacterial presence is undoubtedly not 
irrelevant for the exceptional chemodiversity of invertebrates, but the real 
contribution of the microorganisms to the host secondary metabolism has not yet 
been fully understood and evaluated; this is essentially due to the failure of most 
attempts to culturing permanently the sponge-associated bacteria outside their host. 
However, often there are evidences that suggest the involvement of associated 
microorganisms in the biosynthesis of compounds collected from the invertebrate 
host. This happens when one organism is shown to contain an unusual variety of 
classes of metabolites, when the metabolite concentrations are exceedingly low, or 
when the structures of the metabolites are reminiscent of bacterial biogenetic 
pathways. Thus, the major reason for marine natural products unique molecular 
diversity likely resides in the marine environmental conditions, which favour close 
and permanent associations between different organisms. 
The limited availability of most bioactive compounds elaborated by marine 
invertebrates currently does not represent a serious obstacle for their structure 
determination as well as for preliminary biological tests. Problems actually arise 
when preliminary positive assays refer the product for a more advanced 
investigation. They can be easily overcome, if the research continues using the 
molecule as a lead; in this case, preliminary information on the structure-activity 
relationships often can be obtained taking advantage from the frequent co-occurrence 
of a series of closely related compounds rather than a single example of a compound 
type. The presence of a pool of analogues is probably a chemical defence strategy, by 
which the organism is protected against an array of organisms, since resistance 
against a broad range of compounds with similar structures is less likely to occur. 
The various compounds may display synergism in their biological activity and this 
property may be of interest for drug development.  
The limited availability of a natural compound often prevent the research aimed to its 
direct use in therapy, which develops according to the usual procedure, involving 
16 
 
first the assays in vivo, followed by preclinical evaluations and then by clinical trials, 
where gram quantities are needed. The supply of a natural product becomes a large-
sized, very often insoluble, problem, when it is licensed, as drug and an economically 
convenient synthesis cannot be carried out. The industrial use of marine species 
requires large amounts of raw material to be collected from natural stocks. This 
collection will, in the long run, exert significant impacts on the benthic community 
and will be a severe pressure on the targeted species. The production of sponges, 
tunicates and bryozoans in specially designed mari-culture plants has been 
considered. Currently, a number of multidisciplinary researches are targeting the 
development of new technologies for mari-culture plants of marine invertebrates for 
the environmentally compatible production of pharmaceutical relevant species. Even 
if the obtained yields of biomass are still far from those that should be needed for 
commercial purposes, encouraging progress has been made in this field and now the 
bryozoan B. neritina and the tunicate E. turbinata, the sources of ET-743 and of 
bryostatins, respectively, can be successfully cultured.
7
 
The possible microbial origin of bioactive molecules recovered from marine 
invertebrates recently opened new and interesting perspectives for their synthesis at 
commercial level. Isolation and cultivation of the suspected microbial producers 
either from the surrounding seawater or from tissue of invertebrates could provide a 
more satisfying answer to the pressing supply problem. If bacteria are indeed, the 
producers of bioactive metabolites of interest, transfer of the gene clusters 
responsible for the biosynthesis of the respective natural products to a vector suitable 
for large-scale fermentation could provide an alternative strategy thereby avoiding 
the foreseeable difficulties in culturing symbiotic bacteria. 
In conclusion, it is clear that marine environment will continue to be a major source 
of new drug leads but effective utilization of these resources will require advances in 
technologies and the opening of new frontiers in science. The increasing genomic 
information and progress in molecular biology in general, combined with 
biochemical studies leading to a comprehensive understanding of complex natural 
product biosynthesis at the molecular level, as well as technologies exploiting this 
knowledge, are expected to give marine natural products research a promising future.
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CHAPTER 2 
METHODOLOGY IN ISOLATING AND CHARACTERIZING 
MARINE NATURAL PRODUCTS. 
 
The marine environment has many limits, such as the difficulty in the collecting 
biological material and its identification, but also the necessity to safeguard marine 
ecology. For these reasons, for the discovery of new compounds from marine source 
it is important a constant need to separate small quantities of mixture efficiently and 
then it is necessary to characterize these new compound in a non-destructive way, 
with sub-milligram samples.  
The study of natural compounds consists of some steps: 
1. Isolation and purification of new compounds from biologic material; 
2. Structural determination of the isolated compounds; 
3. Determination of absolute and relative stereochemistry of the new compounds. 
 
2.1. ISOLATION PROCEDURES 
The isolation of natural products from natural sources poses numerous problems, 
because these compounds may only be present in infinitesimal quantities. The nature 
of separation problems varies considerably, from the isolation of small quantities 
(milligrams or less) for structure determination purposes to the isolation of very 
much larger amounts (hundred milligram to gram quantities) for comprehensive 
biological testing, for semi-synthetic work or even for production of therapeutic 
agents. For these purposes, a good selection of different techniques and approaches is 
essential. The problem of separation and isolation of new metabolites from natural 
sources was solved with the development of refined techniques, such as the various 
analytical and preparative chromatographic methods. We have successfully 
performed a procedure of purification. Usually, after biomass extraction with 
adequate solvents (usually methanol, acetone, and/or chloroform), the first step in the 
isolation of a natural compound from the main extract consists of a sequential 
gradient partition with solvents. The fractions so obtained contain compounds 
19 
 
distributed according to their polarity. In the case of bioactive extract, this process 
can be guided by the appropriate assay to localize the active component. Next, in 
accordance with the diverse properties of the components of these fractions, different 
procedures for purification can be followed. Particularly, the fractions of low or 
medium polarity, usually monitored, contain lipophilic organic compounds that can 
be usually separated by standard normal or reverse phase column chromatography 
and/or MPLC and finally HPLC to get individual components. 
Medium Pressure Liquid chromatography (MPLC) is a liquid-solid chromatography, 
in which the liquid mobile phase is forced through the solid stationary phase at 
medium pressure. MPLC is more efficient in resolution than the open-column and 
flash chromatography methods and the separation involves a considerable gain in 
time. The solid stationary phase can be a normal phase, like silica gel or bonded 
phase (RP-8, RP-18). The technique makes use of pressures of ca. 5-40 bar and can 
easily accommodate much larger sample loads (100 mg-100 g) than are generally 
applied in other separations. As far as separating power is concerned, MPLC lies 
somewhere between flash chromatography and semi-preparative HPLC. 
High Performance (or High Pressure) Liquid Chromatography (HPLC), both normal-
phase and reverse-phase, is the most widely used chromatographic method, and finds 
application in the preparative separation of samples to “pilot” the preparative 
isolation of natural products (optimization of the experimental conditions, checking 
of the different fractions throughout the separation). On the whole, however, HPLC 
is commonly applied as the last step in purification processes affording pure 
compounds in high yields, and, in this respect, the quantities involved tend to be at 
the lower end of the scale.  
Finally the compounds, so isolated, are structurally characterized and are submitted 
to pharmacological assays. 
 
2.2. STRUCTURAL DETERMINATION METHODS 
Recently, natural products chemistry has undergone explosive growth due to 
advances in isolation techniques, synthetic and biosynthetic approaches as well as 
spectroscopic and chromatographic methods. Structural determination described in 
this thesis is largely based on spectroscopic techniques, mostly mass spectrometry 
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(MS) and nuclear magnetic resonance (NMR), and sometimes degradation methods, 
coupled with circular dichroism (ECD) and computational methods. 
2.2.1. Mass Spectrometry 
Mass Spectrometry is an analytical technique, particularly used in organic chemistry, 
which allows to measure molecular masses of unknown compounds and thus to 
determine their elementary formula. Unlike other spectroscopic techniques, mass 
spectrometry is a destructive analytical technique, that is not based on the interaction 
between radiations and matter. Any molecule has first to be ionized and transferred 
to gas phase in the ion source and then it is transmitted to the mass analyzer where its 
mass properties are measured. These three fundamental steps of the process occur in 
three different parts of the mass spectrometer, namely the ionisation source, the 
analyzer , and the detector. In order to obtain a mass spectrum, in the ion source, 
must be produced ions in a gas-phase. they are subsequently accelerated, by an 
electric field, until they get to a specific speed and they are transferred to the mass 
analyzer, which separate different ions on the base of their mass/charge (m/z) ratio. 
The separated ions are then measured on the detector and the results displayed. 
Most of compounds described in the following chapters have been analyzed by 
Electrospray Ionisation (ESI) mass spectrometry through an Orbitrap system.  
ESI mass spectrometry allows the determination of non-volatile molecules to be 
analyzed directly from the liquid phase (Figure.2.1). The electrospray process is 
governed by a large number of chemical and physical parameters that together 
determine the quality of the process. Its start and end can be defined by an electrical 
circuit that drives the spray of liquid-charged droplets. 
 
Figure 2.1. ESI mass spectrometry 
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In this process the biomolecule starts out as an entity or complex, usually charged 
and dissolved in a water-rich environment. At the end of the process the same 
biomolecule is represented and harvested through the orifice of a mass analyser as a 
series of „naked‟ multicharged ions. In a vacuum, the biomolecular ions then are 
selectively analysed according to their mass/charge ratio.
 
Because of the electric 
potential of the capillary, each droplet of the spray carries an excess positive or 
negative charge, and this causes extensive protonation or deprotonation of the 
molecules of the sample, which become ions. An uncharged carrier gas such as 
nitrogen is used to help the liquid to nebulize and the neutral solvent in the droplets 
to evaporate. 
Orbitrap is a new type of mass analyzer introduced by Makarov.
1 
The LTQ-Orbitrap 
combines the most advanced Ion Trap and Fourier Transform technologies into a 
single instrument with unprecedented analytical power and versatility. The 
instrument provides a high mass resolution, accurate mass determinations, and 
MS
n
 for routine high-throughput analysis. 
In an orbitrap, ions are injected tangentially into the electric field between the 
electrodes and trapped because their electrostatic attraction to the inner electrode is 
balanced by centrifugal forces. Thus, ions cycle around the central electrode in rings. 
In addition, the ions also move back and forth along the axis of the central electrode. 
Therefore, ions of a specific mass-to-charge ratio move in rings which oscillate along 
the central spindle (Figure 2.2). The frequency of these harmonic oscillations is 
independent of the ion velocity and is inversely proportional to the square root of the 
mass-to-charge ratio (m/z ).  
 
Figure 2.2. Ion trajectories in an Orbitrap mass spectrometer. 
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By sensing the ion oscillation similar as in the FT-MS (Fourier transform mass 
spectrometry), the trap can be used as a mass analyzer. Orbitraps have a high mass 
accuracy (1-2 ppm), a high resolving power (up to 200,000). Currently, there are two 
commercial LTQ-Orbitrap instruments, the Discovery and XL models. One of the 
primary differences is that the XL has a linear octopole collision cell (absent in the 
Discovery model), in which collisional activation and fragmentation can be 
performed. Although this feature provides additional versatility to MS/MS 
experiments, the analytical performance and fundamental principles of operation of 
the Orbitrap analyzers in both instruments are identical.
2 
2.2.2 Nuclear Magnetic Resonance
3-5
 
Nuclear Magnetic Resonance spectroscopy is a powerful and theoretically complex 
analytical tool used for structure elucidation of the isolated secondary metabolites. It 
involves reorientations of nuclear spins with respect to an applied static magnetic 
field. In addition to standard 
1
H and 
13
C NMR spectra, a large use of 2D NMR 
experiments has been made in the course of my research activity. They are superior 
to their 1D NMR counterparts both for the information on the connection of nuclei 
and for the easier assignment of nuclei resonating in crowded regions of the spectra 
(signal overlapping is much less likely in two dimensions than in one). 
The COSY (COrrelation SpectroscopY) experiments allow you to determine the 
connectivity of a molecule by determining which protons are spin-spin coupled. In 
spite of the many modifications which have been proposed along the years, the very 
basic sequence composed of two π/2 pulses separated by the evolution period t1 is 
still the best choice if one is simply dealing with the presence or the absence of a 
given coupling, but not with the value of the relevant coupling constant. 
The HSQC (Heteronuclear Single Quantum Correlation) experiment is 2D NMR 
heteronuclear correlation experiment, in which only one-bond proton-carbon 
couplings (
1
JCH) are observed. The HSQC experiment correlates the chemical shift of  
proton with the chemical shift of the directly bonded carbon.  
The HMBC (Heteronuclear Multiple Bond Correlation) experiment is a 
heteronuclear two-and three-bond 
1
H-
13
C correlation experiment; its sequence is less 
efficient than HSQC because the involved 
2,3
JCH couplings are smaller (3-10Hz). 
Moreover, while 
1
JCH are all quite close to each other, 
2,3
JCH can be very different, 
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making necessary the optimization of the experiment for each type of coupling. As a 
consequence, in many HMBC spectra not all of the correlation peaks which could be 
expected from the structure of the molecule are present. Cross peaks are between 
protons and carbons that are two or three bonds away while direct one-bond cross-
peaks are suppressed. This experiment, finally, allows the connection of the 
fragments and the assembling of the structure of the molecules. 
2.2.3 Circular Dichroism 
First-principles calculations of electronic circular dichroism (ECD) are widely used 
to determine absolute configurations of chiral molecules. Circular Dichroism (CD) is 
observed when a molecule is optically active, it absorbs right-and left-handed 
circularly polarize light to different extents. The CD spectroscopy takes advantage of 
the different absorption shown by chiral compounds of left and right circularly 
polarized UV/Vis light. Plane polarised light can be viewed as being made up of 2 
circularly polarised components of equal magnitude, one rotating counter-clockwise 
(left handed, L) and the other clockwise (right handed, R). Circular dichroism (CD) 
refers to the differential absorption of these 2 components (Figure 2.3).  
 
Figure 2.3. Origin of the CD effect. (a) The left (L) 
and right (R) circularly polarised components of 
plane polarised radiation: (I) the two components 
have the same amplitude and when combined 
generate plane polarised radiation; (II) the 
components are of different magnitude and the 
resultant (dashed line) is elliptically polarised. (b) 
The relationship between absorption and CD spectra. 
Band 1 is not chiral; band 2 has a positive CD 
spectrum with L absorbed more than R; band 3 has a 
negative CD spectrum. 
 
If, after passage through the sample being examined, the L and R components are not 
absorbed or are absorbed to equal extents, the recombination of L and R would 
regenerate radiation polarised in the original plane (Figure 2.3). However, if L and R 
are absorbed to different extents, the resulting radiation would be said to possess 
elliptical polarization (Figure 2.3).
6 
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In practice, the CD instrument (spectropolarimeter) does not recombine the 
components but detects the two components separately; it will then display the 
dichroism at a given wavelength of radiation expressed as either the difference in 
absorbance of the two components: Δε = εL – εR. Δε as a function of the incident 
light frequency ω is called CD spectrum.  
The CD of pure enantiomers differs in sign, but not in magnitude. There is no simple 
relation between the absolute conﬁguration of an enantiomer and the sign of its ECD 
spectrum: CD depends on details of the electronic and geometric molecular structure. 
However, ab initio electronic structure calculations are nowadays able to predict 
ECD accurately and thus allow an assignment of the absolute configuration by 
comparison of experimental and computed ECD spectra.  
2.2.4. Computational methods for configuration determination 
The increasing improvement of computer performances and the development of 
methods and algorithms ever more advanced and efficient, has led to the emergence 
of computational chemistry, a branch of chemistry that uses quantum mechanical 
principles to get the realistic representation of the three-dimensional structure of a 
molecule. To determine the conformation of a molecule, using a computer and a 
process called "minimization", the atoms must be moved from their positions 
evaluating the resulting changes of the total energy of the system. The geometry 
corresponding to the minimum energy is the most favored and, therefore, the most 
representative of the structure in solution. It is thus possible to compare the distances 
between protons in different stereoisomers and verify which of these corresponds to 
the spectroscopic data previously obtained. The molecular mechanics provides the 
force field for every molecule that describe the conformation and behavior of 
molecules. Force field allows to calculate the energy of each rearrangement of atoms 
in a system and allows you to evaluate how it changes with the position of the atoms. 
In this way, it is possible to find the minimum point of this function, determining 
both conformation and minimum energy. 
This process, known as minimization, leads to a relative minimum, while the 
absolute minimum, in simple cases, can be find with processes known as 
conformational search (systematic search, random search, simulated annealing). The 
experimental information on the conformation of the molecule, mainly derived from 
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NMR experiments (NOE effects) may be included in the force field to "help" to 
determine the actual conformation at low energy. In simulated annealing method, the 
molecule is subjected to a molecular dynamics simulation, starting at high 
temperature and gradually lowering the until get to absolute zero. At low 
temperatures the molecule is locked the energetically lowest conformer. An 
alternative and complementary method to molecular dynamics for configuration 
determination of compounds structurally complex for flexibility or number of 
stereoisomers, is ab initio method that allows the prediction of chemical shifts of 
protons and carbons by values of coupling constants. Good matching between the 
calculated chemical shifts for one of the potential structures with the experimental 
values constitutes an excellent tool to support structural analysis of organic 
compounds. Density functional theory (DFT) has emerged in recent years as a 
promising alternative to conventional  ab initio methods in quantum chemistry.  
All calculations reported in my thesis have been performed using Gaussian 03.33
7
 
while the preliminary conformational search was performed by Simulated Annealing 
in the INSIGHT II package. 
 
26 
 
References 
1. Hu, Q.; Noll, R. J.; Li, H.; Makarov, A.; Hardmanand, M.; Cooks, R. G.; J. 
Mass Spectrom,. 2005, 40, 430–443. 
2. Perry, R. H.; Cooks, R. G.; Noll, R. J.; Mass Spectrometry Reviews, 2008, 27, 
661– 69. 
3. Bax, A.; Two Dimensional Nuclear Magnetic Resonance in Liquids, Delft 
University Press, Dordrecht, 1982. 
4. Palmer III, A. G.; Cavanagh, J.; Wright, P. E.; Rance, M.; J. Magn. Reson, 
1991, 151-170. 
5. Bax, A.; Summers, M. F.; J. Am. Chem. Soc, 1986, 2093. 
6. Kelly, S. M.; Price, N.C.; Current Protein and Peptide Science, 2000, 1, 349-
384. 
7. Gaussian 03-Revision B05: Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; 
Scuseria, G. E.; Robb, M. A.; Cheeseman, J. A.;  Montgomery, Jr., J. A.; 
Vreven, T.; Kudin, K. N.;  Burant, J. C.;  Millam, J. M.; Iyengar, S. S.; 
Tomasi, J.;  Barone, V.; Mennucci, B.;  Cossi, M.; Scalmani, G.;  Rega, N.; 
Petersson, G. A.; Nakatsuji, H.;  Hada, M.; Ehara, M.;  Toyota, K.; Fukuda, 
R.; Hasegawa, J.; Ishida, M.;  Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.;  
Klene, M.; Li, X.;  Knox, J. E.;  Hratchian, H. P.; Cross, J. B.;  Bakken, V.;  
Adamo, C.; Jaramillo, J.;  Gomperts, R.; Stratmann, R. E.;  Yazyev, O.; 
Austin, A. J.;  Cammi, R.;  Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; 
Morokuma, K.; Voth, G. A.;  Salvador, P.;  Dannenberg, J. J.; Zakrzewski, V. 
G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; 
Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; 
Baboul, A. G.; Clifford, S.;  Cioslowski, J.; Stefanov, B. B.; Liu, G.; 
Liashenko, A.;  Piskorz, P.;  Komaromi, I.;  Martin, R. L.; Fox, D. J.; Keith, 
T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, 
P. M. W.; Johnson, B.;  Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. 
Gaussian03W, Revision B05, Inc., Wallingford CT, 2004. 
27 
 
CHAPTER 3 
RESULTS AND DISCUSSION. 
 
3.1 CHEMICAL AND PHARMACOLOGICAL 
CHARACTERIZATION OF NEW BIOACTIVE COMPOUNDS 
FROM MARINE INVERTEBRATES 
The world of nature provides a never-ending set of fascinating problems for the 
chemist. Many of the most intriguing problems, however, concern compounds 
available in only truly minute quantities. One solution is to focus on bioassay-guided 
separations. In so doing one can isolate compounds with novel structures or 
unsuspected activities from almost any phylum, including tunicates, sponges, insects, 
or plants. Moreover, newer spectroscopic techniques, especially fast atom 
bombardment mass spectrometry and tandem mass spectrometry, enhance one's 
ability to study compounds present in minute quantities, including those of 
importance to the host organism. Traditionally, natural product research usually 
involved isolating the most abundant compound, assigning its structure, and then 
hoping to find a use for it. Today we are more likely to be guided by biology, that is, 
by bioassay, to direct our attention to the truly important compounds present in a 
species. Most bioassays are exceedingly sensitive, so that the active compound may 
be present in only minute quantities. Fortunately, modern structural techniques 
require only miniscule quantities of the material. 
Part of my research work is collocated within this area and concerns the investigation 
of the natural products deriving from marine invertebrates, such as sponges and 
tunicates. Among marine organisms, the chance of finding bioactive compounds is 
remarkably higher in these invertebrates. Presently, more than 35% of useful medical 
compounds from the sea are isolated from porifera, well known as sponges.  
Sponges, lacking any nervous, digestive, circulatory, muscular systems or any 
physical defence from their predators, produce secondary metabolites, involved in 
their chemical defence, which is essential for their survival. In fact many species 
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contain toxic substances, probably to discourage predators. The chemicals also 
probably play a role in competition among sponges and other organisms, as they are 
released by sponges to insure themselves space in the marine ecosystem.  
A number of promising compounds have been identified from marine sponges that 
possess pronounced biological activity and are already at advanced stages of clinical 
trials, mostly for the treatment of cancer, or have been selected as promising 
candidates for extended preclinical evaluation. 
Recently, ascidians have increasingly become the target of natural products research. 
In fact, in the last 30 years an incredible surge of interest in ascidian chemistry 
yielded many new ascidian metabolites. These results, which include structurally 
unprecedented families of biologically active secondary metabolites, have attracted 
the attention of both synthetic chemists and pharmacologists.  
Ascidians belong to the phylum Chordata, which encompasses all vertebrate animals, 
including mammals. Therefore, they represent the most highly evolved group of 
animals commonly investigated by marine natural products chemists. Together with 
the two other classes included in the subphylum Urochordata (= Tunicata), members 
of the class Ascidiacea are commonly referred to as tunicates, because their body is 
covered by a saclike case or tunic, or as sea squirts, because many species expel 
streams of water through a siphon when disturbed. While adult ascidians are 
exclusively marine invertebrates and bear little resemblance to the other chordates, 
their larvae resemble amphibian tadpoles and contain notochorods, dorsal hollow 
nerve cords, and pharyngeal slits, all of which are lost during development. There are 
roughly 2000 living species of tunicates, of which ascidians are the most abundant. 
Adult ascidians are sessile filter feeders, either solitary or colonial, and live 
preferentially in regions which are free from extensive wave shock, but receive 
considerable freely flowing sea water. Ascidian morphology is diverse. Solitary 
tunicates may be up to 15 cm in length, or as small as 1 cm. Colonial species are 
often found encrusting rocks and may be extremely thin and delicate, or as thick as 5 
cm. Some are of undefined shape, and so disguised by their tunic that they 
superficially resemble sponges or fleshy coelenterates, yet the contractions which 
cause a sea squirt to spray streams of water provide the inexperienced observer with 
a means to distinguish tunicates from other marine invertebrates.  
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3.1.1 Tetracyclic cytotoxic meroterpenes from the Mediterreanean ascidian 
Aplidium conicum 
Since the discovery by Fenical in 1976 of geranylhydroquinone in an unidentified 
species of Aplidium,
1
 many diverse meroterpenes, have been isolated from ascidians. 
These compounds form a class of complex metabolites derived from a mixed 
terpenoid-polyketide biosynthetic pathway which display a wide range of structural 
diversity. A large number of meroterpenes have been isolated so far from marine 
ascidians, almost exclusively belonging to the Aplidium genus; their carbon skeletons 
originate from intra- and intermolecular cyclizations and/or rearrangements of the 
terpene chains to give unique polycyclic or macrocyclic structures, often linked with 
diverse functionalities.
2
 The Mediterranean species A. conicum has been extensively 
studied; the peculiarity of this ascidian is that the nature and/or the abundance of its 
meroterpenes content apparently depends on the geographical place of collection. 
Specimens of A. conicum collected off Tarifa Island, in Spain, were shown to contain 
geranyl hydroquinone, a number of its hydroxylated  and/or cyclized analogues as 
well as the relevant chromenols.
3
 From samples of the same ascidian, collected in 
Italy along Sardinia coasts, a large group of new meroterpenes, with different 
polycyclic skeletons but all featuring an unusual dioxo-thiazine ring condensed to a 
benzoquinone ring have been isolated.
4-6
 The geographical variation of A. conicum 
metabolic content is now highlighted by the results I obtained by analyzing another 
specimen of the ascidian collected along southern Italy coasts (Porto Cesareo, 
Lecce). I have isolated two novel meroterpenes, conithiaquinones A and B (1 and 2). 
in addition to the two chromenols (3 and 4) and conicaquinones A and B (5 and 6) 
found in the previously investigated  samples of A. conicum. The new molecules 
have been characterized using standard spectroscopic techniques as well as on the 
basis of  quantum mechanical chemical shift calculations, as I will discuss in the 
paragraph 3.2.2. 
Both conithiaquinones A and B were assayed for their effect on human skin 
keratinocyte (HaCaT line) and human breast adenocarcinoma (MCF-7 line) cells 
growth and viability in vitro, demonstrating a moderate cytotoxicity but especially 
directed against the human breast cancer cells (Figure 3.1).  
30 
 
O
HO
O
HO
Y
X
O
O5 X= SO2; Y=NH
6 X= NH;  Y=SO2
9
3
N
H
S
O
O
OR
O
O O
H
H
11
5
5a
10a
10 9
6
6a
9a
8
4a
11a
13
7
12
1514
3
2
1 R= H
2 R= CH3
O
O
OH
OH
H
H
4
O
O
R2
OH
H
H
HO
R1
COOH7 R1= H; R2=OH
8 R1= OH; R2=H
16
A B C D
 
 
Figure 3.1. Structures of compounds (1-9) 
 
Freshly thawed specimens of A. conicum (Olivi, 1792) collected at Porto Cesareo 
(Lecce, Italy) were exhaustively extracted with methanol and subsequently with 
chloroform. The concentrated extracts were combined and then partitioned between 
ethyl acetate and butanol. Medium pressure flash chromatography over a silica gel 
column of the ethyl acetate soluble portion, followed by extensive HPLC separations 
of the most polar fractions, afforded conithiaquinones A (1) and B (2) in the pure 
state. ESI mass spectrum (positive ion mode) of compound 1 revealed an ion peak at 
m/z 418.2 corresponding to [M + Na]
+
. A facile loss of 64 amu was observed in the 
mass spectrum, attributable to the expulsion of SO2, and suggested the presence of a 
sulfone functionality. HRESIMS (positive ions) established a molecular formula of  
C19H25NO6S for 1, indicating eight unsaturation degrees. The 
13
C NMR spectrum 
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(CD3OD) revealed the presence of nineteen signals which, on the basis of the data 
obtained from a HSQC experiment, were sorted as four methyls, four methylenes, 
three methines, and eight unprotonated carbons. Six carbon resonances were due to 
sp
2
 quaternary carbons, and two of them, at δC 180.5 and 181.5 ppm were assigned to 
two conjugated carbonyl groups (Table 3.1). Thus, 1 must be tetracyclic to satisfy 
the unsaturation number implied by the molecular formula. The 
1
H NMR spectrum 
of 1 (CD3OD) was interpreted also on the basis of 
13
C NMR and HSQC information. 
Besides the resonance of a methoxyl group (H: 3.24, s, 3H; C: 48.5), it contained: i) 
three upfield shifted methyl singlets at  1.23 (C: 18.6, Me-14), 1.24 (C: 25.4, Me-
15), 1.40 (C: 21.2, Me-12); ii) three methine protons at  1.62 (dd, J=13.6, 9.1 Hz, 
H-9a; C: 51.8), 1.86 (dt, , J=13.6, 9.1 Hz,  H-6a; C: 47.5), and 5.12 (d, J= 9.1 Hz, 
H-10; C: 65.1,), this latter presumably being an oxymethine proton; iii) four sp
3
 
methylenes, including  two deshielded signals [1.55 (m, Ha-7) and 1.67 (m, Hb-7), 
C: 21.1; 1.44 (m, Ha-8) and 2.09 (m, Hb-8), C: 33.1;  3.32 (t, J = 6.5 Hz, 2H-2), 
C: 48.3; 3.94 (m, 2H-3, C: 39.4)]. Moreover, the 
1
H NMR spectrum of 1 performed 
in CDCl3 showed, in addition to the aforementioned signals, two D2O-exchangeable 
broad singlets at  6.56 (NH) and 3.65 (OH). Interpretation of COSY map (CDCl3) 
revealed that the NH proton was coupled to the multiplet at  3.94 (2H-3) which was, 
in turn, coupled to the multiplet at d 3.32 (2H-2); this spin system was consistent 
with a -NHCH2CH2SO2- moiety. Since the presence of two conjugated carbonyl 
signals (δ 180.5 and 181.5) and two tetrasubstituted double bonds (δ 146.1, 110.0, 
147.5, and 148.0 ppm) were indicative of a p-quinone ring, it was hypothesized that 
structure of conithiaquinone A contained the same 1,4-benzoquinone/1,1-dioxo-1,4-
thiazine bicyclic system (A and B rings) present in the meroterpenes previously 
isolated  from A. conicum.
4-6 
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 Table 3.1. NMR spectroscopic data for conithiaquinones A and B
[a]  
  Conithiaquinone A (1)  Conithiaquinone B (2)  
Pos. C
 H,
  
mult.(J in Hz) HMBC[b] ROESY
 [e]  C H, mult.(J in Hz) HMBC
[b] ROESY 
2 48.3 
 
3.32, t (6.5) 3 3  48.2 3.32, m 3 3 
3 39.4 3.94,  m 2, 4a 2  39.3 3.95, m 2, 4a 2 
4a 146.1 - - -  146.4 - - - 
5 181.5 - - -  181.5 - - - 
5a 148.0 - - -  150.0 - - - 
6 37.5 - - -  37.5 - - - 
6a 47.5 1.86, dt (13.6, 9.1) 6, 7, 9a, 14, 15 10, 7b,15  48.1 1.77, m 6, 7, 9a, 10, 14, 15 10, 15 
7 21.1 
Ha: 1.55, m - 9a, 14  
21.7 
Ha:1.51
[c] 6 14 
Hb: 1.67, m 6a, 9, 9a 6a, 8b, 15 Hb:1.68, m 6a, 8, 9, 9a 15 
8 33.1 
Ha: 1.44, m - -  
33.7 
Ha:1.52
[c] - - 
Hb: 2.09, m 6a, 9a, 9 13, 7b Hb:2.06, m 6a, 7, 9, 9a -          
9 82.7 - - -  82.4 - - - 
9a 51.8 1.62, dd (13.6, 9.1) 
6, 6a, 8,10, 
10a, 12 
7a, 12, 14 
 
52.1 1.71 dd (13.7, 8.7) 6, 6a, 9,10,12 12, 14 
10 65.1 5.12, d (9.1) 5a, 9, 9a, 10a 
6a, 13, -
OH 
 
74.4 4.84, d (8.7) 5a, 9, 9a, 10a,11,16 6a 
10a 147.5 - - -  149.7 - - - 
11 180.5 - - -  179.7 - - - 
11a 110.0 - - -  110.3 - - - 
Me-12 21.2 1.40, s 8, 9, 9a 9a 
 
21.6 1.40, s 8, 9, 9a 
9a, 13, 
16 
MeO-13 48.5 3.24, s 9 8b, 10  48.5 3.25, s 9 12 
MeO-16 - - -   58.0 3.51, s 10 12 
Me-14 18.6 1.23, s 5a, 6, 6a, 15 7a, 9a   18.4 1.22, s 5a, 6, 6a, 15 7a, 9a 
Me-15 25.4 1.25, s 5a, 6, 6a, 14 6a, 7b  25.7 1.25, s 5a, 6, 6a, 9a, 14 6a, 7b 
-OH - 3.65, bs[d] - 10  - - - - 
-NH - 6.56, bs[d] - -  - - - - 
[a]  Spectra are recorded in  CD3OD (H = 3.34 ppm and δC = 49.0 ppm) at 700 MHz. [b] Carbon atoms coupled with the given proton(s). [c] 
Overlapped. [d] The chemical shift value was obtained from an 1H NMR spectrum performed in CDCl3 (δH = 7.26 ppm).
 
[e] Recorded in CDCl3 
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This hypothesis was corroborated by a key 
3
J correlations observed in the HMBC 
spectrum between the H-3 protons at H 3.94 and the quaternary sp
2
 carbon at  146.1 
(C-4a) and supported by comparison of NMR data of 1 with those reported in the 
literature.
4-6 Careful analysis of the HSQC spectrum allowed the chemical shifts of 
H-9a, 2H-8, and 2H-7 to be determined in the poorly resolved region of the proton 
spectrum ( 1.4-2.1). This helped to readily identify a second isolated spin system, 
including H-10, H-9a, H-6a, 2H-7, and 2H-8 protons, by analysis of COSY 
connectivities starting at the oxymethine proton at  5.12 (H-10). The spin system 
was enlarged through analysis of COSY spectrum in CDCl3, where H-10 was further 
coupled to the D2O exchangeable proton at  3.65, thus indicating the presence of a 
hydroxyl substituent linked at C-10. HMBC spectrum showed that methyl singlets at 
 1.40 (Me-12) and 3.24 (MeO-13) were both long range coupled to the quaternary 
carbon at  82.7 (C-9). This quaternary center, bearing both the methyl and methoxyl 
groups, was connected to C-8 and C-9a carbons through its HMBC correlations with 
the relevant protons (H-9a and Ha-8), to give the five membered ring D. The 
remaining two identified methyl groups (Me-14 and Me-15) were judged to be 
geminal since HMBC spectrum showed mutual correlations as well as three shared 
carbon correlations for both resonances. They were indeed coupled to the methine 
carbon at  47.5 (C-6a) as well as to the quaternary carbons at  148.0 (C-5a) and 
37.5 (C-6). This latter carbon was in turn long range coupled to the methine proton at 
 1.86 (H-6a); further diagnostic HMBC correlations were those between H-9a and  
both C-10 and C-10a as well as between H-10 and both the quaternary sp
2
 carbons at 
 147.5 (C-10a) and 180.5 (C-11). These data allowed the ring C to be closed and 
connected to the p-quinone ring, thus delineating the whole skeleton of compound 1 
which incorporates the uncommon linearly fused 6, 6, 5-ring core reported in very 
few natural products. This tricyclic moiety is indeed the skeleton of the plant-derived 
pycnanthuquinones A and B (7 and 8),
7 
of the algal metabolite pycnanthuquinone C 
(9),
8 
and of the ascidian metabolites rossinones.
9,10
 It has been also found 
incorporated into the larger policyclic scaffolds of the terrestrial metabolites pinnatal, 
isopinnatal, and sterekunthal B.
11-13 
A 
3
JH6a-H9a value of 13.6 Hz implied a trans-fused ring junction at C-6a/C-9a. The 
magnitude of this coupling constant was  comparable to that observed for the 
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relevant protons in pycnanthuquinone C (9) (13.9 Hz) and in the other related 
compounds (pycnanthuquinones A and B, rossinones) having a trans-fused 6,5-rings 
system.
7-10 
On the other hand,  structures featuring a cis relationship between the 
protons of the five- and six-membered rings (pinnatal, isopinnatal, and sterekunthal 
B) displayed clearly smaller coupling constant values.
11-13
 Similarly, the  magnitude 
of 
3
JH9a-H10 in 1 (9.1 Hz) suggested the -orientation of the OH group at C-10; it was 
indeed comparable to that reported for 8 (8.8 Hz) but more than the double of those 
in 9 (4.3 Hz) and 7 (3.6 Hz).
7,8
 Both these conclusions were strongly supported by a 
number of observed ROESY correlations, listed in Table 3.1, which also allowed the 
orientation of the substituents at C-9 to be determined.  In detail,  ROESY spectrum 
(CDCl3) of 1 contained cross-peaks from H-6a to H-10, Me-15, and H-7b; further 
diagnostic cross-peaks were observed from H-9a to Me-12, Me-14, and H-7a. These 
observations allowed the relative configuration of 1 to be assigned as 6aR*, 9R*, 
9aR*, 10S*. 
The high-resolution mass spectrum ( ESI positive-ion mode) of compound 2 showed 
an ion peak at m/z 432.1449 corresponding to [M+Na]
+
 (calculated value: m/z 
432.1451); the molecular formula of 2 was thus established as C20H27NO6S. The 
comparison of NMR spectra of 1 and 2 evidenced a close similarity between the two 
compounds and indicated that they differed only in the nature of the  substituent at C-
10. Taking into account the molecular formula and considering the presence of 
additional signals in 
1
H and 
13
C NMR spectra (H: 3.51, s, C: 58.0) the substituent in 
2 was identified as a methoxyl group. This conclusion was fully corroborated by 2D 
NMR spectra analysis which also led to the full assignment of all NMR resonances 
in 2 (Table 3.1).  
The significant cytotoxic activity showed by several members of meroterpenes 
family, probably related to their capacity to interfere with the cellular redox 
systems,
11
 prompted us to investigate the effects of 1 and 2 on tumour and non-
tumour cell lines cell growth and viability. To this aim, human skin keratinocyte cells 
(HaCaT line) and human breast adenocarcinoma cells (MCF-7 line) were treated for 
48 h with various concentrations of compounds 1 and 2. Then, the bioscreenings 
were performed by measuring the level of mitochondrial dehydrogenase activity and 
by counting the number of live and death cells. The results showed that both 1 and 2 
posses a significant and concentration-dependent cytotoxic profile, especially against 
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mammalian cancer cells, as indicated by the calculated IC50 values reported in Table 
3.2.  
Table 3.2. Cell growth inhibition (IC50, µM
[a]
) 
Compound  HaCaT cells  MCF-7 cells 
1 98.6 ± 4 44.5 ± 3.8 
2 162.6 ± 5  125 ± 5 
CDDP 6 ± 3 3.5 ± 3 
[a] IC50 values are expressed as mean  ± SEM (n = 24) of three independent experiments 
Interestingly, compound 1 displayed an higher toxic effect toward lines, in particular 
showing an IC50 value against tumour MCF-7 cells within the micromolar range (~45 
µM), which is generally considered as a marker of a moderate cytotoxic activity. 
Positive control for cytotoxicity was performed using cisplatin (CDDP), a well-
known antiproliferative drug showing IC50 values lower than 10 µM in the same 
experimental conditions.
14 
 
In conclusion, conithiaquinones A and B represent a further example of the great 
structural diversity generated into the meroterpene family. It has been speculated on 
the origin of some of these molecules; the formation of chromene derivatives and of 
other cyclized compounds from the relevant quinones/hydroquinones can be also 
easily rationalized through a sequence of acid-catalyzed cyclizations. However, with 
the data available, it is not possible to argue whether these transformations occur in 
the organism, either enzymatically or not, prior to its extraction, or they take place 
during isolation and/or chromatographic purification. Concerning this, we considered 
the possibility that conithiaquinones A and B could be artifacts derived from a 
hypothetic methylation during the extraction procedure. To rule out this possibility, 
samples of A. conicum were extracted with chloroform and acetone and subsequently 
subjected at the same procedure above reported. The spectrum 
1
H NMR of the 
MPLC fractions eluted with 100% AcOEt was identical to that of corresponding 
fractions obtained from extraction using methanol. Furthermore there was no 
evidence of the presence of even small amounts of the putative demethylated 
conithiaquinones, thus confirming that the conithiaquinones are not artifacts, but 
genuine metabolites from A. conicum. 
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3.1.2 New bioactive alkyl sulfates from the ascidians Ciona edwarsii and 
Aplidium elegans 
Ascidians have been an extremely rich source of sulfur-containing molecules which, 
on the other hand, are quite unusual in marine organisms. A number of 
sulfides/polysulfides, sulphur heterocycles, sulfoxides, and alkyl sulfates have been 
isolated from marine ascidians.
15,16
 In particular, these latter compounds, although 
occasionally reported from marine source,
17-20
 have shown to be often present in 
remarkable amounts in solitary ascidians of the families Ascididae and Pyuridae, as 
well in colonial Polyclinidae species.
21-28
 They often have quite simple structures, 
mostly of polyketide derivation even though in some frameworks an isoprenoid 
origin is clearly recognized; almost all the isolated compounds are endowed with 
cytotoxic and/or antiproliferative activity. In the course of our program on discovery 
of cytotoxic metabolites from Mediterranean ascidians,
29,30
 we have analyzed the 
chemical composition of methanol extracts of two species, Aplidium elegans 
(Monniot & Monniot, 1983) and Ciona edwardsii (Roule, 1884), both collected in 
the Bay of Naples, Italy. This investigation yielded compounds 10 and 11 from A. 
elegans, and compound 12 from C. edwardsii, in addition to the known sulfated 
terpenoids 13
 
and 14.
24-28 
(Figure 3.2).  
 
Figure 3.2. Structures of compounds 10–14.  
37 
 
Fresh thawed tissues of both A. elegans and C. edwardsii, collected in the bay of 
Naples, immediately frozen, and kept at −28 °C until extraction, were exhaustively 
extracted with methanol and, subsequently, with chloroform. For each ascidian 
sample, the extracts were combined and concentrated; the resulting aqueous 
suspensions were then partitioned between water and butanol. The butanol extract of 
A. elegans was fractionated by MPLC over a reversed phase C-18 column using 
stepwise elution with aqueous MeOH. The fractions eluted with 50% aqueous MeOH 
were further separated and purified by reversed-phase HPLC eluting with 70% 
aqueous MeOH containing 0.1% TFA, thus affording compounds 10 and 11 in the 
pure state. The butanol extract of C. edwardsii was fractionated by reversed-phase 
MPLC under the same conditions as described for that of A. elegans. Further 
separation and purification of both fractions eluted with 70% and 50% aqueous 
MeOH by repeated reversed-phase HPLC yielded compounds 12–14 in the pure 
state.A first survey of the 1D NMR spectra (CD3OD) of 10 and the comparison with 
those of the already known compound 13 readily allowed us to hypothesize that 10 
was the 15-hydroxy analogous of 13. The proton spectrum of 10 lacked indeed the 
signals due to the isopropyl terminus portion of 13, whereas it contained a quite 
deshielded methyl signal ( 1.14), resonating as a singlet and integrating for six 
protons. Likewise, the 
13
C-NMR spectrum of 10 contained a quaternary carbon 
resonance (δ 70.8) attributable to an oxygen-bearing carbon while the methine signal 
at δ 29.1 due to C-15 in 13 was absent. Chemical shifts and coupling patterns of the 
remaining signals of 10, assigned by aid of COSY, HSQC, and HMBC experiments 
were very similar to those of 13. Mass data analysis confirmed the assumption made. 
ESI mass spectrum (negative ion mode) contained an ion peak at m/z 511; an intense 
fragment at m/z 453 was present and it was interpreted as the result of an  cleavage 
at C-15. High resolution analysis on the pseudomolecular ion peak gave m/z 
511.1987, which was consistent with the molecular formula C20H40NaO9S2 
corresponding to [M−Na]− (calculated value: 511.2006). The location of the 
hydroxyl group at C-15 was unambiguously established through 2D-NMR 
experiments which allowed us also to assign all the proton and carbon resonances of 
compound 10 (Table 3.3). In particular, diagnostic 
3
JC-H long-range couplings were 
observed in the HMBC spectrum between the signal at δ 1.14 (s, 6H, CH3-16/20) and 
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both the oxygenated quaternary carbon at δ 70.8 (C-15) and the methylene carbon at 
δ 44.4 (C-14). 
Table 3.3. 
1
H and 
13
C-NMR data of compounds 10–12 in CD3OD. 
 10 11 12  
Pos. H (mult., J in Hz) C H (mult., J in Hz) C H (mult., J in Hz) C 
1 4.02 (m) 66.7 3.80 (Ha, dd,6.6, 9.1) 73.2 3.79 (Ha, dd, 6.6, 9.4) 73.6 
   3.88 (Hb, dd,6.6, 9.1)  3.87 (Ha, dd, 6.6, 9.4)  
2 1.42 
a (Ha) 
1.68 
36.7 1.78 (m) 33.5 1.79 (m) 34.1 
 1.68 (m, Hb)      
3 1.60 (m) 29.9 1.14 (m)  
1.40 
33.7 1.14 (m)  
1.43 
34.3 
   1.41 
a  1.4 a  
4 1.10 
a 
 
37.6 1.33 a 24.5 1.32 a 25.1 
 1.30 
a      
5 1.30 
a 24.6 1.10 a 
1.30 
37.6 1.11 a 
1.32 
38.1 
   1.30 
a  1.30 a  
6 1.10 
a (Ha) 
1.30 
37.6 1.39 a 33.0 1.41 a 33.5 
 1.28 
a (Hb)      
7 1.40 
a 33.1 1.10 a 
1.30 
37.6 1.11 a 
1.32 
38.1 
   1.30 
a  1.30 a  
8 1.09 
a (Ha) 
1.28 
37.7 1.33 a 24.5 1.32 a 25.1 
 1.28 
a (Hb)      
9 1.29 
a 24.6 1.31 a 
1.36 
31.7 1.23 a 
1.33 
31.9 
   1.36 
a  1.32 a  
10 1.30 a 
1.38 
32.0 1.66 (m) 38.4 1.44 (m) 41.4 
 1.38 a      
11 1.65 (m) 38.4 1.30 a 
1.38 
31.9 1.23 a 
1.33 
31.9 
   1.38 a  1.32 a  
12 1.36 a 31.7 1.33 a 24.5 1.33 a 25.2 
13 1.30 a 24.6 1.42 a 44.4 1.19 (m) 40.3 
14 1.42 a 44.4 - 70.7 1.55 (m) 28.9 
15 - 70.8 1.15 (s) 28.3 0.89 (d., 6.4) 22.8 
16 1.14 (s) 28.4 0.94 (d, 6.6) 16.3 0.96(d., 6.6) 16.9 
17 0.90 (d, 6.6) 18.9 0.86 (d, 6.6) 19.2 0.88(d., 6.4) 19.9 
18 0.85 (d, 6.6) 19.2 3.92 (d, 5.4) 70.8 3.44 (d, 5.4) 65.5 
19 3.91 (d, 5.4) 70.7 1.15 (s) 28.3 0.89 (d., 6.4) 22.8 
20 1.14 (s) 28.4 - - - 
3.86 
- 
a 
Signals overlapped by other resonances. 
 
The negative HRESI mass spectrum (negative ions) of compound 11 displayed an 
ion peak at m/z 497.1825 corresponding to [M−Na]− (calculated value: m/z 
497.1849); the molecular formula of 11 was thus established as C19H38NaO9S2. The 
1
H- and 
13
C-NMR spectra of compound 11 displayed a close resemblance to those of 
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10, and the observed differences were due to the initial segment of the linear skeleton 
of both compounds (C1-C3/C16 in 11 and C1-C4/C17 in 10). The multiplet at  4.02 
due to 2H-1 in compound 10 was replaced by an ABX system at δ 3.80 (1H, dd, J = 
9.1 and 6.6 Hz, H-1a) and 3.86 (1H, dd, J = 9.1 and 6.6 Hz, H-1b). COSY 
connectivities, which allowed to delineate the large spin system C1-C13 through 
CH3-16, CH3-17 and CH2-18, as well as HMBC information, clearly evidenced 11 as 
the 1-nor-derivative of 10 or, alternatively, the 15-hydroxy analogue of 14 (Table 
3.3). 
The NMR features (CD3OD) of compound 12 appeared almost identical to those of 
14, except for the chemical shift of the C-18 methylene protons as well as that of the 
relevant carbon, both showing a significant upfield shift : 3.94 in 14 vs. 3.44 in 
12; C: 73.9 in 14 vs. 65.5 in 12). The negative ion HRESI mass spectrum of 12 
displayed an ion peak at m/z 379.2522 which was consistent with the molecular 
formula C19H39O5S
−
, corresponding to [M−Na]− (calculated value 379.2513). These 
few data readily allowed us to deduce that 12 was the 18-desulfated analogue of 14; 
this conclusion was fully corroborated by 2D NMR spectra analysis which also led to 
the full assignment of all NMR resonances in 12 (Table 3.3). 
The cytotoxic effect of compounds 10–12 was evaluated on J774A.1 (BALB/c 
murine macrophages) and C6 (rat glioma) cell lines in vitro. Compounds 10 and 11 
induced a concentration-dependent mortality on J774A.1 (Figure 3.3) whereas both 
drugs were inactive on C6 cells, with a LC50 > of 300 µM (data not shown). When 
comparing optical density values of control and treated cells, the cytotoxic effect of 
compound 10 and 11 was significant at the highest concentrations (p < 0.05, 
compound 10 at 100 µM; p < 0.05 and p < 0.01, compound 11 at 30 and 100 µM, 
respectively). The LC50 value of compound 11 on J774A.1 cell line was 45.12 µM, 
while that of compound 10 was > of 100 µM (Figure 3.3). The compound 12 was 
ineffective on both J774A.1 and C6 cells (data not shown). On the basis on these 
although preliminary data, a sulfate group in R2 and/or a hydroxyl group in R1 
seems to be essential for the cytotoxic activity, since they are absent in compound 12 
which proved inactive. Nevertheless, previous reports showed that compounds 13 
and 14, possessing exclusively the sulfate group in R2, are still active therefore,
24,28
 
we can conclude that only the latter functionality has an obligatory role for the 
cytotoxic activity showed by compounds 10 and 11 against the macrophagic cell line. 
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The slightly different potency of compounds 10 and 11 could be ascribed to the 
different length chain; this hypothesis is supported by cytotoxicity data reported in 
literature for compounds 13 and 14, where compound 14, characterized by a shorter 
C-chain, resulted more active than its higher analogue 13.
 24,28 
 
Figure 3.3. Cytotoxic effect of compounds 10 and 11 at increasing concentrations on 
J774A.1 cells. Each per cent value is the mean ± SEM of three independent 
experiments. 
In conclusion, the structures of compounds 10–12, isolated from the Mediterranean 
ascidians Aplidium elegans and Ciona edwardsii, have been elucidated using mass 
spectrometry and NMR experiments and their in vitro cytotoxic effects have been 
evaluated on J774A.1 (BALB/c murine macrophages) and C6 (rat glioma) cell lines. 
A moderate but selective cytotoxic effect on J774A.1 cell line has been evidenced for 
compounds 10 and 11; the inactivity of 12, as well as further pharmacological data 
available in the literature,
 24,28
 indicated that the hydroxyl group does not confer per 
se cytotoxic activity, while the contribution of the sulfate is of pivotal importance. A 
slight influence of alkyl chain length on the potency of the active compounds has 
been also evidenced.  
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3.1.3 Phallusiasterols A, B and C: three new sulphated sterols from the 
Mediterranean tunicate Phallusia Fumigata and their effects as modulators 
of the PXR receptor 
Marine invertebrates are a prolific source of unconventional steroids. More than 
1600 new steroidal structures have been so far isolated
31,32 
with structural 
modifications including oxygenation, alkylation, esterification, and sulfation of both 
the nucleus and the side chain, extensive modification of the latter, or bond cleavage 
in the rings of the tetracyclic nucleus leading to degradation of the conventional 
carbon backbone.
33-36
 Steroids of marine origin have exhibited a diverse array of 
pharmacological activities, such as antimicrobial, cytotoxic, antifouling, 
ichthyotoxic, and antiinflammatory.
31-34
 Nevertheless, the sterol composition of 
marine ascidians has received much less attention than those of other invertebrates. It 
has been showed that, in general, tunicates contain 5 sterols bearing conventional 
side chains with cholesterol as the major component and cholestanol and cholest-7-
en-3-ol as the minor ones.31 Among the minor unconventional sterols isolated from 
tunicates, 5,8-endoperoxides from several 5,7,9(11) sterols37 together with 24-
hydroperoxy-24-vinylcholesterol and the corresponding 24-hydroxy derivative from 
Phallusia mamillata and Ciona intestinalis,
38
 4-3-keto steroids, 5-stanols, and 4-
methyl sterols in addition to endoperoxides from Ascidia nigra,
39,40
 two short side 
chain sterols (C-22 and C-23) from Polizoa opuntia,
41
 and four 9,11- secosterols 
from Aplidium conicum
42
 have been reported. These findings, although few number, 
show that ascidians can produce sterols with unique structural features and they 
could be a good source of interesting novel compound. 
As a part of our research 
program aimed to discover new 
bioactive metabolites from 
marine tunicates, we have 
investigated the Mediterranean 
ascidian Phallusia fumigata.  
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This study led to the isolation of three new sulfated sterols phallusiasterols A (15), B 
(16) and C (18) (Figure 3.4), which, to our knowledge, represent the first example of 
sulfated sterols isolated from tunicates. Based on the reported activity of sulfated 
marine sponge steroids as nuclear receptor ligands, the effects of phallusiasterols A, 
B and C as modulators of PXR receptor have been investigated in vitro. 
 
Figure 3.4. Structures of phallusiasterols A-C 
 
These studies revealed that phallusiasterol A induces PXR transactivation in HepG2 
cells and stimulates the expression of the PXR target genes CYP3A4 and MDR1 in 
the same cell line. 
PXR is a master gene orchestrating the expression of a wide family of genes 
involved in uptake, metabolism, and disposal of a number of endo- and xenobiotics, 
including drugs, bile acids, steroid hormones, and metabolic intermediates in 
mammalian cells. PXR is almost exclusively expressed in the gastrointestinal tract 
and liver, with lower levels in the kidney and ovary. PXR dysfunction is associated 
with immune disorders and inflammatory bowel diseases, including ulcerative colitis 
and Crohn‟s disease. Chemical and pharmacological characterization of marine 
steroid libraries has allowed the identification of a number of selective PXR agonists 
(natural and synthetic compounds) which have been effective in reducing nuclear 
factor (NF)-kB activity and intestinal inflammation. These findings open the 
possibility of discovering potential leads for the treatment of liver and intestinal 
disorders.
43
  
A series of subsequent normal-phase chromatographies of the ethyl acetate extract of 
the ascidian P. fumigata collected from the bay of Pozzuoli (Napoli, Italy), allowed 
the isolation of compounds 15 and 16 (Figure 3.4) in pure form. 
The high field region of the 
1
H NMR spectrum (pyridine-d5) of phallusiasterol A (15) 
contained signals for five methyl groups of a steroidal nucleus: two singlets a 0.67 
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(Me-18) and 1.60 (Me-19) and doublets at  0.96 (J = 6.5 Hz, H3-21), 0.89 and 0.88 
(J = 6.6 Hz, H3-26 and H3-27). A pseudomolecular ion at m/z 545.2858 [M+Na]
+
 was 
observed in the high-resolution ESI mass spectrum (positive ion mode), indicating 
for 15 a molecular formula of C27H47SO6Na (calcd. 545.2889). The MS/MS 
fragmentation pattern of 15 was compatible with the presence of a sulfate group, 
displaying the peak at m/z 425.3392 [M − NaHSO4 + Na]
+
. Consistent with the MS 
data, the 
1
H and 
13
C- NMR spectra of 15 contained two hydroxymethine signals 
[H4.33, bs, C 75.3 (CH); H4.79, m, C 67.2 (CH)] and a highly deshielded 
unprotonated carbon ( 87.8), presumably the locus of the sulfate group. This 
assumption was verified by acetylation of phallusiasterol A (15) which gave the 
corresponding diacetate 17, thus confirming, according to MS information, the 
presence of two secondary alcohols and a quaternary sulfoxy group in 15. 
The whole series of 2D NMR data allowed to locate the hydroxyl groups at C-3, C-6, 
and the sulfate group at C-5. Analysis of COSY spectrum of 15 (pyridine-d5), 
assisted by TOCSY information, allowed the sequential assignment of all the protons 
of the tetracyclic system
 
(Figure 3.5) whereas the protonated 
13
C signals were 
assigned to the relevant protons from HSQC data (Table 3.4). 
The steroidal skeleton of 15 was assembled on the base of key HMBC correlations of 
H3-19 with C-1, C-5, C-9, and C-10 and of H3-18 with C-12, C-13, C-14, and C-17 
(Figure 3.5). Information on the side chain were also provided by analysis of 2D 
NMR data; in the COSY spectrum , the spin system from H-6 to H-17 (through H-
14) was extended to the side chain protons through the correlation between H-17 ( 
1.10) and the multiplet at δ 1.36 (H-20), which is in turn coupled to both the methyl 
doublet at  0.96 (H3-21) and the methilene protons at δ 1.38 and 1.03 (H-22a and H-
22b). The sequence was extended to the H3-26 and 27 methyls, taking also advantage 
of HSQC and TOCSY information.  
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Figure 3.5. COSY connectivities (bold bonds) and selected HMBC (from H to C) 
correlations of 15 
The relative stereochemistry of phallusiasterol A (15) was established through 
analysis of ROESY data (Figure 3.6) and consideration of both coupling constants 
and solvent shifts ( = CDCl3 -  pyridine-d5) observed for some key signals in the 
1
H NMR spectrum of 15. The equatorial orientation of the hydroxyl group at C-3, 
assigned to the  face, was easily deduced by the presence of an axial-axial coupling 
constant (J= 13.1 Hz) found for the vicinal H-4. Furthermore, a large pyridine-
induced downfield shift (-0.46 ppm) was observed for the H-3 signal, which 
resonates at  4.33 when the proton spectrum is recorded in CDCl3 (see experimental 
section). This indicated a 1,3-diaxial interaction of H-3 proton with the polar sulfate 
group linked at C-5, which therefore must be -oriented.44-46 The axial orientation of 
H-8, H-9, and H-14 was apparent from the coupling constants values of these protons 
(Table 3.4). These data, combined to the observation of ROESY correlations of H3-
19 to H-4, to H-2, and to H-8, of H3-18 to H-8, and of H-9 to H-14 (Figure 3.6), 
defined the A/B, B/C, and C/D trans ring junctions of the 5-cholestane nucleus of 
15.  
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Figure 3.6. Key ROESY correlations detected for 15 
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The small coupling constants showed by H-6 ( 4.33, bs) suggested a -orientation 
of the OH group at C-6. This was confirmed by the signal large pyridine-induced 
downfield shift observed for H-4(-0.75 ppm). According to Fujimoto et al.,
47
 the 
resonances of H-4 protons in 3, 5, 6-cholestanetriols show a diagnostic 
dependence on the configurations at C-6. Their resonances are strongly influenced by 
a deshielding effect of the 6-OH group through a 1,3- diaxial (with the 6 isomer) or 
1,3-diequatorial (with the 6 isomer) interaction, which is intensified in pyridine 
solution. Further significant pyridine-induced shifts were observed for H3-19 (- 0.32 
ppm) and H-8 (- 0.31 ppm), which supported the axial orientation of the hydroxyl 
group at C-6. The orientation of substituents at C-17 and C-20 in phallusiasterol A, 
as shown in Figure 3.4, was assumed to be the same as in related polyhydroxysterols 
due to the almost identical values of carbon chemical shifts around these carbon 
atoms.
46-48
 The structure of phallusiasterol A was hence established as 3, 6-
dihydroxy- 5-cholestan -5-yl sodium sulfate.  
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Table 3.4. 
1
H (700 MHz) and 
13
C (125 MHz) NMR data for phallusiasterols A and B in pyridine-d5. 
 Phallusiasterol A (15)  Phallusiasterol B (16) 
Pos. C H
 ( mult., J in Hz) HMBC  C H
 ( mult., J in Hz)  
1ax  34.4 1.90 (dt,13.4, 4.2) 2, 5, 10, 19  33.8 2.10, m  
1eq  1.56, m 2, 3, 5, 10, 19   1.50, m  
2eq 31.8 2.20, m 1, 3, 10  32.5 2.22, m  
2 /ax  2.01a 1, 3, 9   1.97, m   
3/ax 67.2 4.79, m 1, 2, 4  67.4 4.72, m  
4 /eq 43.2 2.51 (dd, 13.6, 4.5) 2, 3, 5, 6, 10  43.3 2.30 (dd, 13.0, 4.0)  
4 ax  3.10, m 2, 3   2.81, m  
5 87.8 - -  75.8 -  
6 75.3 4.33 (bs) 4, 5, 8, 10  66.1 4.34, (d, 5.5)   
7 /ax 35.1 1.88a 5, 6, 8, 9  35.7 1.93, m   
7 eq  2.21, m 8, 14   2.45, m   
8ax 31.1 2.05 (qd, 11.6, 4.3) 7, 9, 14  30.9 1.99 (qd, 11.0, 3.4)  
9ax  46.9 1.75, (ddd, 13.6, 11.1, 3.6) 8, 10, 11, 19  45.5 1.88 (ddd, 13.5, 11.2, 3.6)  
10 40.6 - -  39.8 -  
11eq 21.8 1.47 (dq, 14.1, 3.8) 9, 10, 12  21.7 1.48, m  
11ax  1.37a 9, 12, 17   1.38a  
12ax 40.2 1.13, m 11, 14  40.8 1.17a  
12eq  1.95a 9, 13, 14   1.94 (dt, 12.4, 3.4)  
13 42.9 - -  43.4 -  
14 56.2 1.05, m 8, 13, 15, 16, 18  56.1 1.02, m  
15 24.4 1.57a 13, 14, 16, 17  24.4 1.55, m  
15  1.04, m 8, 14, 16   1.07, m  
16 28.5 1.82 (ddd, 13.6, 9.5, 3.7) 13, 15, 17  29.1 1.83 (ddd, 13.6, 9.4, 3.8)  
16  1.21a 13, 17, 20   1.23, m  
17 56.4 1.10, m 13, 15, 16, 20, 22  56.9 1.11, m  
18 12.4 0.67, s 12, 13, 14, 17  12.3 0.71, s  
19 18.7 1.60, s 1, 5, 9, 10  18.5 1.47, s  
20 36 1.36, m 17, 21, 22, 23  36.8 1.35, m  
21 19 0.96 (d, 6.5) 17, 20, 22  19 0.96 (d, 6.5)  
22ª 36.5 1.38a 20, 21, 24  36.5 1.37a  
22b  1.03, m 20, 21, 24   1.01, m  
23ª 24.2 1.38a 24  24.1 1.36a  
23b  1.18a 24   1.17, m  
24ª 39.7 1.13, m 23, 26, 27  39.7 1.14, m  
24b  1.13, m 23, 26, 27   1.14, m  
25 28.3 1.51, m 23, 24, 26, 27  28.7 1.52a  
26 22.7 0.88 (d, 6.6) 24, 25  22.8 0.88 (d, 6.5)  
27 22.9 0.89 (d, 6.6) 24, 25  22.9 0.88 (d, 6.5)  
[a] Overlapped by other signals  
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The molecular formula C27H47SO6Na established for the second metabolite 
phallusiasterol B (16) by HRESIMS and NMR data was identical to that of 15, 
indicating that the compounds were isomers. The 
1
H and 
13
C NMR resonances of 16 
closely resembled those of 15, except for some signals surrounding C-6 (Table 3.4). 
Interpretation of COSY, TOCSY, HSQC and HMBC 2D NMR experiments provided 
evidence for the same planar structure for 16 as that of 15. The difference between 
15 and 16 was traced to a different stereochemistry at C-6, with the OH group  
oriented in compound 16. This was deduced from the different shape of H-6 signal in 
16 ( 4.34, d, J = 5.5 Hz) when compared to that of H-6 in 15 ( 4.33, bs). The 
upfield shift of C-6 in the 
13
C NMR spectrum of 16 ( 66.1) relative to that observed 
for 15 ( 75.3) added support to this assignment.48-50 Conclusive evidence was 
achieved from ROESY spectrum; a strong correlation was observed between H-6 and 
H3-19 and the  orientation of H-6 is the only position according with this demand. 
In addition, on comparison of the proton spectra of 16 recorded in CDCl3 and 
pyridine-d5, a pyridine-induced deshielding was observed for H-4 (- 0.64 ppm), 
comparable to that observed for H-4in 15, indicating a 1,3-diequatorial interaction 
of this proton with the 6 OH group.47 Thus, phallusiasterol B was identified as the 
epimer at C-6 of phallusiasterol A. 
Medium pressure flash chromatography  of the butanol soluble portion on a reversed 
phase C-18 column, followed by HPLC separations, gave phallusiasterol C (18) in 
the pure state (Figure 3.4).  
The 
1
H spectrum (recorded in CD3OD) of phallusiasterol C showed signals typical of 
a sterol (two upfield methyl singlets at H 0.72 e a δH 1.03; two methyl doublets at δH 
1.02 (d, J= 6.2 Hz) and at δH 1.03 (d, J= 6.4 Hz) (Table 3.5). Furthermore the down 
field region of the same spectrum contained three signals at  δH 5.38 (m) δH 5.35 (dd, 
J= 15.3, 8.5) and at δH 5.28 (dd, J= 15.3, 7.0), indicated the presence of three olefinic 
protons. The presence of two double bonds was confirmed by the signals at δC 141.5 
(C), 138.5 (CH), 130.2 (CH) 123.4 (CH) contained in the 
13
C NMR.  
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Table 3.5. 
1
H (700 MHz) and 
13
C (125 MHz) NMR data for phallusiasterol C (18) in CD3OD 
Pos. H,
 mult. (J in Hz) C 
 1.90, dt, (13.5, 3.6) 38.4 
 1.10, m 
 1.63, m 29.9 
 2.07, m 
 4.14, dddd, (11.4, 11.4, 4.8, 4.8) 80.0 
 2.34, m 40.3 
 2.53, ddd, (13.2, 4.7, 2.2) 
 - 141.5 
 5.38, m 123.4 
 1.98, m 33.0 
 1.55, ovl 
 1.48, m 33.2 
 0.96, m 51.7 
 - 37.7 
 1.55, ovl 22.1 
 1.51, m 
 2.01, dt, (12.9, 3.5) 41.0 
 1.18, m 
 - 43.4 
 1.02, ovl 58.2 
 1.07, m 25.3 
 1.58, ovl 
 1.28, m 29.7 
 1.71, m 
 1.17, m 57.2 
 0.72, s 12.5 
 1.03, s 19.7 
 2.06, m 41.5 
 1.03, d, (6.4) 19.7 
 5.35 dd, (15.3, 8.5) 138.5 
 5.28, dd, (15.3, 7.0) 130.2 
24 2.44, m 37.6 
24’a 3.88, dd, (9.3, 6.0) 73.8 
24’b 3.74, dd, (9.3, 7.8) 
25 1.02, d, (6.2) 21.2 
 
A pseudomolecular ion at m/z 567.2064 [M–Na+]¯ was observed in the high 
resolution ESI mass spectrum (negative ion mode), indicating for 18 a molecular 
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formula of C26H40NaO8S2, which indicated six unsaturation degrees. The ESI and 
MS/MS spectra showed pseudomolecular and fragment ions compatible with the 
presence of sulfate groups: 465 [M– NaSO3]
¯ 
, 447 [M–NaHSO4-Na
+
]
¯
, 272 (double 
charged species). 
1
H and 
13
C spectra, together with mass data, evidenced the 
presence of one secondary and one primary sulfoxy groups (δH 4.14, dddd, J= 11.4, 
11.4, 4.8, 4.8 Hz, δC 80.0, CH; δHa 3.88, dd, J=9.3, 6.0 e δHb 3.74, dd, J = 9.3, 7.8 Hz, 
δC 73.8, CH2). The location of the secondary sulfoxy group at C-3 of the steroidal 
nucleus was determined of 
1
H NMR, COSY, HSQC and HMBC spectra. 
The COSY spectrum revealed useful information concerning the side chain. Starting 
from the methine proton at H 1.17 (H-17), COSY correlations could be observed to 
the methine proton at H 2.06 (H-20), which in turn was coupled to both of the 
methyl protons at H 1.03 (H3-21) and the methine proton at H 5.35 (H-22). This 
latter proton was coupled to the methine proton at  5.28 (H-23). These correlations 
allowed us to locate the double bond between C-22 and C-23. The E configuration of 
the double bond was assigned on the basis of the coupling constant (J  15 Hz) of H-
22 and H-23. Furthermore COSY spectrum revealed that the proton at H 5.28 was 
coupled to the methine proton at  2.44 (H-24), which in turn was coupled to both of 
the methyl protons at 1.02 (H3-25) and the methylene protons at  3.74 and at 
3.88 (H2-24‟), suggesting a 24‟-sulfoxy-C24‟ side chain. 
The axial orientation of H-8, H-9 and H-14 was apparent from their respective 
coupling constants, that of the angular methyl groups from the ROESY correlations 
of both H3-18 and H3-19 with H-8 and the axial H-11On this skeleton, the 
coupling constants showed by H-3 with H-2and H-1 illustrated their axial 
orientation, and therefore the equatorial orientation of the sulfate group. (Figure 3.7) 
H
NaO3SO
H
H
H
H
CH3
H
H
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Figure 3.7. Key ROESY correlations detected for 18 
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The role of marine steroids as nuclear receptor ligands has been recently 
highlighted
43
 and several sulfated marine steroids have been identified as a new class 
of the pregnane X receptor (PXR) agonists.
51,52
 Based on this background, we have 
investigated a possible role of phallusiasterols A (15), B (16) and C (18) in regulating 
the PXR activity. A transactivation assay on HepG2 cells, a human hepatocarcinoma 
cell line, has been performed, as described in the Experimental Part. As shown in 
Figure 3.8A, only compound 15 acted as PXR agonist at concentration of 10 M; its 
activity was comparable to that of rifaximin, a well characterized ligand for the 
human PXR. As shown in Figure 3.8B, all compounds 15, 16 and 18 failed to reverse 
the induction of luciferase activity caused by rifaximin, indicating that they were not 
PXR antagonists. Similar results have been obtained by analyzing the effect exerted 
by 15, 16 and 18 in terms of regulation of PXR mediated induction of two PXR 
target genes, CYP3A4 (Figure 3.8C) and MDR1 (Figure 3.9D), in the same cell 
line. Compound 15 effectively stimulated the expression of both target genes, 
whereas 16 and 18 failed to induce them. These results have an important implication 
in terms of structure-activity relationship, because they highlight a crucial role in the 
ligand-receptor binding of phallusiasterols of the configuration at C-6. 
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Figure 3.8 (A, B, C, D) Luciferase reporter assay.  
HepG2 cells were transiently transfected with pSG5-PXR, pSG5-RXR, pCMV-βgalactosidase and 
p(CYP3A4)-TK-Luc vectors and then stimulated with (A) 10 μM rifaximin, phallusiasterol A (15) or 
phallusiasterol B (16) or phallusiasterol C (18) for 18 h, or (B) 10 μM rifaximin alone or in 
combination with 50 μM of compounds 15, 16 or 18. Relative Luciferase Units were normalized with 
β-galactosidase Units (RLU/βgal). (C, D) Real-Time PCR analysis of CYP3A4 and MDR1 expression 
in HepG2 cells primed with 10 μM rifaximin, compounds 15, 16 or 18 for 18 h. Values were 
normalized relative to GAPDH mRNA and expressed relative to those of not treated cells, which were 
arbitrarily set to 1. All experiments were performed in triplicate. NT, not treated cells. R, Rifaximin. * 
P < 0.05 versus NT cells. Data are mean ± SE. 
 
We then analyzed by means of molecular docking calculations the interactions of 
phallusiasterol A with hPXR. The calculations were run by Autodock4.2 software.
53
 
The hPXR presents a large ligand binding cavity, allowing the accommodation of 
both small and large ligands and the number of chemicals has grown rapidly, 
52 
 
including many drugs in use such as statins, antibiotic rifampicin and its derivative 
rifaxim, antihypertensive drugs nifedipine, as well as pesticides, environmental 
toxicant, plasticizers. 
In a previous work
51
the possible interactions of solomonsterols A and B with hPXR 
has been reported. In this model, the 2-O and 3-O sulfate groups exert hydrogen 
bonds with His407 and Ser247, respectively. In this study three different x-ray 
structures of the PXR LBD (pdb codes: 3hvl, 1nrl and 1m13) have been used. As 
shown in Figure 5, the OH at C-6 and the 5-O sulphate groups form hydrogen bonds 
with NH of His407 and OH of Ser247, respectively. The steroidal scaffold engages 
Van der Waals interactions with hydrophobic residues of LBD, such as Leu209, 
Met243 and Phe251, and the flexible side chain is settled in a hydrophobic pocket 
establishing several favourable contacts with Met250, Phe288, Trp299 and Tyr306 
(Figure 3.9). Noteworthy, in this pose, the phallusiasterol A is oriented to form 
further hydrophobic interactions with Phe420 and Met425. These last residues are on 
a flexible -helix (AF-2 helix) in the activation function 2-region (AF-2). This part 
of receptor is responsible for binding of the co-activator or co-repressor peptides. In 
conclusion the present docking analysis revealed that phallusiasterol A fitted well in 
the LBD of PXR and could be stabilized PXR in agonist conformation with 
consequent conformational change and co-activator recruitment. 
 
Figure 3.9. Binding mode of phallusiasterol A (15) (cyan sticks), predicted by 
docking calculations in the PXR LBD (PBD code 3HVL). PXR is shown as 
green cartoon, AF-2 helix is coloured in violet. Amino acids involved in ligand 
binding are shown as green and violet sticks. All hydrogen are omitted for 
clarity. 
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3.1.4. Phosphoeleganin, a new cytotoxic phosphopolyketide from the 
ascidian Sidnyum elegans 
Polyketides represent a large family of complex natural products built from simple 
carboxylic acid residues; they are produced primarily by microorganisms and find 
wide ranging applications as pharmaceuticals.
54
 In the marine environment, they 
have been frequently isolated from invertebrates-associated bacteria and/or fungi.
55,56
 
Most marine natural polyketides possess polyhydroxy and polyoxy substituents in 
their structures, but the phospate group is a less recurring functionality. In the course 
of our search for cytotoxic compounds from Mediterranean ascidians, we have 
investigated the ascidian Sidnyum elegans (Giard, 1872) collected in Sardinia; this 
study resulted in the isolation of a potent cytotoxic phosphate-containing linear 
polyketide, named phosphoeleganin (19) whose isolation, structure determination, 
partial absolute stereochemistry assignment, and biological activities are reported 
herein (Figure 3.10). 
 
Figure 3.10 Chemical structure of phosphoeleganin (19) and its semisynthetic 
derivatives 20 and 21 
The methanol and chloroform extracts of specimens of Sidnyum elegans (Giard, 
1872) collected in Sardinia were combined and concentrated; the resulting aqueous 
residue was partitioned between n-butanol and H2O. Medium pressure 
chromatography (MLPC) over C-18 column of the n-butanol soluble material, 
followed by repeated RP-18 HPLC separation and purification steps, yielded 
phosphoeleganin (19) in the pure state. 
The high resolution ESI mass spectrum of 19 (negative ion mode) displayed a 
pseudomolecolar ion at m/z 668.3832 corresponding to [M-H]
-
. These MS data and 
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the information provided by 
13
C NMR spectrum, which contained 32 carbon 
resonances, allowed the molecular formula C32H63NO11P (calculated value: 
668.4049) to be established for compound 19. The 
13
C-NMR spectrum (CD3OD) 
revealed the presence of two carbonyl signals (176.6 and  172.0), which 
accounted for the only two unsaturation degrees indicated by the suggested 
molecular formula.  
Analysis of the 
1
H-NMR spectrum (CD3OD) and HSQC data revealed the presence 
of five oxymethines [H 3.38,C 76.3 (2H, H-11 and 12); H 3.54, C 72.9, (H-8); H 
3.70, C 74.7 (H-15); H 4.19, C 82.8 (H-16)], an aliphatic methyl at  0.90 (t, J = 
7.3 Hz, Me-30), a deshielded methylene signal resonating as a singlet at 3.92 (C 
41.8, 2H-2') , and an aliphatic methylene at  2.25 (t, J = 7.6 Hz, 2H-2). Several 
unresolved methylene signals (1.29-1.36), attributable to the protons of a long 
unbranched carbon chain, were also present. When the proton spectrum of 19 was 
recorded in DMSO-d6, an additional signals at δ 8.05 (bs, NH) appeared, which did 
not display any correlations in the HSQC spectrum; on the other hand, the COSY 
spectrum (DMSO-d6) evidenced this proton to be coupled to a methilene doublet at δ 
3.70 (J=5.8 Hz, 2H-2') which replaced the methilene singlet at  3.92 present in the 
spectrum recorded in CD3OD. Both the signals at δ 8.05 and 3.92 in the HMBC 
spectrum (DMSO-d6) were correlated to the carbonyls at  170.8 (C-1') and 172.0 
(C-1), this latter carbon being coupled to the C2 methilene protons resonating at  
2.10. Thus, the presence of a glycine residue linked trough the amide linkage at one 
end of the long chain of 19 was assumed. According to the remaining features of the 
NMR spectra and MS data, the presence of four secondary alcohol and of a 
phosphate groups in the molecule was supposed. 
The latter hypothesis was verified by the use of 
31
P-NMR spectroscopy. A single 
resonance at  0.90 ppm was present in the 31P NMR spectrum of 19; furthermore, a 
1
H-
31
P-HMBC cross peak was observed from this signal and the oxymethine proton 
at  4.19 (3JH,P=8.2, H-16). Attachment of a phosphate group at C-16 was also 
deduced from the splitting of this carbon resonance ( 82.5) by 2JC,P=6.2 Hz in the 
13
C NMR spectrum (Table 3.6).  
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Table 3.6. 
1
H (700 MHz) and 
13
C (125 MHz) NMR data for phosphoeleganin in CD3OD and DMSO. 
Phosphoeleganin A in CD3OD Phosphoeleganin A in DMSO 
Pos. C
a H (mult, J in Hz)
a C
a H (mult, J in Hz)
a 
1 176.9 - 172.0 - 
2 36.7 2.25 (t, 7.5) 34.4 2.10 (t, 7.5) 
3 26.5 1.64
b 24.5 1.48 
4 29.9 1.36
 b 28.0 1.22 
5 26.4 1.34 
b 24.5 1.20 b 
6 26.4 1.34 
b 24.5 1.20 b 
7 38.4 
1.46 b 
1.41 b 
36.3 
1.33 
1.27 
8 72.9 3.54 (m, 3.9, 3.9, 8.1) 69.5 3.34 
9 34.9 
1.72 b 
1.37 b 
33.2 
1.56 b 
1.22 b 
10 29.7 
1.81 b 
1.37  b 
28.3 
1.64 
1.20 
11 76.3 3.38
 b 73.6 3.15 
12 76.3 3.39
 b 73.6 3.15 
13 29.8 
1.89  
1.37 b 
28.6 
1.76 
1.14 
14 29.7 
1.83 b 
1.44 b 
27.5 
1.60 
1.22 
15 74.7 3.71 (dt,3.7, 3.7, 9.2) 72.6 3.37 b 
16 82.8 4.18 (m, 3.7, 3.7, 8.3) 77.6 4.01 (m) 
17 31.6 
1.69 b 
1.61 b 
28.6 
1.45 b 
1.23 b 
18 26.0 
1.54 b 
1.40 b 
24.5 
1.34 b 
1.22 b 
19/26 30.0 1.31
 b 28.2 1.20 
27 30.2 1.29
 b 30.7 1.22 b 
28 33.1 1.29
 b 30.8 1.22 b 
29 23.5 1.30
 b 21.5 1.28 b 
30 14.4 0.90 (t,7.0) 13.3 0.85 (t,7.0) 
1’ 172.0 - 170.8 - 
2’ 41.8 3.92 (s) 40.0 3.70 (d, 5.8) 
NH - . . 8.1 
 
56 
 
The whole of the 2D NMR data (COSY, TOCSY, HSQC, HMBC, and HSQC-
TOCSY) allowed us to distribute these functionalities into three partial segments (A-
C, Figure 3.11) but the severe overlapping of the remaining methylene resonances in 
the NMR spectra prevented the gross linear skeleton of 19 to be delineated from 
spectroscopic analysis. 
OH
OH
OR2OH
OH
HN
O
COR1
2
8 12
15
16
30
A
B
C
segment
HMBC (H tro C)  
Figure 3.11. Segments A-C deduced from COSY, TOCSY, HSQC, HMBC, and 
HSQC-TOCSY experiments, and selected HMBC correlation 
To determine the number of methilene units separating segments A and B and 
segments B and C, respectively, and, thus, to complete the planar structure 
assignment of phosphoeleganin (19), the natural metabolite was degraded using 
HIO4 and then reduced by NaBH4 to give the fragmentation products 22 and 23 
(Figure 3.12) corresponding to the C1-C11 and C12-C30 portions of the molecule. 
Chemical characterization and, above all, ESIMS analysis of both compounds 22 and 
23 (see experimental section) allowed us to complete the assignment of the planar 
structure of the parent compound 19. 
 
Figure 3.12. Periodate degradation reaction scheme 
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The effects of phosphoeleganin on the growth and viability of tumor and non-tumor 
cell lines have been investigated. Phosphoeleganin (19) showed significant 
cytotoxicity against different cell lines in vitro. Preliminary pharmacological studies 
showed that phospoeleganin exhibited a significant and concentration-dependent 
cytotoxic activity toward the human epithelial cells (HaCaT cells), prostate cancer 
cells (DU145) and cells of neuroblastoma (N2a-APP695). To identify the biological 
target responsible of the pharmacological activity of phospoeleganin, its ability to 
inhibit a number of kinases and phosphatase has been evaluated. In collaboration 
with ManRos therapeutics, the phosphoeleganin has been tested on a panel of protein 
kinases relevant to human disease. No correlations have been observed between the 
cytotoxic activity and the inhibition kinases (Table 3.7). 
Whereas, studies aimed to explore the drug target evidenced its inhibitory effect on 
protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 7.25 ± 1.55 mg / mL. 
Interestingly, the preliminary cytotoxicity screening performed on the degradation 
products 22 and 23 revealed that the fragments were both less active or even inactive 
with respect to the original molecule. This suggested that both portions of 
phosphoeleganin  molecule play an important role for the cytotoxic activity. Further 
studies on the effects of these derivatives as phosphatase modulators are currently in 
progress. 
 
Table 3.7. Effects of phosphoeleganin (19) and its derivatives 22 and 23 on protein kinases. 
Compound CDK5/p25 CDK9/cyclinT CK1 CLK1 DYRK1A GSK3 
19 110 107 90 104 98 83 
22 86 91 90 111 92 103 
23 96 90 111 110 114 73 
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3.1.5. Investigation of the Mediterranean sponge Axinella polypoides: 
isolation of a new cyclonucleoside and a new betaine 
Diverse natural products found within sponges mediate many of their ecological 
interactions, including defense against predators and fouling organisms. Marine 
sponges of genus Axinella are an interesting target for chemo-ecological 
investigations. They are a well-known source of pyrrole-imidazole alkaloids (PIAs), 
which have been found only in the marine environment to date. Historically, this 
family of alkaloids has attracted the attention of natural product chemists because of 
their structural complexity and pharmacological activity; their role in chemically 
mediated interactions of Caribbean sponges has also been proven.
57,58
 In addition, the 
systematic recurrence of PIAs in Axinellidae sponges, as well as in Agelasidae, 
allowed for speculation as to their taxon-specificity and consideration of these 
secondary metabolites as chemical markers for phylogenetically related sponges.
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However, the setting up of a chemical “fingerprint” of a sponge, collected from 
different ecosystems, requires exhaustive chemical studies. An illustrative example is 
the sponge Axinella polypoides (Schmidt 1862), widely distributed in the rock reefs 
of the Mediterranean Sea. Early studies are reported in literature on the chemistry of 
this sponge, mainly concerning its steroid and lectin content;
60-64
 actually, recent re-
examinations of samples of A. polypoides, coming from different Mediterranean 
areas, demonstrated that the sponge has an efficient biosynthetic potential, revealing 
a great variety and abundance of secondary metabolites, some of them being new 
molecules (Figure 3.13). In detail, two new modified amino acids, 
axiphenylalaninium (24) and axityrosinium (25), were found in specimens of the 
sponge collected off Marseille city
65
 along with the known metabolites C
2
-α-D-
mannopyranolsyl-L-tryptophan (29),
65–68
 palythine (27),
65,69,70
 N
3,5′-cycloxanthosine 
(30), 
65,67,71
 and taurine;
65,72
 no data was reported on the presence of PIAs in the 
sponge. Successively, during our ongoing search for new bioactive alkaloids from 
Axinellidae sponges, my research group isolated compounds 24 and 25 in specimens 
of A. polypoides collected along Corsican coasts, together with a new betaine, 
polyaxibetaine (26).
73
 
59 
 
 
Figure 3.13. Secondary metabolites isolated from A. polypoides. 
 
In the present PhD thesis, I describe the results obtained from a further and more 
exhaustive exploration into the metabolic content of a larger sample of A. polypoides, 
which resulted in the isolation of a new pyridinium derivative, compound 28, and the 
new cyclonucleoside 31. All the previously reported secondary metabolites from the 
sponge were re-isolated, except for palythine (27). We did not find any member of 
the PIAs family in the sponge extract but, interestingly, it was shown to contain the 
already known cyclodipeptides 32 (verpacamide A) and 33. The cyclo(L-Arg-D-Pro) 
dipeptide 33 was first isolated from a marine bacterium, Pseudomonas sp. IZ208;
74 
the relevant cyclo(L-Arg-L-Pro) stereoisomer, verpacamide A (32), was first reported 
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as a natural metabolite of the sponge Axinella vaceleti along with the analogues 
verpacamides B–D and these metabolites were considered as possible precursors of 
PIAs. 
Specimens of A. polypoides were collected in the bay of Calvi (Corsica, France), 
they were immediately frozen after collection, and kept at −20 °C until extraction. 
For the extraction, fresh thawed tissues of the sponge were homogenized and 
exhaustively extracted at room temperature with MeOH and CHCl3 successively. 
The extracts were combined and concentrated; the resulting aqueous suspension was 
then partitioned between butanol and H2O. Both organic and aqueous layers were 
fractionated by MPLC over a reversed-phase C-18 column and by DCCC, 
respectively. All the fractions thus obtained were subjected to a combined 
NMR/ESIMS-based monitoring for the rapid identification of PIAs, also exploiting, 
as reference compounds, the copious chemical library of these alkaloids available in 
our laboratories. None of the already described PIAs was detected; fractions of 
interest were separated by repeated HPLC, resulting in the isolation of pure 
compounds 24–26 and 28–33. Taurine, as well as compounds 24–26, 29, 30, 32, and 
33 were readily identified by comparison of their spectroscopic data with those 
reported in literature,
65–73 
while the structures of the new compounds 28 and 31 were 
established as follows. 
HRESI mass spectrum (positive ions) of 28 revealed two pseudomolecular ion peaks 
at m/z 210.1130 and 232.0950, corresponding to [M + H]
+
 (calculated value: 
210.1125), and [M + Na]
+
 (calculated value: 232.0944), respectively. The molecular 
formula C11H15NO3 was thus established for 28, indicating five unsaturation degrees. 
1
H-NMR spectrum of 28 (CD3OD), interpreted on the basis of 2D experiments 
(HSQC, COSY) contained a set of aromatic signals, each integrating for one proton; 
the chemical shift and coupling constants values of these signals [δ 9.10 (bs, δC = 
148.7, H-2); 8.84 (bd, J = 8.2 Hz, δC = 146.3, H-4); 8.19 (d, J = 8.2 Hz, δC = 126.6, 
H-5)] were strongly indicative of a 1,2,5-trisubstituted pyridinium ring. Further 
proton resonances were a deshielded methine at δ 5.13 (dd, J = 9.0, 3.3 Hz, δC = 
69.3, H-1′), two AB methilene systems at δ 1.72/1.81 (δC = 38.9, 2H-2′) and 
1.54/1.63 (δC = 19.9, 2H-3′), as well as a methyl resonating as a triplet at δ 1.00 (J = 
7.5 Hz, δC = 14.0, 3H-4′), which were arranged in a single spin system on the basis of 
COSY connectivities. The signal at δ 5.13 was correlated in the HSQC spectrum 
61 
 
with a signal at δ 69.3 attributable to an oxygen bearing carbon, thus evidencing a 1-
hydroxybutyl unit.  
An N-methyl signal δ 4.38 (δC = 46.1) was also present in the proton spectrum of 28; 
it was correlated in the ROESY spectrum (CD3OD) with the aromatic proton singlet 
at δ 9.10 (H-2) and with the oxymethine proton at δ 5.13 (H-1′). This latter 
information, according to the coupling constants pattern of the aromatic signals, 
provided convincing evidence for an N-methyl-2,5-disubstituted pyridinium ring and 
indicated that the 1-hydroxybutyl unit must be linked at one of the N-flanking 
carbons. Diagnostic C–H long range couplings, evidenced by HMBC map (CD3OD, 
see Table 1), substantiated the proposed structural features and allowed to identify 
the third substituent, obviously liked at C-3.  
Table 3.8. NMR data (CD3OD) of compound 28. 
Pos δH (mult., J in Hz) δC HMBC 
1-NMe 4.38 (s) 46.1 2, 6 
2 9.10 (bs) 148.7 1-NMe, 4, 6, COO
- 
3 - 137.8 - 
4 8.84 (bd, 8.2) 146.3 2, 6, COO
−Na+ 
5 8.19 (d, 8.2) 126.6 3, 6, 1′ 
6 - 163.0 - 
1′ 5.13 (dd, 3.3, 9.0) 69.3 6, 2′ 
2′ 
1.72 (m) 
1.81(m) 
38.9 6, 1′, 3′, 4′ 
3′ 
1.54 (m) 
1.63 (m) 
19.9 1′, 2′, 4′ 
4′ 1.00 (t, 7.5) 14.0 2′, 3′ 
–COO- - 167.0 - 
 
Particularly, the N-methyl signal at  4.38 was correlated to the carbon at  148.7 (C-
2) and a quaternary carbon at  163.0 (C-6) which, in turn, was coupled to the signal 
at  5.13 (H-1′) and 8.19 (H-5); the latter signal was correlated with the oxymethine 
carbon at  69.3 (C-1′) and the quaternary carbons at  163.0 (C-6) and 137.8 (C-3). 
Moreover, both aromatic signals at  9.10 (H-2) and 8.84 (H-4) were coupled to a 
low-field carbon resonance at  167.0, attributable to a carbonyl; this datum, 
according to the mass data, allowed to locate a carboxylate function at C-3, thus 
accounting for the last unsaturation degree indicated by the molecular formula. 
Therefore, the planar structure of compound 28 was unambiguously defined as 6-(1-
hydroxybutyl)-1-methylpyridinium-3-carboxylate. 
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A pseudomolecular peak was present in the HRESI mass -spectrum (positive ions) of 
31 at m/z 283.0673 [M + H]
+
 (calculated value: 283.0679), thus supporting the 
molecular formula C10H10N4O6. 
1
H-and 
13
C-NMR spectral data of 31 strongly 
resembled those of the known cyclonucleoside 30 (Table 3.9). The proton spectrum 
of 31 (d6-DMSO) contained indeed resonances relevant to a sugar moiety which 
were nearly identical to those of 30, with regard to the number and shape of the 
signals (Table 3.9); the striking difference was confined to the chemical shift value 
of the anomeric proton (H-1′,  5.67 in 31 versus 6.15 in 30). As for the heterocyclic 
moiety, the 
1
H-NMR spectrum of 31 lacked the signal due to the single aromatic 
proton of xanthosine present in that of 30 at  7.79 but a further exchangeable proton 
at 11.2 (NH-7) was present. On the other hand, 13C-NMR spectrum (d6-DMSO), 
interpreted also on the basis of the HSQC experiment, contained a further deshielded 
quaternary carbon resonance at  149.6 instead of the C-8 methine carbon resonating 
at 134.5 in the 13C-NMR spectrum of 30. All these findings indicated the 8-oxo-
N
3
,5-cycloxanthosine structure for compound 31, according to MS data and HMBC 
correlations (Table 3.9).  
 
Table 3.9. NMR data (d6-DMSO) of compounds 30 and 31. 
Position 
30 31 
δC δH (J in Hz) δC δH (J in Hz) HMBC 
a 
1 - - - - - 
2 151.0 - 150.7 - - 
3 - - - - - 
4 140.7 - 136.8 - - 
5 117.8 - 98.8 - - 
6 157.4 - 153.4 - - 
7 - - - - - 
8 134.5 7.79 (s) 149.6 - - 
9 - - - - - 
1′ 92.5 6.15 (s) 91.1 5.67 (s) 4, 8, 2′, 3′, 4′ 
2′ 75.8 3.87 (dd, 5.2, 5.0) 75.0 3.90 (t, 5.3) 1′, 4′ 
3′ 70.1 4.20 (m) 70.7 4.23 (m) 5′ 
4′ 83.7 4.55 (m) 83.6 4.46 (m) - 
5′a 51.3 4.56 (m) 52.3 4.51 (dd, 14.4, 2.4) 2, 4, 3′, 4′ 
5′b 51.3 3.71 (dd, 15.2, 3.2) 52.3 3.72 (dd,14.4, 2.8) 2, 4, 3′, 4′ 
OH-2′ - 5.62 (d, 5.0) - 5.60 (d, 5.3) - 
OH-3′ - 5.62 (bs) - 5.35 (d, 7.1) - 
NH-1 - 11.2 - 11.3 5, 6 
NH-7 - - - 11.2 4, 5, 8 
a
 HMBC correlations are from proton(s) stated to the indicated carbon. 
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While highlighting the uncommon chemodiversity of A. polypoides, these results 
pointed out that the sponge does not elaborate PIAs. This finding is in agreement 
with the results of a recent investigation on the chemical defense of A. polypoides 
and the co-occurring species A. verrrucosa, against microbial fouling and in feeding 
deterrence of a potential predator,
76
 activities which are believed to be mediated by 
PIAs.
57,58
 This study indicated in A. polypoides neither chemical defense against 
microbial fouling nor chemically mediated feeding deterrence activity. In contrast, 
the sympatric sponge A. verrucosa has a chemical defense which, as in many other 
species of the genera Axinella and Agelas, is mediated by its bromopyrrole 
compounds,
77-79
 such as hymenidin, which exhibits multiple defensive roles.
76
 
Recent studies have reported on the phylogenetic status of the genus Axinella,
80
 
which is difficult to define on the basis of its morphological character and includes a 
heterogeneous assemblage of species. A new phylogenetic hypothesis of Axinellidae 
and Axinella, based on two independent molecular markers (18S and 28S rRNA), 
has been proposed. In this taxonomic reconstruction, A. polypoides and A. vaceleti 
belong to a distinct clade (Axinellidae
P
) than Axinella verrucosa; this latter sponge is 
now included in a new clade, named Cymbaxinella
P
, which could be interpreted also 
as a new genus. The new clade Cymbaxinella
P
 constitutes a well supported clade 
sister-group to Agelas
P
, according to the chemotaxonomic hypothesis proposed by 
Braekman et al.
81 
on the basis of the presence of pyrroles. The clades Agelas
P
 and 
Cymbaxinella
P
 constitute a new clade: Agelasida
P
. Our results, thus, provide a 
chemotaxonomic support for the above mentioned molecular analysis, demonstrating 
that A. polypoides does not contain pyrroles, whereas it shares with A. vaceleti the 
presence of diketopiperazine derivatives.  
3.1.6. Conclusions 
In conclusion, the extraction and chemical analysis of different species of sea squirts 
(Aplidium conicum, Ciona edwarsii, Aplidium elegans, Phallusia fumigata and 
Sidnyum elegans) and of the sponge Axinella polypoides led to the isolation of new 
bioactive molecules, which are structurally different. Among these, two new 
meroterpenes, conithiaquinones A and B, and three alkyl sulphates with cytotoxic 
properties. Three sulfated sterols, phallusiasterols A-C, one of them with agonist 
activity on the pregnane X receptor (PXR) in HepG2 cells. The phosphoeleganin, a 
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potent inhibitor of protein tyrosine phosphatase 1B (PTP1B). An analysis of the 
metabolic content of the sponge Axinella polypoides has provided important chemo-
taxonomic information about the organism, in addition, led to the isolation of a new 
betaine and a new cyclonucleoside.  
The structural diversity of the metabolites above reported highlighted that marine 
organisms continue to be rewarding sources of chemodiversity associated to a very 
large array of pharmacological activities. These products provide a rich source of 
chemical diversty that can be used to design and develop new potentially useful 
therapeutic agents. 
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3.2. THE STEREOCHEMISTRY ASSIGNMENT: A HARD 
CHALLENGE IN NATURAL PRODUCTS RESEARCH 
Stereocomplexity often distinguishes the structures of natural products from 
synthetic medicinal drugs, however, many complex natural products are listed in the 
US and other pharmacopeia. Thus, the determination of relative and absolute 
configuration of a natural substance is a key step in the process of its structural 
characterization. Only by knowing the stereochemistry of a molecule can be traced 
back to its three dimensional structure and approach to biological studies, e.g. studies 
of drug-receptor interaction, or chemical, such as the studies related to the total 
synthesis of complex molecules with a good pharmacological activity. Most of the 
natural compounds has one or more chiral centers. Usually, in the configuration 
determination, we start by establishing the relative configuration of chiral centers. 
NMR can be very useful trough the values of chemical shifts (δ), coupling constants 
(J) and NOE effects.  
The chemical shifts of protons are influenced by their chemical around, so the 
protons of two diastereomers have different values. 
The  Karplus‟s equation82 describes the influence of relative arrangements of protons 
in a molecules on the values of coupling constants (JH-H). 
                                                  
3
J= Acosθ2 + Bcosθ + C   
This equation evidences that the values of homonuclear (
3
JH-H) and heteronuclear 
(
3
JC-H) coupling constants are related to the value of the dihedral angle θ between 
atoms. The superscript "3" indicates that a 
1
H atom is coupled to another 
1
H atom 
three bonds away, via H-C-C-H bonds. The magnitude of these couplings are 
generally smallest (0-1,5 Hz) when the torsion angle is close to 90° and largest at 
angles of 0 and 180°. In some cases the axial-axial coupling constant for an 
antiperiplanar 180
o
 H-C-C-H configuration may be more than 9.5 Hz. Indeed for 
rigid cyclohexanes it is around 9-13 Hz, because the dihedral angle is close to 180
o
, 
where the orbitals overlap most efficiently. 
Additional information about relative configuration of stereogenic centers can be 
obtained from the so-called NOE effect (N.O.E.: "Nuclear Overhauser 
Enhancement").
83
 This effect can be observed upon irradiation, during the acquisition 
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of the spectra, on a specific signal. In this way, the  relaxation times of all the protons 
surrounding the irradiated proton (distance < 2.5 A°), even though not belonging to 
the same spin system, are influenced and thus, their height changes. The NOE effect 
establishes a spatial relationship between substituents of fixed molecules, but this 
effect is dependent from the dimensions of the molecule. The ROESY (Rotating-
frame Overhauser SpectroscopY) experiment is a chemical shift homonuclear 
correlation which can detect ROEs (Rotating-frame Overhauser Effect). ROE is 
similar to NOE, being related to dipolar coupling between nuclei, and depending on 
the geometric distance between the nuclei. While NOE is positive for small 
molecules and negative for macromolecules, ROE is always positive. Therefore, the 
ROESY experiment is particularly useful for mid-size molecules, which would show 
a NOE close to zero. Sometimes we couldn‟t assign the stereochemistry of a new 
compound exclusively on the basis of the methods described above, so we had to 
appeal to other techniques, as I will describe in this chapter. 
The following section describes the main stereochemical issues I have dealt with 
during the structure determining of the isolated compounds. They have been 
separately discussed also in order to highlight the diversity of methods and/or 
approach which can be used in stereostructure determination of new molecules, 
although most of them are original strategies adapted to the current problem. 
3.2.1. Absolute configuration of axibetaine through ab initio calculations  
 
Absolute configuration (AC) of compound 28 was established with the help of 
electronic circular dichroism (ECD) spectroscopy assisted by quantum mechanical 
calculations. The application of ab initio time-dependent density functional theory 
(TDDFT) to the calculation of ECD spectra has greatly enhanced the reliability with 
which they can be predicted and, thus, this methodology is being increasingly 
utilized in determining ACs of natural products.
73,84–86 
The experimental ECD 
spectrum of 28 was virtually compared to that predicted by TDDFT calculations for 
one of the two enantiomers. In detail, an initial conformational analysis of the S 
stereoisomer was performed, using the Simulated Annealing procedure (INSIGHT II 
Software Package). The resulting conformers were ranked on the basis of their 
conformational energy values and grouped into families. Twelve minima for S-28 
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were obtained and all conformers were optimized with the software package 
Gaussian 03
87
 by using DFT at the RB3LYP/6-31G(d) level (the conformational 
families of S-28, as well as their resulting relative (∆E) and free (∆G) energies, are 
provided as Supporting Information). For all conformers of S-28, the excitation 
energies, as well as the oscillator and rotatory strengths of the electronic excitation 
were calculated, using the TDDFT methodology at the RB3LYP/6-31G(d,p) level; 
their ECD spectra were then simulated by the overlapping Gaussian function. To 
obtain the final ECD spectrum of each compound, the simulated spectra of the lowest 
energy conformations were averaged, by following the Boltzmann statistic, and were 
UV corrected. The theoretical curve was then compared to the experimental 
spectrum of compound 28, recorded in MeOH. As shown in Figure 3.14, the 
agreement between the simulated and experimental ECD spectra of 28 was very 
satisfactory and, thus, the absolute configuration of 28 was established as S.  
 
 
 
Figure 3.14. Theoretical CD curve (
__
) of S-28 model vs. experimental curve (
__
) of 
compound 28. 
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3.2.2. Ab initio calculations to determine the stereochemistry and the 
regiochemistry of conithiaquinone A  
 
The whole of the NMR data recorded for conithiaquinone A (see section 3.1.1) 
allowed determining its planar structure but, unfortunately, they were not enough to 
unambiguously define the relative position of the sulfur and nitrogen atoms in the 
heterocyclic ring. The regiochemistry of the 1,1-dioxo-1,4-thiazine ring was thus 
clarified by ab initio calculation of NMR shifts, an increasingly popular tool for the 
stereostructure assignment of natural products.
88
 By  using the recently developed 
DP4 NMR prediction method of Smith and Goodman,
89 
the experimental 
13
C and 
1
H 
NMR chemical shifts of conithiaquinone A (1) were compared to those calculated for 
structures A1-A4 (Figure 3.15). Calculations were performed on both epimers at C-9 
for each regioisomer in order to gain further support to the relative stereochemistry 
suggested by NMR data. The DP4 analysis was designed specifically for the situation 
where one set of experimental data is available to which one possible isomeric 
structure out of many must be assigned. It is based on calculated error probabilities 
for scaled computed chemical shifts for each hydrogen and carbon atom, assuming a 
statistical t distribution for these errors. A mathematical algorithm is then used to 
quantify the probability of the correct assignment of each structure.
90
 The calculated 
chemical shifts for structures A1-A4 as well as those observed for conithiaquinone A 
were uploaded to the DP4 method online applet (http://www-jmg.ch.cam.ac.uk/ 
tools/nmr/DP4). DP4 analysis identified structure A3 as the most likely, with a 
probability of 99.9% (the remaining 0.1% probability was assigned to structure A4). 
The computational evidence strongly indicated that A3 or its enantiomer is the true 
structure of conithiaquinone A (Figure 3.15).  
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Figure 3.15 Results of DP4 analysis using both carbon and proton data. 
 
In an effort to resolve this last ambiguity, we employed TDDFT methodology to 
calculate the ECD spectra for the two possible enantiomers of 1 which were then 
compared with the experimental data (MeOH) obtained for 1.
91,92 
Although the 
calculated absorption wavelengths did not exactly fit with the experimental peak 
positions, the general features of ECD spectrum calculated for the 6aR, 9R, 9aR, 10S  
isomer showed a much better match with the experimental data than the inverted 
spectrum calculated for its enantiomer (Figure 3.16). Differences between the 
calculated and experimental spectra presumably resulted from an overestimation of 
the UV absorbance in the calculations or may be due to minor differences between 
calculated and solution conformers.
93,94
 These observations allowed us to propose the 
6aR, 9R, 9aR, 10S absolute configuration for compound 1. The assignment of both 
regiochemistry and absolute configuration of 2 was achieved following the same 
procedure as described for 1 (for details, see the Supporting Information). 
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3.2.3. Determination of phosphoeleganin stereochemistry by NMR and 
microscale derivatization studies  
 
The determination of the absolute configuration of the five stereogenic centers of the 
phosphoeleganin (19) required a series of microscale derivatization reactions and 
spectroscopic analysis of their products. 
In order to investigate the relative configuration of the 11,12 - diol system in the 
phosphoeleganin, the five-membered acetonide (34) was prepared.
95  
To this purpose, 
phosphoeleganin (19)  was treated with 2,2-dimethoxypropane and a catalytic 
amount of Dowex 50W-X8 to give the corresponding 11,12-O-isopropylidene 
derivative. As reported in the literature,
95
 the difference in the chemical shifts of the 
methyl groups in the five membered acetonide is larger for the cis-isomer (Δδ 0.12–
0.14) when compared to the trans-isomer (Δδ 0.01–0.04). The observed Δδ value of 
0.09 ppm between the two methyl groups in the phosphoeleganin acetonide (see 
Experimental) points towards the cis-isomer allowing us to suggest a 11,12-erythro 
relative stereochemistry (Figure 3.17). 
 
 
 
Figure 3.17. Partial 
1
H NMR spectra relevant to trans- and cis- acetonides 
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To assign the absolute stereochemistry at C8 we used the chiral derivatizing reagent 
(CDA) MPA and the periodate degradation product 22. At first the compound 22 was 
subjected to acidic methanolysis with 1 M HCl and then derivatizated with (R)-(−)-
and S-(+)-methoxyphenylacetic acid (MPA) using 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide (EDC)
96-98
 (Figure 3.18). 
 
 
Figure 3.18. Synthesis of (R)-MPA (35) and (S)-MPA (36) esters. 
 
The MPA may be a more reliable CDA because only two major ester conformers are 
present leading to  values of greater magnitude. The model for MPA places the 
methoxy group, ester carbonyl, and carbinol proton in the same plane. L1 is shielded 
in the (R)-MPA ester and L2 is unaffected, and the opposite effects are observed with 
the (S)-MPA esters. The phenyl group lies on the opposite side of the CO plane with 
respect to the MTPA esters. For this reason,  values are defined by a different 
formula (=R-S). The choice of using the MPA derivate, instead of the more 
traditional MTPA derivate, was due to the larger anisotropic chemical shift changes 
observed for secondary alcohols using this chiral agent (Figure 3.19). The MPA 
derivative was chosen due to the larger anisotropic chemical shift changes observed 
in secondary alcohols relative to the more traditional MTPA derivative.  
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Figure 3.19. Conformers for (R)-MPA (35) and (S)-MPA (36) esters. 
 
Thus, the analysis of the ΔδRS (δR − δS) values in the 
1
H spectrum of two esters (35 
and 36) of phosphoeleganin allowed us to assign the configuration at C-8 as 8S. 
(Figure 3.20)  
 
Figure 3.20. ΔδRS (δR − δS) values in the 
1
H spectrum of two esters (35 and 36). 
 
The absolute stereochemistry at C15-C16 was determined through double 
derivatization method of 23 with a chiral auxiliary reagent developed by Riguera,
99
 
which is based on the use of polystyrene-bound chiral derivatizing agents (CDA-
resins) speciﬁcally designed to achieve the high-yield formation of the covalent 
linkages (amide or ester bonds) between the substrate and the chiral auxiliary within 
the NMR tube, without the need for other manipulations, on a microscale level and in 
73 
 
a short time. We first removed the phosphate group from the molecule through an 
alkaline phosphatase and then we used Riguera‟s approach. (Figure 3.21) 
 
 
 
 
 
Figure 3.21. Determination of the absolute stereochemistry at C15-C16. 
 
A consistent distribution of positive and negative  values around C15-C16 allowed 
the assignment of S-configuration and R-configuration at C15-C16 respectively. 
(Figure 3.21) 
In conclusion, the configuration analysis performed on phsphoeleganin allowed us to 
determine the stereostructure of the molecule to be one of the alternative structures 
19a and 19b (Figure 3.22) 
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Figure 3.22. Alternative structures 19a and 19b of phosphoeleganin (19) 
 
 
3.2.4 Conclusions 
Although modern developments in spectroscopic techniques enable the identification 
of the structures of microgram samples of complex small molecules, there is no 
general solution to the absolute configuration (AC) of a compound, those even 
containing only one or a few stereocenters; absolute stereostructures are solved on a 
case-by-case basis. The above examples demonstrate the execution of complete 
solutions to stereocomplex marine natural products using modern NMR/CD 
instrumentation, often augmented by synthesis, requiring only a few milligrams or 
even micrograms of a natural product. Natural products are a significant and 
important source for new small molecule drug leads. The deficit in new drugs for 
treatments for many disease conditions, make it likely that natural products will 
continue to provide leads to supply pipelines of drug discovery. The foregoing 
examples illustrate the power of integrated structure analysis by spectroscopic 
techniques and chemical methods augmented by rational asymmetric synthesis. 
Reliable solutions to their structures are likely to be refined as current needs remain 
and new rare chemical entities are discovered. 
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3.3 NATURAL QUINONES AS LEAD COMPOUNDS IN DRUG 
DISCOVERY PROCESSES. 
 
Naturally occurring prenylated 1,4-benzoquinones and hydroquinones are commonly 
found in a variety of organisms and play important roles in several metabolic 
processes, such as photosynthesis and electron transport.
100,101
 Examples of these 
compounds have been isolated from marine sources, mostly from tunicates belonging 
to the order of Aplousobranchiata (family Polyclinidae), such as ascidians of the 
genus Aplidium. They show a wide array of different structures, originated by intra- 
and inter-molecular cyclizations and/or rearrangements of the original terpene 
hydroquinone/quinone skeleton, thus giving macrocyclic or polycyclic structures; 
they are often linked to amino acids or taurine residues.
102-113
 Recently, the ascidian 
Aplidium conicum has been investigated and this study yielded a large group of new 
prenylated quinones named conicaquinones,
114
 thiaplidiaquinones ,
115
 and 
aplidinones (37–39).116 (Figure 3.23) 
 
 
 
 
 
 
 
 
 
Figure 3.23. Structures of aplidinones A-C (37-39). 
 
These compounds are structurally quite different, but they share the presence of an 
unusual 1,1-dioxo-1,4-thiazine ring fused to a quinone moiety. As for the 
aplidinones, the whole of the NMR data were not enough to unambiguously define 
the structure of the heterocyclic ring; an uncertainty still remained about the relative 
position of the sulfur and the nitrogen position in the ring. The reported 
regiochemistry was assigned as suggested for aplidinone A (37) by comparison of its 
76 
 
experimental 
13
C NMR chemical shifts with those predicted by GIAO
117
 shielding 
calculations for regioisomers models A1 (40) and A2 (41). (Figure 3.24)  
 
 
 
Figure 3.24. Synthetic analogues of aplidinone A 
 
Successively, synthetic studies have been performed in order to validate the 
structural assignment of aplidinone A made by theoretical means. A simple and 
versatile synthetic strategy has been designed in order to produce the model 
compounds A1 and A2 (Figure 3.24) and to confirm the proposed regiochemistry. 
Heterocyclic systems like aplidinone A, having a 1,1-dioxo-1,4-thiazinic ring 
condensed with a benzoquinone ring, are not common in literature. This kind of 
compounds has been synthesized for the first time in 1988
118
 by condensation of 
hypotaurine with naphthoquinone using the known conjugate addition reaction of 
amines and sulfinic acids with naphthoquinones
119
 to give substituted 
naphthoquinones. Later, Harada et al. worked out the synthesis of adociaquinones A 
and B using the same protocol.
120
 Although this route has the disadvantage of being 
not regioselective (Figure 3.25), we recognized it as a simple and versatile way to 
synthesize in relatively few steps aplidinone A derivatives, starting from an 
appropriate benzoquinone derivative. 
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Figure 3.25. General synthetic protocol. 
 
In addition, the designed procedure has been adapted to prepare further quinone 
analogues, 42-45. (Figure 3.24) Both aplidinone A and its synthetic analogues were 
shown to possess interesting cytotoxic effects; SAR studies revealed that 44 is the 
most potent cytotoxic and pro-apoptotic agent against several tumor cell lines and 
also inhibits TNFainduced NF-jB activation in a human leukemia T cell line. 
This study well exemplifies the potential of a natural product to qualify as lead 
structure for medicinal chemistry campaigns, affording simplified analogues with 
better bioactivity and easier to synthesize. 
 
3.3.1 Synthesis of structurally simplified analogues of aplidinone B 
On the basis of the results obtained for the aplidinone A and its analogues, we 
decided to synthesise some analogues of another meroterpene isolated from the 
ascidian Aplidium conicum, the aplidinone B (38), both to fully confirm the 
regiochemistry of its heterocyclic structure, and to investigate its biological activity. 
In addition, this study also helped us to understand if this activity depended on the 
size of the hydrocarbon substituent as noted in the past among the aplidinone A 
analogous. 
121 
In collaboration with the University of Rome “La Sapienza” we slightly modified the 
synthetic path designed for the synthesis of aplidinone A analogues. Also in this 
case, the key step of the synthesis was the reaction between hypotaurine and a 
suitable benzoquinone to give the dioxothiazine ring. 
The 2,5-dimethoxy-aniline (46) has been chosen as starting compound, because it 
already contains the amino group and it is a cheap product. The first performed 
synthetic step (Scheme 3.1) was the transformation of the amino group into an amide 
function by treating (46) with pivaloyl chloride. We chose this chloride because the 
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lack of alfa-hydrogens ensured a better stability during the next reactions. The amide 
(47) was obtained with a very good yield.  
 
Scheme 3.1 
 
 
The reaction of (47) with n-BuLi and DMF afforded selectively the benzaldehyde 
(48) because the carbon between the ones linked to amide and methoxy group was 
the most reactive even if the direct alkylation by BuLi and alkyl bromides, analogous 
reaction to that performed in the aplidinone A synthesis,
121
 gave the alkylation 
product only in little quantity. The obtaining of the compound (48) was supported by 
the presence in its 
1
H-NMR spectrum of the two just ortho-coupled aromatic protons 
signals (two doublets, 6.74 and 7.12 ppm respectively, J=9.3Hz) as well as that of the 
aldehyde function (singlet, 1H, 10.38 ppm).(Scheme 3.2) 
 
Scheme 3.2 
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The aldehyde (48) is a key intermediate for the obtaining of aplidinone B analogous 
with hydrocarbon chains having different length; in fact the Grignard reaction 
between (48) and any alkylmagnesium iodide always afforded the corresponding 
benzylic alcohol (49) with a very good yield. (Scheme 3.3). The 
1
HNMR spectrum 
of 49 showed the characteristic signal of the benzylic methyne proton (multiplet 
centered at 4.96 ppm) coupled both with the vicinal methylene aliphatic protons and 
also with the geminal alcoholic group (doublet, 3.60 ppm). 
 
Scheme 3.3 
 
 
The subsequent easy hydrogenolysis of (49) by using Pd-C (10%) as catalyst gave 
the compound (50) with the desired hydrocarbon chain, whose 
1
HNMR spectrum 
shows the signals of the two aromatic protons (two very close doublets between 6.67 
and 6.73 ppm), those of the aliphatic protons of the chain (benzylic protons signals at 
2.58ppm) and the singlet (9 protons, 1.34ppm) of the pivaloyl residue. (Scheme 3.4) 
 
Scheme 3.4 
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The quinone (51) was obtained by the oxidation of (50) with a large excess of CAN 
(molar ratio 8:1). The steps from (49) to (51) do not require any intermediate 
purification, so simplifying the carrying out of the whole synthesis.(Scheme 3.5) 
 
Scheme 3.5 
 
 
The quinone (51) was treated with hypotaurine as reported in literature.
119
 Also in 
this reaction the two regioisomers (52 and 53) form in different amount. The 
1
HNMR 
spectra of the two regioisomers are very similar, the main difference lying in the 
chemical shift value of the signal of the more deshielded heterocycle methylene 
group, 4.07ppm in the spectrum of natural regioisomer and 3.31ppm in the spectrum 
of non natural one. The values here reported are relative to the aplidinone B 
analogues with ethylic lateral chain, those of other analogous are very close to these. 
(Scheme 3.6) 
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Scheme 3.6 
 
 
A large number of quinones, both synthetic and naturally occurring, have been 
screened for their antitumor activity; particularly, it has been shown that they lead to 
oxidative stress by means of an increase of oxygen reactive species (ROS) and the 
depletion of reduced glutathione (GSH) amount
122
 and this action has been related to 
the beginning of apoptosis.
123,124
 
In previously works it has shown that
 
thiaplidiaquinones 3 and 4 induce generation of 
ROS and apoptosis in the Jurkat cell line.16 On this cell line we have now 
investigated the cytotoxic activity of aplidinone A (37), as well as that of its synthetic 
analogues 40-45. Aplidinone A induced cytotoxicity with an IC50 about 45 M; the 
cytotoxic activity was enhanced with the modifications introduced in 44 (IC50 ~ 20 
M) and decreased in 40–42, 43, and 45  
On the basis of the results reported, the analogues of aplidinone A and B have been 
tested on human microvascular endothelial cells (HMEC).Compound 52a resulted 
the most cytotoxic of the series with an IC50 about 1.50 M. 
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3.3.2. Potential of quinones as antimalarial agents 
There is an urgent need to discover new antimalarials, due to the spread of 
chloroquine resistance and the limited number of available drugs. A number of 
quinones have been shown to be effective antimalarials. In addition some have been 
shown to have oxidant effects on glucose-6-phosphate dehydrogenase-deficient red 
cells. The mitochondrial respiratory chain is an effective target for antimicrobial 
agents directed against P. falciparum. Differences between respiratory chain 
enzymes of mammals and pathogenic organisms have been exploited to develop 
compounds used for drug therapy such as atovaquone. Atovaquone is a 
hydroxynapthoquinone active against different parasitic diseases including malaria 
and toxoplasmosis, Atovaquone inhibits the activity of the bc1 complex activity, a 
central enzyme of the respiratory chain .  
Antiplasmodial activity of quinone structures of marine origin has been reported. 
Examples are xestoquinone and halenaquinone, their derivative orlaquinone, and 
ketoadociaquinones, isolated from Xestospongia sponges, and thiaplakortones, 
isolated from Plakortis lita. It has been also evidenced that the presence of a 
dioxothiazine moiety enhances the antiplasmodial activity. Based on these reports, 
synthetic derivatives of the natural aplidinones A and B, isolated from the 
Mediterranean tunicate Aplidium conicum, have been tested in vitro against D10 
(chloroquine-sensitive) and W2 (chloroquine-resistant) strains of Plasmodium 
falciparum, in collaboration with Dipartimento di Sanità pubblica, Microbiologia e 
Virologia of University of Milan. 
Using the pLDH assay, the synthetic analogues of aplidinones A and B (Figure 3.26) 
were assayed against D10, CQ-S strain and W2, CQ-R strain of P. falciparum.  
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Figure 3.26. Structures of synthetic analogues of aplidinones A and B 
 
The synthetic derivatives have shown a significant pharmacological activity and 
many structural requirements, critical for their activity, have been evidenced (Table 
3.10).  
 
Table 3.10. In vitro antiplasmodial activity compounds 1-12 against the cloroquine-sensitive 
(D10) and the cloroquine-resistant (W2) strains of P. falciparum  and cytoxicity against 
human microvascular endothelial (HMEC-1) cells. 
 
Compound D10 
IC50 (M)  
W2 
IC50 (M)  
HMEC-1 
IC50 (M)  
40 >28  >28  >100  
41 2,4  2,4  110,29  
42 >28  >28  >100  
44 0,8  0,8  5,52  
43 >28  >28  >100  
45 1,7  1,3  4,41  
52a 0.39  0,58  1,60  
53a 6,15  6,31  102,72  
52b 1,56  2,70  0,90  
53b 6,93  7,87  41,45  
52c 0,56  1,06  0,44  
53c >11  >11  6,87  
CQ 0.04  0.54  >100  
 
In particular, for methoxy derivatives it has been evidenced that: 
• Compounds 41, 44 and 45 show a very good antiplasmodial activity which do 
not depend on the cloroquine sensitivity of the strain tested. the compound 42 is 
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completely inactive, indicating that the regiochemistry of the dioxothiazine ring 
showed for 41, 44, and 45 is critical for the  activity.  
• 44 is the most potent in the series, with a potent antiplasmodial activity (0,8 
M); however, it resulted significantly cytotoxic (5,52 M). 
• The activity depends on the lenght of the side chain; it increased with the 
number of carbon atoms from 41 to 44 and then decreased from 44 to 45.  
• Compound 41 is not cytotoxic (>100 M) though keeping a good 
antiplasmodial activity (2,4 M)  
 
Whereas for the ammido derivatives series it has been evidenced that: 
• Compound 52a was inactive and unstable, thus the ammino-protected 
derivatives were tested. 
• The ammido derivatives were all active, although the activity depends on the 
thiazine ring regiochemistry: compounds 52a, 52b, and 52c, sharing the same 
regiochemistry, resulted more active than the relevant compound in the other series 
of regioisomers. 
• The change in the regiochemistry seems to affect more the ctytotoxicity than 
antiplasmodial activity, especially in the absence of a side chain (52a vs. 53a). 
• The activity depends on the lenght of the side chain; it decreased with the 
number of carbon atoms from 52a/53a (2 C) to 52b/53b (5C) and then increased 
from 52b/53b (5C) to 52c/53c (11C) 
• 52a is the most potent in the series, with a potent antiplasmodial activity(0,39 
M) but it resulted significantly cytotoxic (1.6 M). 
 
The interesting aspect is that this antimalarial activity is due to the interaction 
between the quinone structures and some of the P. falciparum enzyme targets, such 
as protein farnesyl transferase (PFTasi) and Pfnk kinase-1, thus implying a 
mechanism different from that showed by other antimalarial agents. Based on these 
considerations our compounds have been tested on a platform of kinases, but no 
correlation was seen between the observed activitites (both the antiplasmodial effects 
and cytotoxicity) and kinase inhibition (Table 3.11). 
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Table 3.11. .Results from protein kinase assays  
Compound CDK5/p25 CDK9/cyclinT CK1 CLK1 DYRK1A GSK3 
41 102 92 97 88 93 73 
44 105 102 91 107 90 68 
45 105 92 88 108 93 84 
52a 106 84 86 91 93 89 
53a 109 90 83 111 90 79 
52b 97 82 115 101 100 100 
53b 86 80 105 101 108 85 
52c 102 93 92 98 94 110 
53c 125 102 95 111 97 96 
 
 
 
 
3.3.3 Conclusions 
 Interesting conclusions can be drawn by comparing the cytotoxic effects with 
antimalarial ones. Compound 52a is the most active in the series, with a very potent 
antiplasmodial activity but also strongly cytotoxic. Compound 44 is also very potent 
as antiplasmodial agent, also cytotoxic but with a better therapeutic index. 
Compound 41 is very potent as antiplasmodial agent and not cytotoxic (Table 3.10). 
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3.4. FROM THE MACROSCOPIC TO THE MICROSCOPIC 
WORLD: THE HABITAT OF MICROORGANISMS 
 
3.4.1. History of microbial drug discovery 
The chemistry of marine bacteria has received increasing attention over the past 
twenty years. Principal reasons for this interest are their abundance and 
phylogenetical diversity, as well as the capacity of most of them to survive in 
extreme environmental conditions due to the unusual enzymatic and metabolic 
adaptations. In the late 1930‟s, stimulated by the discovery of penicillin by 
Alexander Fleming, terrestrial microorganisms became the focal point for one of the 
most prolific drug discovery efforts ever recognized. The discovery of penicillin and 
later actinomycin led to the “Great Antibiotic Era”, which yielded more than 120 
drugs for the treatment of infectious diseases, cancer, elevated cholesterol, 
immunomodulation and others. From the period from 1950 to 1990 most of the 
pharmaceutical companies invested heavily in microorganism-based drug discovery. 
The intensity of these explorations led to discoveries of new microorganisms from 
virtually all accessible terrestrial environment from arctic, and cold temperate 
regions to tropical environments.
125
 Interestingly, although the world‟s ocean occupy 
more than 70% of the surface of the Earth, this massive resource was never explored. 
Convinced by some that the ocean was a simple repository for terrestrial strains, and 
that cultivation of true marine microbes was difficult if not impossible, this 
component of planet Earth never received serious consideration. However, in 2009 
microorganisms are no longer the focus of most drug industries, even though marine 
researchers are now demonstrating the enormous drug discovery potential of 
microorganisms isolated from this source. Given the growth in this field, it is 
important to emphasize the unambiguous criteria that separate marine 
microorganisms from their terrestrial counterparts. Three such traits that help define 
some of the more distinctly marine microorganisms are their ability to display 
barophily (adaptation to high pressure), halophily (adaptation to high salt 
environments), and chemoautotrophic growth (ability to use CO2 as a carbon source 
and derive energy from chemicals rather than light) properties. One tool that has 
been essential to define distinctions between marine and terrestrial microbes is the 
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use of 16S ribosomal RNA analysis (16S rRNA). Many true marine microorganisms 
from oceanic environments contain previously unobserved 16S signatures; this is 
especially true in the case of invertebrate microbial symbionts, as the phenomenon of 
symbiosis is prevalent in the ocean. Given the aforementioned properties, it remains 
difficult to prove whether a microorganism collected from an oceanic environment is 
truly „marine‟ or whether it is simply a terrestrial strain that has been rinsed into the 
ocean. Over decades of study, one most simply illustrate that microbes are regularly 
found in the ocean and not in terrestrial environments. For example, fungi are 
cosmopolitan organisms that are incredibly adaptive to new environments. Several 
investigators mistakenly label fungi collected from the ocean as “marine fungi”. This 
label is unwarranted until it is demonstrated that a fungal species has an obligate 
requirement for life in the sea. Until more can be learned, a more appropriate label is 
“marine-derived fungi”.126-128 
One very important aspect of these microorganisms is their capacity to produce 
secondary metabolites, but little is known about the origin, diversity, and role that 
secondary metabolites fulfill in their surrounding microenvironments. 
 
3.4.2 Cytotoxic quinazolinone isolated from the fungus penicillium sp 
endogenous with the mangrove Bruguiera gymnorrhiza 
Marine microorganisms, especially marine-derived fungi, are widely recognized as 
emerging sources of secondary metabolites.
129-131
 Mangrove-associated fungi, the 
second largest ecological group of the marine-derived fungi, have been reported to 
produce a wide variety of structurally unique and biologically active compounds.
132
 
In particular, many fungi were recently isolated from the mangrove Bruguiera 
gymnorrhiza. Chemical investigation of these fungi led to the isolation of an already 
known cytotoxic quinazolinone 54. (Figure 3.27)
133
 
 
 
Figure 3.27. Structure of 2-(1-hydroxyethyl)-4(3H)quinazolinone (54). 
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During my PhD I have been involved in an “staff exchange” activity within the 
project IRSES- 7° Framework. During my stage at Institute of Materia Medica 
(SIMM), Shanghai, I started the chemical analysis of a fungal strain Penicillium sp., 
isolated from the Chinese mangrove Bruguiera gymnorrhiza collected from 
Zhanjiang. 
The whole culture of Penicillium sp. was extracted with CH3OH and CHCl3 and then 
partionated between EtOAc and H2O and n-BuOH and H2O. Separation of the 
EtOAc-soluble material (0.6 g) was achieved by gradient silica gel MPLC (ether → 
ethyl acetate → dichloromethane→methanol). Ten fractions were obtained. The 
fraction eluted with EtOAc/ether 1:1 v/v (10,0 mg) was chromatographed by HPLC 
on a SiO2 column (Luna 5x 4.60 mm) eluting with hexane/ EtOAc 4:6 v/v, 
yielding the compound 54 (4.9 mg). (Figure 3.28). 
 
 
Figure 3.28. Isolation procedure of compound 54 
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The analysis of the 1H-NMR spectrum (CD3OD) and  HMBC data allowed us to 
identify the compound 54 as the already known cytotoxic alkaloid 2-(1-
hydroxyethyl)-4(3H)quinazolinone (Table 3.12).
133
  
 
       Table 3.12. NMR data (CD3OD) of compound 54 
Pos. δH (mult., J in Hz) δC HMBC 
2  161.6 
- 
4  164.3  
5  122.2  
6  149.6  
7 7.66 127.5 122.2, 127.8 
8 7.79 135.9 127.2, 149.6 
9 7.49 127.8 122.2, 127.2 
10- 8.18 127.2 135.9, 149.6 
1’ 4.73 68.6 22.4, 161.6 
2’ 1.53 22.4 68.6, 161.6 
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CHAPTER 4 
EXPERIMENTAL. 
 
4.1 Aplidium conicum 
 
Extraction and Isolation Procedures: Specimens of A. conicum were collected in 
November 2007 at Porto Cesareo (Lecce, Italy). They were frozen immediately after 
collection and kept frozen until extraction. A reference specimen is deposited at the 
Dipartimento di Chimica delle Sostanze Naturali, University of Naples. The fresh 
thawed animals (6,7 g of dry weight after extraction) were homogenized and 
extracted twice with methanol and then twice with chloroform (4 x 200 mL). The 
combined extracts were concentrated in vacuo, and then partitioned between H2O 
and EtOAc and, subsequently, between H2O and n-BuOH. Separation of the EtOAc 
soluble material (2,24 g) was achieved by gradient silica gel MPLC (hexane → 
EtOAc → MeOH). The fraction eluted with EtOAc 100% (v/v) was 
chromatographed by HPLC on a SiO2 column (Luna 5 m, 250 x 4.60 mm) eluting 
with EtOAc/hexane 75:25 (v/v), yielding a fraction (4.2 mg) which has been further 
purified by reverse HPLC on a  Luna 3 m PFP 100 Ǻ column, eluting with 
MeOH/H2O 8:2, thus affording conithiaquinones A (1.2 mg) and B (0.7 mg) as pure 
compounds. 
Conithiaquinone A (1): Colorless amorphous solid. []D
25
 = + 3.2 (c=0.11 in 
methanol). 
1
H NMR (700 MHz, CD3OD) and 
13
C NMR (175 MHz, CD3OD): see 
Table 3.1. HRESI-MS (positive ion mode, MeOH): calcd. for C19H25NO6SNa 
[M+Na]
+
 418.1295; found 418.1290. 
1
H NMR (700 MHz, CDCl3):  6.56 (H, br s, 4-
NH), 5.16 (10-H, d, J = 9.1 Hz), 4.06 (3-2H, m), 3.65 (H, br s, OH), 3.29 (2-2H, m), 
3.23 (13-3H, s), 2.04 (8-Hb, m), 1.84 (6a-H,dt, J= 13.6 and 9.1 Hz), 1.68 (7-Hb, m), 
1.60 (9a-H,dd, J= 13.6 and 9.1 Hz), 1.49 (7-Ha, m), 1.42 (12-3H, s), 1.41 (8-Ha, 
overlapped), 1.22 (15-3H, s), 1.21 (14-3H, s). 
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Conithiaquinone B (2): Colorless amorphous solid. []D
25
 = +9.5 (c=0.06 in 
methanol). 
1
H NMR (700 MHz, CD3OD) and 
13
C NMR (175 MHz, CD3OD): see 
Table 3.1. HRESI-MS (positive ion mode, MeOH): calcd. for 
C20H27NO6SNa[M+Na]
+
432.1451; found 432.1449.  
Computational calculations: DFT calculations were performed on a Pentium-4 
processor at 3.0 GHz using the Gaussian03 package (Multiprocessor). DP4 NMR 
prediction analysis was carried out as described by Smith and Goodman.
 
Gaussian 03 
was used to calculate both the carbon and proton GIAO NMR shielding tensors at the 
mPW1PW91 functional and 6-31G(d,p) basis set, using as input the geometry 
previously optimized at the mPW1PW91/6-31G(d) level. For these calculations, the 
IEF-PCM solvent continuum model, as implemented in Gaussian (methanol solvent), 
was used. TDDFT calculations were run using the functional B3LYP and the basis 
sets TZVP including at least 30 excited states in all cases, and using IEF-PCM for 
MeOH. ECD spectra were generated. 
Cell cultures and microcultures bioassay: Biological activity was investigated on 
tumour MCF-7 human breast adenocarcinoma cells and non-tumour HaCaThuman 
skin keratinocytes, purchased from ATCC
®
(American Type Culture Collection, 
Manassas, Virginia, USA). HaCaT cells were grown in Dulbecco's modified Eagle's 
medium (DMEM, Invitrogen, Paisley, UK) containing high glucose (4.5 g/l), while 
MCF-7 cells were grown in RPMI 1640 medium (Invitrogen, Paisley, UK). Media 
were supplemented with 10% fetal bovine serum (FBS, Cambrex, Verviers, 
Belgium), L-glutamine (2 mM, Sigma, Milan, Italy), penicillin (100 units/ml, Sigma) 
and streptomycin (100 μg/ml, Sigma), according to ATCC recommendations. All 
cells were cultured in a humidified 5% CO2 atmosphere at 37°C. For bioactivity and 
cytotoxicity studies, cells were seeded in a 96-microwell culture plates at density of 
10
4
 cells/well. Cells were allowed to grow for 24 h, then the medium was replaced 
with fresh medium and cells were treated for further 48 h with different 
concentrations of the tested compounds. In detail, both compounds (1) and (2) were 
dissolved in dimethyl sulphoxide (DMSO, Sigma) and 1 or 2 µL of DMSO solutions 
were added to cell culture medium to give various concentration ranging from 1 to 
250 µM; 1 or 2 µL of DMSO alone (vehicle) were added into control cells (0.5 and 
1% v/v final concentrations, respectively). Positive control for cytotoxicity was 
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performed using cisplatin (CDDP, Sigma). Live/death cell number was determined 
by the trypan blue dye exclusion test. After the treatments, the medium was removed 
and the cells were washed twice with PBS buffer solution (Sigma) and then 
incubated with a trypsine-EDTA solution (Sigma) at 37°C for 5 min. Trypsine was 
inactivated by re-suspending the cells in medium containing 10% FBS (Cambrex). 
The cells were pelleted at 250 x g and resuspended in PBS. Viable cells, cells that 
excluded 0.4% trypan blue (Sigma), were then counted with a Burker 
haemocytometer chamber.
1 
Concurrently, cell viability was evaluated with an MTT 
assay procedure, which measures the level of mitochondrial dehydrogenase activity 
using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, 
Sigma) as substrate. The assay was based on the redox ability of living mitochondria 
to convert dissolved MTT into insoluble formazan. Briefly, after treatments with the 
test compounds, the medium was removed and the cells were incubated with 20 
µL/well of an MTT solution (5 mg/mL) for 1 h in a humidified 5% CO2 incubator at 
37°C. The incubation was stopped by removing the MTT solution and by adding 100 
µL/well of DMSO to solubilize the formazan. Finally, the absorbance was monitored 
at 550 nm by using a Perkin-Elmer LS 55 Luminescence Spectrometer (Perkin-Elmer 
Ltd, Beaconsfield, UK).
2
 The calculation of the concentration required to inhibit the 
net increase in the 48 h cell count and viability by 50% (IC50) is based on plots of 
data carried out in triplicates and repeated three times. IC50 values were obtained 
using a dose response curve by nonlinear regression using a curve fitting program, 
GraphPad Prism 5.0, and are expressed as mean ± SEM. 
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4.2 Ciona edwarsii and Aplidium elegans 
 
Extraction and Isolation Procedures: Specimens of A. elegans were collected at 
−40 m depth in the autumn of 2003 in the Bay of Naples (Bacoli) and kept frozen 
until used. The freshly thawed tunicate was homogenized and extracted at room 
temperature with methanol (3 × 1 L) and, subsequently, with chloroform (3 × 1 L) 
(31.8 g dry weight of the tunicate after air drying). The combined extracts were 
concentrated in vacuo to give an aqueous suspension that was subsequently 
partitioned initially with EtOAc and then with n-BuOH. The butanol-soluble material 
obtained after evaporation of the solvent (4.1 g of a dark brown oil), was 
chromatographed on a RP-18 silica gel flash column using a gradient elution 
(H2O/MeOH 9:1→ H2O/MeOH 7:3→ H2O/MeOH 1:1→ H2O/MeOH 3:7→ MeOH 
100%→ MeOH/CHCl3 9:1→ MeOH/CHCl3 7:3→ MeOH/CHCl3 1:1→ CHCl3 
100%). The fractions eluted with H2O/MeOH 1:1 were rechromatographed by HPLC 
on an RP-18 column (Luna, 3 μm, 150 × 4.60 mm), using H2O/MeOH 7:3 containing 
TFA 0.1% as the eluent (flow 0.5 mL/min). This separation afforded pure compound 
10 (1.2 mg) and pure compound 11 (1.0 mg). Specimens of C. edwardsii were 
collected at −75 m depth in the autumn of 2006 in the Bay of Naples (at −65/−75 
meter in Meta di Sorrento Punta Gradelle) and kept frozen until used. The freshly 
thawed tunicate was homogenized and treated at room temperature with methanol (3 
× 1 L) and, subsequently, with chloroform (3 × 1 L) (21.9 g dry weight of the 
tunicate after air drying). The combined extracts were concentrated in vacuo to give 
an aqueous suspension that was subsequently partitioned initially with EtOAc and 
then with n-BuOH. The butanol-soluble material obtained after evaporation of the 
solvent (5.4 g of a dark brown oil), was chromatographed on a RP-18 silica gel flash 
column using a gradient elution (H2O/MeOH 9:1→ H2O/MeOH 7:3→ H2O/MeOH 
1:1→ H2O/MeOH 3:7→ MeOH 100%→ MeOH/CHCl3 9:1→ MeOH/CHCl3 7:3→ 
MeOH/CHCl3 1:1→ CHCl3 100%). The fractions eluted with H2O/MeOH 3:7 were 
rechromatographed by HPLC on an RP-18 column (Luna, 3 μm, 150 × 4.60 mm), 
using H2O/MeOH 72:28 containing TFA 0.1% as the eluent (flow 0.5 mL/min). This 
separation afforded 2.4 mg of pure compound 12. 
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Compound 10: colorless amorphous solid; []D
25
 = +2.5 (c = 0.002, CH3OH). ESI-
MS (negative ion mode): m/z = 511 [M−Na]−; HRESIMS (negative ion mode): m/z = 
511.1987; the molecular formula C20H40NaO9S2
−
 requires 511.2006; 
1
H-NMR and 
13
C-NMR data (CD3OD, 500/125 MHz) are reported in Table 3.3. 
Compound 11:colorless amorphous solid; []D
25
 = +3.4 (c = 0.002, CH3OH). ESI-
MS (negative ion mode): m/z = 497 [M−Na]−; HRESIMS (negative ion mode): m/z = 
497.1825; the molecular formula C19H38NaO9S2
−
 requires 497.1849; 
1
H-NMR and 
13
C-NMR data (CD3OD, 500/125 MHz) are reported in Table 3.3. 
Compound 12:Colorless amorphous solid; [ ]D
25
 = +1.8 (c = 0.002, CH3OH). ESI-
MS (negative ion mode): m/z = 379 [M−Na]−; ESI-MS (positive ion mode): m/z = 
403 [M+H]
+
; HRESIMS (negative ion mode): m/z = 379.2522; the molecular 
formula C19H39O5S
−
 requires 379.2513; 
1
H-NMR and 
13
C-NMR data (CD3OD, 
500/125 MHz) are reported in Table 3.3. 
Cell Culture: J774A.1 cell line (BALB/c murine macrophages) was cultured in 
Dulbecco‟s modified Eagle‟s medium (DMEM) supplemented with 4.4% NaHCO3 
(HyClone), penicillin (100 U/mL), streptomycin (100 g/mL), 2 mM glutamine, 25 
mMHepes, 130 µg/mL Na pyruvate and 10% foetal calf serum (FCS) (Hy Clone). 
The rat astrocyticglioma C6 cell line was cultured in DMEM supplemented with 
10% FCS, penicillin (100 U/mL), streptomycin (100 g/mL), and L-glutamine 2 
mM. All cells were cultured in plastic tissue culture flasks and kept at 37 °C under 
5% CO2 atmosphere. 
Cytotoxicity Assay: cytotoxicity studies in both tumour cell lines were performed in 
a 96-well plate 
3,4
 J774A.1 were mechanically scraped, while C6 cells were 
enzymatically detached. The cells were plated 12.5 × 10
4
/well (J774A.14) or 2.5 × 
10
3
/well (C6) to a final volume of 200 L. After 4 h J774A.1, cells were incubated 
with compounds 10–12 at increasing concentrations (10–100 M) for 22 h; 
conversely, after 3 days C6 cells were incubated with compounds 10–12 (10–300 
µM) for 22 h. Then, 25 L of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, 5 mg/mL) was added in each well, 3 h later the cells were lysated 
with 100 L of lysis buffer (20% SDS and 50% DMF, pH 4.7). After an incubation 
103 
 
of 22 h at 37 °C the optical densities (OD620) for the serial dilutions of both 
compounds were compared with the OD of the control wells to assess the 
citotoxicity
5
 LC50 for each cell line was obtained by statistical computer program. 
Data Analysis: data are reported as mean ± SEM values of three independent 
determinations. All experiments were performed at least three times, each time with 
three or more independent observations. Statistical analysis was performed by 
ANOVA test, and multiple comparisons were made by Dunnett. 
 
4.3 Phallusia fumigata 
 
Collection, Extraction, and Isolation: specimens of Phallusia fumigata were 
collected in April 2008 at in the bay of Pozzuoli (Napoli, Italy). The samples were 
frozen immediately after collection and stored at −20 °C until extraction. A reference 
specimen is deposited at the Dipartimento di Farmacia, University of Naples. The 
fresh thawed animals (424 g of dry weight after extraction) were homogenized and 
extracted twice with methanol and then twice with chloroform (4 x 200 mL). The 
combined extracts were concentrated in vacuo, and the resulting aqueous residue was 
extracted with EtOAc and subsequently with n-BuOH. Separation of the EtOAc 
soluble material (1,04 g) was achieved by gradient silica gel MPLC (hexane → 
EtOAc → MeOH). The fraction eluted with hexane/EtOAc 3:7 v/v, (37.0 mg) was 
chromatographed by HPLC on a SiO2 column (Luna 5 m, 250 x 4.60 mm) eluting 
with hexane/EtOAc 55:45 (v/v), yielding a fraction (3.3 mg) which has been further 
purified by HPLC on a SiO2 column (Luna 5 m, 250 x 4.60 mm), eluting with 
hexane/propan-2-ol 93:7, thus affording phallusiasterol A (2.0 mg) and B (1.1 mg) as 
pure compounds. Separation of the BuOH soluble material (2,0 g) was achieved by 
reversed-phase silica gel (RP18) MPLC, using a gradient elution 
(H2O→MeOH→CHCl3). The fraction eluted with H2O/MeOH 3:7 v/v, (170.4 mg) 
was chromatographed by HPLC on a Synergi 4 Polar-RP 80 Ǻ (250 x 4.60 mm) 
column, eluting with MeOH/H2O 65:35 (v/v) and 0.1 % of trifluoroacetic acid, 
yielding a fraction (40.6 mg) which has been further purified by HPLC on a Synergi 
4 Hydro-RP 80 Ǻ (250 x 4.60 mm) column, eluting with MeOH/H2O 7:3 (v/v) and 
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0.1 % of trifluoroacetic acid, thus affording phallusiasterol C (4.7 mg) as pure 
compound. 
Phallusiasterol A (15):colorless amorphous solid, [α]D
25
 -3.5 (c 0.1, CHCl3); 
HRESIMS (positive ion mode, CH3OH) m/z 545.2858 ([M + Na]
+
, calcd. for 
C27H47SO6Na2
+
 545.2889); 
1
H and 
13
C NMR (C5D5N): see Table 3.4 
1
H NMR 
(CDCl3): δ 4.33 (1H, m, H-3), 3.96 (1H, br s, H-6), 2.34 (1H, dd, J = 13.1, 10.5 Hz, 
H-4), 2.02 (1H, m, H-7), 1.99 (1H, overlapping, H-4), 1.98 (1H, overlapping, H-
12), 1.90 (1H, m, H-2), 1.83 (1H, ddd, J=13.6, 9.5, 3.7, H-16), 1.74 (1H, qd, J = 
12.0, 4.3 Hz, H-8), 1.68 (1H, dt, J= 13.4, 4.2 Hz, H-1), 1.60 (1H, overlapping, H-
7), 1.57 (1H, overlapping , H-2), 1.57 (1H, overlapping , H-15), 1.54 (1H, m, H-
9), 1.51 (1H, m, H-25), 1.48 (1H, ddd, J= 13.4, 4.5, 2.3, H-1), 1.41 (1H, dq, J = 
14.1, 3.8, H-11), 1.37 (1H, m, H-20), 1.35-1.33 (2H, overlapping, H-22a and H-
23a), 1.29 (1H, overlapping, H-11), 1.28 (3H, s, Me-19), 1.26 (1H, overlapping, H-
16), 1.25 (1H, m, H-14), 1.24 (1H, overlapping, H-23b), 1.18 (1H, m, H-12), 
1.15-1.10 (3H, m, H-17, H-24a, and H-24b), 1.07 (1H, m, H-15), 1.00 (1H, m, H-
22b), 0.91 (3H, d, J = 6.5 Hz, Me-21), 0.87 (3H, d, J = 6.6 Hz, Me-26), 0.86 (3H, d, 
J = 6.6 Hz, Me-27), 0.67 (3H, s, Me-18).
 13
C NMR (CDCl3): δ 84.2 (C-5), 75.8 (C-
6), 67.8 (C-3), 56.0 (C-17), 55.8 (C-14), 46.0 (C-9), 42.8 (C-13), 41.3 (C-4), 39.8 (C-
10 and C-12), 39.6 (C-24), 36.2 (C-22), 35.8 (C-20), 34.0 (C-7), 33.6 (C-1), 30.5 (C-
2), 30.4 (C-8),28.2 (C-16), 28.0 (C-25), 24.0 (C-15), 23.8 (C-23), 21.3 (C-11), 22.7 
(Me-26), 22.5 (Me-27), 18.8 (Me-21), 18.2 (Me-19), 12.1 (Me-18). 
Phallusiasterol B (16): colorless amorphous solid, [α]D
25
 +7.9 (c 0.1, CHCl3); 
HRESIMS (positive ion mode, CH3OH) m/z 545.2870 ([M + Na]+, calcd. for 
C27H47SO6Na2
+
 545.2889); 
1
H and 
13
C NMR (C5D5N): see Table 3.4.
 1
H NMR 
(CDCl3): δ 4.05 (1H, m, H-3), 3.84 (1H, d, J=5.4, H-6), 2.25 (1H, t, J = 13.2, H-4), 
1.99 (1H, dt, J = 12.4, 3.4, H-12), 1.96 (1H, m, H-7), 1.67 (1H, dd, J = 13.2, 2.1, 
H-4), 1.87-1.84 (3H, overlapping, H-2H-7H-8 H-16), 1.68 (1H, dd, J = 
13.1, 4.7, H-9), 1.56-1.54 (3H, overlapping, H-1H-2and H-15), 1.51 (1H, m, 
H-25), 1.42-1.41 (2H, m, H-1 and H-11), 1.37 (1H, m, H-20), 1.33 (2H, 
overlapping, H-22a and H-23a), 1.30 (1H, overlapping, H-11), 1.28 (3H, s, Me-19), 
1.27-1.24 (3H, overlapping, H-14H-16, and H-23b), 1.12 (1H, m, H-12), 1.20-
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1.11 (3H, m, H-17, H-24a, and H-24b), 1.07 (1H, m, H-15), 1.00 (1H, m, H-22b), 
0.91 (3H, d, J = 6.5 Hz, Me-21), 0.87 (3H, d, J = 6.6 Hz, Me-26), 0.86 (3H, d, J = 
6.6 Hz, Me-27), 0.70 (3H, s, Me-18).
 13
C NMR (CDCl3): δ 77.2 (C-5), 67.3 (C-3), 
63.5 (C-6), 56.4 (C-17), 55.6 (C-14), 46.1 (C-9), 42.9 (C-13), 41.6 (C-4), 40.2 (C-
12), 39.6 (C-24), 39.4 (C-10), 36.1 (C-22), 35.8 (C-20), 35.2 (C-7), 32.6 (C-1), 30.6 
(C-2), 29.7 (C-8),29.1 (C-16), 27.9 (C-25), 24.0 (C-15), 23.8 (C-23), 21.1 (C-11), 
22.7 (Me-26), 22.5 (Me-27), 18.5 (Me-21), 18.2 (Me-19), 12.0 (Me-18). 
3, 6-diacetate-5-cholestan-5-yl sodium sulfate (17): to a stirred solution of 
0.5 mg of pure 15 in 0.5 mL of dry pyridine was added 0.3 mL of Ac2O. After the 
mixture was stirred for 12 h at room temperature, evaporation under vacuum gave 
0.7 mg of 17 as a white solid: HRESIMS (positive ion mode, CH3OH) m/z 629.3089 
([M + Na]
+
, calcd. for C31H51SO8Na2
+
 629.3100); 
1
H NMR (C6D6):  0.61 (3H, s, 
Me-18), 0.94 (6H, d, J = 6.6 Hz, Me-26and Me-27), 0.98 (3H, d, J = 6.6 Hz, Me-21), 
1.14 (3H, s, Me-19), 1.52 (3H, s, COMe), 1.70 (3H, s, COMe), 5.43 (1H, br s, H-6), 
5.72 (1H, m, H-3); 13C NMR (C6D6): 11.9 (C-18), 17.2 (C-19), 18.5 (C-21), 20.1 
(COMe), 20.4 (COMe), 22.4 (C-26 and C-27), 69.9 (C-3), 75.1 (C-6), 168.8 (CO), 
169.4 (CO). 
Phallusiasterol C (18): colorless amorphous solid; HRESI-MS (negative ion mode 
CH3OH) m/z 567.2064 [M-Na
+
]
- 
; calcd. for C26H40NaO8S2 567.2062. ESIMS: 465 
[M– NaSO3]
¯ 
, 447 [M–NaHSO4-Na
+
]
¯
, 272 (double charged species). 
Transactivation Experiments: HepG2 cells were plated in a 24-wells plate, at 
5x10
4
cells/well, and transfected with 75 ng of pSG5-PXR, 75 ng of pSG5-RXR, 125 
ng of pCMV-β-galactosidase, and with 250 ng of the reporter vector 
pCYP3A4promoter-TKLuc, using Fugene HD transfection reagent (Roche). At 24 
hours post-transfection, cells were primed with Rifaximin, 15, 16 and 18 (10μM) or 
with the combination of Rifaximin (10μM) plus compounds 15, 16 and 18 (50 μM). 
After treatments, cells were lysed in 100 μLLysis Buffer (25 mM TRIS-phosphate 
pH 7.8; 2mM DTT; 10% glycerol; 1% Triton X-100) and 20 µL cellular lysate was 
assayed for Luciferase activity using the Luciferase Assay System (Promega). 
Luminescence was measured using an automated luminometer (Glomax 20/20, 
Promega). Luciferase activities were normalized for transfection efficiencies by 
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dividing the Luciferase relative light units (RLU) by β-galactosidase activity (βgal) 
expressed from cells co-transfected with pCMVβgal. All experiments were 
performed in triplicate. 
Cells culture, RNA extraction and Real-Time PCR: HepG2 cells were maintained 
at 37 °C in E-MEM supplemented with 10% FBS, 1% L-glutamine and 1% 
penicillin/streptomycin. To evaluate PXR target genes expression, serum starved 
HepG2 cells were stimulated for 18 h with Rifaximinand compound 15, 16 and 18 
(10μM). Total RNA was extracted using the TRIzol reagent (Invitrogen), purified of 
the genomic DNA by DNAase I treatment (Invitrogen) and random reverse-
transcribed with Superscript II (Invitrogen). 10 ng template was amplified using the 
following reagents: 0.2 μM of each primer and 10μl of KAPA SYBR FAST 
Universal qPCR Kit (KAPA BIOSYSTEMS). All reactions were performed in 
triplicate and the thermal cycling conditions were: 3 min at 95 °C, followed by 40 
cycles of 95 °C for 15 s, 58 °C for 20 s and 72 °C for 30 s. The relative mRNA 
expression was calculated and expressed as 2
−(ΔΔCt)
. Primers used for qRT-PCR were: 
hGAPDH: GAAGGTGAAGGTCGGAGT and 
CATGGGTGGAATCATATTGGAA; 
hCYP3A4: CAAGACCCCTTTGTGGAAAA and CGAGGCGACTTTCTTTCATC; 
hMDR1: gtggggcaagtcagttcatt and tcttcacctccaggctcagt. 
Statistical Analysis: all values are expressed as means ± standard error (SE) of n 
observations/group. Comparisons of two groups were made with a one-wayANOVA 
with post hoc Tukey‟s test. Differences were considered statistically significant at 
values of P < 0.05. 
Computational Details: molecular docking of phallusiasterol A in the three-
dimensional X-ray structures of the PXR LBD (PDB codes: 3hvl, 1nrl and 1m13) 
without the co-crystallized inhibitor and waters were carried out using the AutoDock 
software package (version 4.2). Ligands and receptor structures were converted to 
AutoDock format files using the ADT software, and the Gesteiger-Marsili partial 
charges were then assigned. A box around the binding pocket has defined the 
docking area and grids points of 48×40×38 with 0.375 Å spacing were calculated 
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within the this area for all the ligand atom types using AutoGrid4. For each ligand, 
100 separate docking calculations were performed. Each docking run consisted of 25 
million energy evaluations using the Lamarckian genetic algorithm local search 
(GALS) method. Otherwise default docking parameters were applied. The docking 
conformations were clustered on the basis of the root-mean square deviation values 
(rmsd tolerance = 1.5 Å) between the cartesian coordinates of the ligand atoms and 
were ranked based on the AutoDock scoring function. 
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4.4 Sydnium elegans 
 
Collection, Extraction, and Isolation: Specimens of S. elegans were collected at 
Capo Caccia (Alghero, Italy). They were frozen immediately after collection and 
kept frozen until extraction. The fresh thawed animals (39.7 g of dry weight after 
extraction) were homogenised and at room temperature with methanol (3  300 mL) 
and then with chloroform (3  300 mL). The combined extracts were concentrated in 
vacuo and the resulting aqueous residue was extracted with EtOAc and, 
subsequently, with n-BuOH. The n-butanol-soluble material was chromatographed 
by MLPC over a C-18 column followed using a gradient elution 
(H2OMeOHCHCl3). The fraction eluted with MeOH:H2O 7:3 (v/v) was further 
purified by RP-HPLC (Synergi RP-MAX 4 m column, MeOH/H2O 8:2 and 0,1% of 
trifluoroacetic acid) and yielded phosphoeleganin (19) (80.0 mg) in a pure state.  
Phosphoeleganin (19): HRESI-MS (negative ion mode): m/z =668.3832, 
C32H63NO11P requires 668.4049. 
1
H and 
13
C NMR data (CD3OD and DMSO): see 
Table 3.6. 
Preparation of acetonide: A solution of phosphoeleganin (3.5 mg) in 2,2-
dimethoxypropane (1.5 mL) was treated with Dowex 50W-X8 (H
+
 form, 20 mg), and 
the mixture was stirred at room temperature for 3 h. The resin was removed by 
filtration and the solvent from the filtrate was dried obtaining compound 34 (4.5 mg). 
Periodate degradation: phosphoeleganin (6.3 mg) was dissolved in 2 mL of 0.012 
M NaIO4 and stirred at room temperature for 3 h. Then the solution was cooled to 0 
o
C, excess amount of NaBH4 was added and kept for 1 hr. The reaction solution was 
partitioned between water and butanol. The butanol exctract was purificated by 
reverse phase HPLC (Luna C18 3 MeOH/H2O 8:2 with 0.1%TFA) yielded 
compounds 22 and 23 in the pure state. 
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4.5 Axinella Polypoides 
Collection, Extraction and Isolation: specimens of A. polypoides were collected in 
the Bay of Calvi (Corsica, France), frozen immediately and kept frozen until 
extraction. A reference specimen was deposited at the Dipartimento di Chimica delle 
Sostanze Naturali, University of Naples “Federico II”. Fresh thawed animals (105.2 
g dry weight after extraction) were homogenized and extracted twice with MeOH 
and, then, twice with CHCl3 (4 × 500 mL). Extracts were combined and 
concentrated; the resulting aqueous residue was then partitioned between H2O and n-
BuOH. Separation of the organic phase (13.0 g) was achieved by reversed-phase 
silica gel (RP18) MPLC, using a gradient elution (H2O→MeOH→CHCl3). Ten 
fractions (A–L) were obtained, each of them was subjected to a rapid 1H-
NMR/ESIMS-based analysis. Fraction B, eluted with H2O/MeOH 9:1 v/v, (3.4 g) 
was re-chromatographed under medium pressure on a RP18 column eluting with a 
linear gradient of MeOH (from 2% to 100%) in H2O, thus affording twelve fractions 
(1–12). Fraction 8 (219 mg), eluted with H2O/MeOH 92:8 v/v, was separated by 
HPLC on a Synergy Polar-RP 4 μm column (250 × 4.60 mm) eluting with 
H2O/MeOH (98:2, v/v) and 0.1% TFA, to give compounds 30 (22.3 mg) and 31 (4.0 
mg). Fraction 10 (55.8 mg), eluted with H2O/MeOH (85:15, v/v) was separated by 
HPLC in the same conditions as above, to give 32 (7.8 mg) and 33 (4.8 mg). 
Fractions C and D, both eluted with H2O/MeOH 7:3 v/v, were combined (524.5 mg) 
separated by HPLC on a Synergy Polar-RP 4 μm column (250 × 4.60 mm) eluting 
with H2O/MeOH (98:2, v/v), to give axityrosinium (24, 52.0 mg), 
axiphenylalaninium (25, 19.2 mg), polyaxibetaine (26, 6.0 mg) and compound 29 
(9.1 mg).The hydrophilic extract (42.7 g) was subjected to Droplet Counter Current 
Chromatography (DCCC), using a mixture of BuOH-Acetone-H2O (3:1:5) as the 
solvent, in the ascending mode. The flow rate of the mobile phase was adjusted to 25 
mL/h; a total of 150 fractions of 8 mL each were collected and, as for the organic 
extract, analyzed by 
1
H-NMR/ESIMS for the rapid detection of PIAs. Fractions 40–
50 were combined, the solvent was evaporated, and the residue (300 mg) was 
chromatographed by HPLC on a Synergy Polar-RP 4 μm column (250 × 4.60 mm) 
eluting with H2O/MeOH (98:2, v/v) and 0.1% TFA, thus affording pure 28 (16.4 
mg). 
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Compound 28: [α]D +7.59 (MeOH, c = 0.005; HRESI-MS (positive ion mode): m/z 
= 210.1130 [M+H]
+
, 232.0950 [M+ Na]
+
; 
1
H and 
13
C NMR data (CD3OD) are 
reported in Table 3.8. 
Compound 31: [α]D +1.70 (MeOH, c = 0.003); HRESI-MS (positive ion mode): m/z 
= 283.0673 [M+H]
+
, 265.0567 [M−H2O+H]
+
; 
1
H and 
13
C NMR data (d6-DMSO) are 
reported in Table 3.9. 
 
Computational Details: A preliminary conformational search for one of the two 
enantiomers of 28 was performed by Simulated Annealing in the INSIGHT II 
package. The MeOH solution phases were mimicked through the value of the 
corresponding dielectric constant. Using the steepest descent followed by quasi-
Newton-Raphsonmethod (VA09A) the conformational energy was minimized. 
Restrained simulations were carried out for 500 ps using the CVFF force field as 
implemented in Discover software (Accelrys, San Diego, USA). The simulation 
started at 1000 K, and then the temperature was decreased stepwise to 300 K. The 
final step was again the energy minimization, performed in order to refine the 
structures obtained, using the steepest descent and the quasi-Newton-Raphson 
(VA09A) algorithms successively. Both dynamic and mechanic calculations were 
carried out by using 1 (kcal/mol)/Å2 flat well distance restraints. One hundred 
structures were generated. To simulate the solvent chosen for NMR analysis, a 
distance-dependent dielectric constant set to the value of MeOH(ε32.63) was used 
during the calculations. All optimizations were performed with the software package 
Gaussian 03, by using the DFT functional RB3LYP and the basis set 6-31G(d). The 
B3LYP/6-31G(d) harmonic vibrational frequencies were further calculated to 
confirm their stability. Rotatory strength values for the electronic transitions from the 
ground state to the singly excited states for all conformers of S-28 were obtained by 
TDDFT calculations RB3LYP/6-31G(d,p) with Gaussian 03. The rotatory strength 
values were summed after a Boltzmann statistical weighting and ∆ε values were 
calculated by forming sums of Gaussian functions centered at the wavelengths of the 
respective electronic transitions and multiplied by the corresponding rotatory 
strengths. The ECD spectra that was obtained was UV-corrected and compared with 
the experimental one. 
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4.6 Synthesis of quinone derivatives 
General experimental procedures: 
1
H and 
13
C NMR spectra were recorded with a 
Varian Gemini 200 MHz  or a Varian Mercury 300 MHz or a Bruker Avance 400 
MHz. 
Reagents: Sigma–Aldrich. Solvents: Carlo Erba. TLC: Silica Gel 60 F254 (plates 5 
x 20, 0.25 mm) Merck. Preparative TLC: Silica Gel 60 F254 plates (20 x 20, 2 mm). 
Spots revealed by UV lamp then by spraying with 2 N sulfuric acid and heating at 
120 °C. „Acidic‟ silica gel was prepared by treating Silica Gel 60 Merck with 1 N 
HCl for 24 h, washing with water until the chlorine test was negative, activating for 
48 h at 120 °C, then equilibrating with 10% of water. Anhydrous solvents: Sigma–
Aldrich or prepared by distillation according to standard procedures. 
Syntesis of compound 47: To 25 mL of dichloromethane/water 1:1, 3 g (19.6 mmol) 
of 46 and 5 g (47 mmol) of Na2CO3, were added under stirring 2.5 mL of 
pivaloylchloride (0.02 mmol) were then added dropwise and the mixture was stirred 
for 3 hours at room temperature (the end of the reaction was checked by TLC, eluent: 
hexane/ethyl acetate 7:3). The dark liquid was then poured into cold water and 
extracted three times with dichloromethane. The combined organic layers were 
washed with brine, dried with sodium sulfate and filtered; solvent removal under 
reduced pressure afforded gave 47 (4.38 g, 95%) sufficiently pure for the following 
reaction. 
1
H NMR 200 MHz (CDCl3): δ 1.31 (9H, s, -C(CH3)3); 3.77 (3H, s, -OCH3); 
3.84 (3H, s, -OCH3); 6.55 (1H, Dd, J1 = 8.8 Hz, J2 = 2.8 Hz, H-4); 6.78 (1H, d, J =  
8.8 Hz, H-3); 8.17 (1H, d, J =  2.8 Hz, H-6). 
Synthesis of compound 48: 4.00 g (16.88 mmol) of 47 were dissolved in 60 mL of 
anhydrous THF and 32.0 mL of a n-BuLi 1.6 M solution (50.64 mmol) were added, 
under argon atmosphere at 0 °C; the mixture was stirred for 2 h. Then, 5.12 mL of 
DMF (65.84 mmol) were added dropwise and the mixture was left under stirring for 
16 h (the end of the reaction was checked by TLC, eluent: hexane/ethyl acetate 9:1). 
The mixture was poured into cold water (150 mL) and extracted three times with 
ethyl acetate. The combined organic layers were washed with brine, dried over 
sodium sulfate, and filtered. The solvent removal under reduced pressure gave crude 
product 48 (4.1 g), which were purified by chromatography on „acidic‟ silica gel 
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(SiO2/crude 3 50:1; eluent: hexane/ethyl acetate 9:1) to give pure 48 (3.064 g, 11.56 
mmol, 68.5%). 
1
H NMR 300 MHZ (CDCl3): δ 1.32 (9H, s, -C(CH3)3); 3.83 (3H, s, -
OCH3); 3.85 (3H, s, -OCH3); 6.74 (1H, d, J =  9.3 Hz, H-5); 7.12 (1H, d, J =  9.3 Hz, 
H-4); 9.20 (1H, bs, NH); 10.38 (1 H, s, -CHO). 
Synthesis of compounds 49a-c: To a suspension of 73 mg of Mg powder (3 mmol) 
in 2 mL of anhydrous diethyl ether, 2.28 mmol  of iodoalkane (0.14 ml of 
iodomethane or 0.44 ml of iodobutane or 2.05 ml of iododecane respectively) in 5 ml 
of anhydrous diethyl ether were added slowly under stirring at room temperature. 
After completion, the reaction mixture was refluxed for 1 h and then a solution of 
compound 48 (150 mg, 0.57 mmol) in anhydrous diethyl ether (10 mL) was added 
dropwise. The reaction was refluxed for 4 hours (the end of the reaction was checked 
by TLC, eluent: chloroform/ethyl acetate 9:1) and quenched with 6 ml of saturated 
NH4Cl. The mixture was poured into water (20 mL) and extracted three times with 
ethyl acetate. The combined organic layers were washed with brine, dried over 
sodium sulfate, and filtered; solvent removal under reduced pressure gave products 
49a (158.6 mg, 99%), 49b (182.5 mg, 99%) as a colorless crystals sufficiently pure 
for the following reaction and crude product 49c (400 mg), which were purified by 
chromatography on  silica gel (SiO2/crude 3 50:1; eluent: hexane/ethyl acetate 6:4) to 
give pure 49c (174.3 mg, 75%). 
 
1
H NMR 300 MHZ (CDCl3) 49a: δ 1.32 (9H, s, -C(CH3)3); 1.58 (3H, d, J =  6.6 Hz, 
-CHOHCH3); 3.65 (1H, d, J =  8.7 Hz, -OH); 3.75 (3H, s, -OCH3); 3.83 (3H, s, -
OCH3); 4.96 (1H, m, -CHOHCH3); 6.75 (2H, s*, H-4 and H-5); 7.32 (1H, bs, NH). 
1
H NMR 300 MHZ (CDCl3) 49b: δ 0.85 (3H, t, J =  6.8 Hz, -(CH2)3CH3); 1.15 - 
1.44 (13H, -CH2(CH2)2CH3 and -C(CH3)3); 1.74 - 1.97 (2H, m, -CHOHCH2-); 3.55 
(1H, bs, -OH); 3.74 (3H, s, -OCH3); 3.78 (3H, s, -OCH3); 4.80 (1H, m, -CHOH-); 
6.73 (2H, s*, H-4 and H-5); 7.42 (1H, bs, NH). 
1
H NMR 300 MHZ (CDCl3) 49c: δ 0.87 (3H, t, J =  6.5 Hz, -(CH2)9CH3); 1.14 – 1.30 
(16H, -CH2(CH2)8CH3; 1.32 (9H, s, -C(CH3)3); 1.77 - 1.99 (2H, m, -CHOHCH2-); 
3.30 (1H, bs, -OH); 3.75 (3H, s, -OCH3); 3.81 (3H, s, -OCH3); 4.79 (1H, m, -CHOH-
); 6.75 (2H, s*, H-4 and H-5); 7.34 (1H, bs, NH). 
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Synthesis of compounds 50 a-c: to a suspension of 38 mg of 10% Pd-on-charcoal in 
EtOH (5 mL) and HCl conc. (0.2 mL) under atmosphere of H2 (balloon) at rt, 0.31 
mmol of 49 (87 mg of 49a, 100 mg of 49b, 126 mg of 49c) were added. After stirring 
under the same conditions for 2.5 hours (the end of the reaction was checked by 
TLC, eluent: hexane/ethyl acetate 7:3), the hydrogen atmosphere was replaced by a 
argon atmosphere and then the mixture was filtered through a fluted filter paper 
washing the catalyst several times with EtOH (total volume 100 mL). The filtrate 
was concentrated under reduced pressure and 20 mL of saturated NaHCO3 solution 
were added to the residue and extracted three times with ethyl ether. The ethereal 
solution was washed with brine, dried over sodium sulfate, and filtered. The solvent 
removal under reduced pressure afforded 50a (80 mg, 97%), 50b (91.5 mg, 96%) and 
50c (112 mg, 92%) sufficiently pure for the following reaction. 
1
H NMR 300 MHZ (CDCl3) 50a: δ 1.08 (3H, t, J =  7,5 Hz, -CH2CH3); 1.34 (9H, s, -
C(CH3)3); 2.58 (2H, q, J =  7.5 Hz, -CH2CH3); 3.74 (3H, s, -OCH3); 3.78 (3H, s, -
OCH3); 6.67 (1H, d, J =  9.0 Hz, H-5); 6.73 (1H, d, J =  9.0 Hz, H-4); 6.87 (1H, bs, 
NH).  
1
H NMR 200 MHz (CDCl3) 50b: δ 0.87 (3H, t, J =  7.5 Hz, -(CH2)4CH3); 1.18 - 1.49 
(15H, s, -CH2(CH2)3CH3 and -C(CH3)3); 2.54 (2H, m, -CH2(CH2)3CH3); 3.74 (3H, s, 
-OCH3); 3.76 (3H, s, -OCH3); 6.68 (1H, d, J =  9.0 Hz, H-5); 6.74 (1H, d, J =  9.0 
Hz, H-4); 6.87 (1H, bs, NH).  
1
H NMR 300 MHZ (CDCl3) 50c: δ 0.88 (3H, t, J =  7.5 Hz, -(CH2)10CH3); 1.25 - 
1.45 (27H, s, -CH2(CH2)9CH3 and -C(CH3)3); 2.54 (2H, m, -CH2(CH2)9CH3); 3.74 
(3H, s, -OCH3); 3.77 (3H, s, -OCH3); 6.68 (1H, d, J =  8.7 Hz, H-5); 6.73 (1H, d, J =  
8.7 Hz, H-4); 6.86 (1H, bs, NH).  
Synthesis of compounds 51 a-c: 0.91 mmol of 50 (240 mg of 50a, 280 mg of 50b, 
356 mg of 50c) dissolved in 50 mL of acetonitrile were added dropwise to a solution 
of CAN (1.5 g, 2.72 mmol) in water (16 mL) at rt. The mixture was stirred for 5 
minutes at room temperature (the end of the reaction was checked by TLC, eluent: 
chloroform/ethyl acetate 7:3). The orange liquid was then poured into 100 mL of 
cold water and extracted three times with ethyl acetate. The combined organic layers 
were washed with brine, dried over sodium sulfate, and filtered. The solvent removal 
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under reduced pressure afforded 51a (210 mg, 99%), 51b (250 mg, 99%) and 51c 
(326 mg, 99%) sufficiently pure for the following reaction.  
1
H NMR 300 MHZ (CDCl3) 51a: δ 1.07 (3H, t, J =  7.5 Hz, -CH2CH3); 1.32 (9H, s, -
C(CH3)3); 2.47 (2H, q, J =  7.5 Hz, -CH2CH3); 6.73 (1H, d, J =  9.9 Hz, H-5); 6.77 
(1H, d, J =  9.9 Hz, H-4); 7.66 (1H, bs, NH). 
1
H NMR 400 MHz (CDCl3) 51b: δ 0.86 (3H, t, J =  7.0 Hz, -(CH2)4CH3); 1.25 - 1.45 
(15H, m, -CH2(CH2)3CH3 and -C(CH3)3); 2.48 (2H, m, -CH2(CH2)3CH3); 6.73 (1H, 
d, J =  9.9 Hz, H-5); 6.76 (1H, d, J =  9.9 Hz, H-4); 7.62 (1H, bs, NH). 
1
H NMR 300 MHZ (CDCl3) 51c: δ 0.86 (3H, t, J =  6.6 Hz, -(CH2)10CH3); 1.15 - 
1.42 (27H, m, -CH2(CH2)9CH3 and -C(CH3)3); 2.47 (2H, m, -CH2(CH2)9CH3); 6.72 
(1H, d, J =  9.9 Hz, H-5); 6.76 (1H, d, J =  9.9 Hz, H-4); 7.62 (1H, bs, NH). 
Synthesis of compounds 52 a-c and 53a-c: 0.53 mmol of quinone 51 (125 mg of 
51a, 147 mg of 51b, 192 mg of 51c) were dissolved in 7 mL of a mixture of 
EtOH/CH3CN 1:1 and heated in a water bath under stirring; then, a solution of 
hypotaurine (173 mg, 1.59 mmol) in 8 mL of water was added in portions. The 
mixture was stirred for 5 minutes at room temperature (the end of the reaction was 
checked by TLC, eluent: ethyl acetate/hexane 10:3). The yellow solution became 
orange/red. Most of the ethanol was removed in vacuo and the residue was poured 
into water. The mixture was extracted with ethyl acetate (three times) and the organic 
phase was washed with brine, dried over sodium sulfate, and filtered. The solvent 
removal under reduced pressure afforded a crude mixture of the isomers 52 and 53 
(157 mg of 52a/53a, 159 mg of 52b/53b, 270 mg of 52c/53c) which were separated 
by chromatography on „acidic‟ silica gel previously treated with 5% w/w of water 
(SiO2/crude 50:1; eluent: ethyl acetate/hexane 5:1) to give pure 52a (14.5 mg, 8%), 
52b (3.9 mg, 2%), 52c (8.9 mg, 3.6 %), 53a (28 mg, 15.5 %), 53b (8.1 mg, 4%) and 
53c (27 mg, 11%).  
1
H NMR 300 MHZ (C3D6O) 52a: δ 1.01 (3H, t, J = 7.4 Hz, -CH2CH3); 1.30 (9H, s, -
C(CH3)3); 2.39 (2H, q, J = 7.4 Hz, -CH2CH3); 3.31 (2H, m, -CH2 NH-); 4.07 (2H, m, 
-CH2 SO2-); 8.40 (1H, bs, -NHCO-).  
115 
 
13
C NMR 300 MHZ (C3D6O) 52a: δ 181.53 (C8‟); 176.78 (C5‟); 174.44 (C1); 
146.82 (C4a‟); 139.21 (C7‟); 133.86 (C8a‟); 109.04 (C6‟);  49.54 (C2‟); 40.95 (C3‟); 
40.92 (C2); 27.55 (3C3); 21.20 (C1‟‟); 11.83 (C2‟‟).  
1
H NMR 300 MHZ (CD3OD) 53a: δ 1.04 (3H, t, J = 7.5 Hz, -CH2CH3); 1.28 (9H, s, 
-C(CH3)3); 2.46 (2H, q, J = 7.5 Hz, -CH2CH3); 3.35 (2H, m, -CH2 NH-); 3.95 (2H, 
m, -CH2 SO2-). 
13
C NMR 300 MHZ (CD3OD) 53a: δ 181.23 (C8‟); 178.29 (C5‟); 177.34 (C1); 
150.40 (C4a‟); 146.70 (C6‟); 136 (C8a‟); 109.09 (C7‟); 49.55 (C2‟); 40.95 (C3‟); 
40.88 (C2); 28.05 (3C3); 21.30 (C1‟‟); 13.19 (C2‟‟).  
1
H NMR 400 MHz (CD3OD) 53b: δ 0.89 (3H, m, -(CH2)4CH3); 1.23 – 1.48  (15H, 
m, -CH2(CH2)3CH3 and -C(CH3)3); 2.45 (2H, m, -CH2(CH2)3CH3); 3.36 (2H, m, -
CH2 NH-); 3.96 (2H, m, -CH2 SO2-). 
13
C NMR 400 MHz (CD3OD) 53b: δ 181.12 (C8‟); 178.47 (C5‟); 177.09 (C1); 
149.44 (C4a‟); 146.71 (C6‟); 137.04 (C8a‟); 110.57 (C7‟); 49.73 (C2‟); 40.74 (C3‟); 
40.28 (C2); 33.21 (C1‟‟); 29.30 (C2‟‟ or C3‟‟ or C4‟‟); 27.72 (3C3); 26.95 (C2‟‟ or 
C3‟‟ or C4‟‟); 23.42 (C2‟‟ or C3‟‟ or C4‟‟); 14.22 (C5‟‟).  
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CHAPTER 5 
SUPPORTING DATA 
5.1. General methods 
 
This paragraph describes the chromatographic and spectroscopic methods 
employed for the execution of the research. This techniques have been applied for 
all the projects.  
Low and high resolution ESI-MS spectra were performed on a LTQ Orbitrap XL 
(Thermo Scientific) mass spectrometer. Optical rotations (CHCl3) were measured at 
589 nm on a Jasco P-2000 polarimeter using a 10 cm microcell. UV spectra were 
measured on a Thermo Scientific (mod. Nanodrop 2000c) instrument. CD spectra 
were registered on a Jasco J-710 spectropolarimeter (Jasco, Tokyo, Japan) with J-
710 for Windows software (Jasco).
 1
H (700 and 500 MHz) and 
13
C (175 and 125 
MHz) NMR spectra were measured on Varian Unity Inova spectrometers. 
Chemical shifts were referenced to the residual solvent signal (C5D5N: δH 8.71, 
7.55, 7.19, δC 149.9, 135.5, 123.5; CDCl3: δH 7.26, δC 77.0; C6D6: δH 7.15, δC 
128.0; CD3OD: δH 3.31, δC 49.0; d6-DMSO: δH 2.50, δC 39.0). 
1
H connectivities 
were determined by homonuclear COSY experiment. Through-space 
1
H 
connectivities were evidenced using a ROESY experiment with a mixing time of 
500 ms. One-bond heteronuclear 
1
H-
13
C connectivities was determined by the 
HSQC experiment; two- and three-bond 
1
H-
13
C connectivities by gradient 2D 
HMBC experiments optimized for a 
2,3
J of 8 Hz. Medium pressure liquid 
chromatography was performed on a Büchi apparatus using a silica gel (230-400 
mesh) column. HPLC were achieved on a Knauer and Shimazu apparatuses 
equipped with a refractive index detector and Synergy Polar-RP 4(250 × 4.6 
mm), LUNA 5 (Phenomenex) SiO2 or C18 (250 × 4 mm), Luna 3 μm RP-18 ( 150 
× 4.60 mm)  and Synergi RP-MAX 4 m columns.  
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5.2. Mass spectra 
HRESI MS spectrum of conithiaquinone A (1)  
 
 
 
 
HRESI MS spectrum of conithiaquinone B (2)  
 
 
 
Lecce 1 26_11_12HR+ #6 RT: 0.14 AV: 1 NL: 5.97E6
T: FTMS + c ESI Full ms [200.00-600.00]
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Lecce 2 26_11_12HR+ #35 RT: 0.95 AV: 1 NL: 7.08E7
T: FTMS + c ESI Full ms [115.00-600.00]
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HRESI MS spectrum of compound 10 
 
Sidele HPLC 16_7_04 Fr3 HR-_120611171007 #27 RT: 0.73 AV: 1 NL: 1.37E7
T: FTMS - c ESI Full ms [140.00-800.00]
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HRESI MS spectrum of compound 11  
 
Sidele HPLC 14_7_04 Fr4 HR-_120611171007 #74 RT: 2.02 AV: 1 NL: 9.39E6
T: FTMS - c ESI Full ms [140.00-1000.00]
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HRESI MS spectrum of compound 12 
 
AlcanosolfatatoHRneg_111122113312 #65 RT: 0.50 AV: 1 NL: 9.69E5
T: FTMS - c ESI Full ms [200.00-600.00]
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HRESI MS spectrum of phallusiasterol A (15) 
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HRESI MS spectrum of phallusiasterol B (16)  
 
 
 
 
HRESI MS spectrum of phallusiasterol C (18) 
 
Phall fum hplc16-11-11-fr6 neg #1216 RT: 2.48 AV: 1 NL: 2.04E5
T: ITMS - c ESI Full ms [100.00-700.00]
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HRESI MS spectrum of phosphoeleganin (19)  
 
 
 
 
HRESI MS spectrum of betaine (28)  
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HRESI MS spectrum of cyclonucleoside (31) 
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5.3. NMR spectra 
 
1
H NMR spectrum (700 MHz) of conithiaquinone A (1) in CD3OD 
 
 
 
COSY 2D NMR spectrum (700 MHz) of conithiaquinone A (1) in CD3OD 
 
 
 
125 
 
HSQC 2D NMR spectrum (700 MHz) of conithiaquinone A (1) in CD3OD 
 
 
HMBC 2D NMR spectrum (700 MHz) of conithiaquinone A (1) in CD3OD 
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ROESY 2D NMR spectrum (700 MHz) of conithiaquinone A (1) in CD3OD 
 
 
ROESY 2D NMR spectrum (700 MHz) enlargement of  conithiaquinone A (1) in 
CD3OD 
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13
C NMR spectrum (125 MHz) of conithiaquinone A (1) in CD3OD. 
 
 
 
1
H NMR spectrum (700 MHz) of conithiaquinone B (2) in CD3OD 
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COSY 2D NMR spectrum (700 MHz) of conithiaquinone B (2) in CD3OD 
 
HSQC 2D NMR spectrum (700 MHz) of conithiaquinone B (2) in CD3OD 
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HMBC 2D NMR spectrum (700 MHz) of  conithiaquinone B (2) in CD3OD 
 
13
C NMR spectrum (125 MHz) of conithiaquinone B (2) in CD3OD 
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ROESY 2D NMR spectrum (700 MHz) of  conithiaquinone B (2) in CD3OD 
 
1
H NMR spectrum (500 MHz) of coumpound 10 in CD3OD 
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COSY 2D NMR spectrum (500 MHz) of coumpound 10 in CD3OD 
 
HSQC 2D NMR spectrum (500 MHz) of coumpound 10 in CD3OD  
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HMBC 2D NMR spectrum (500 MHz) of coumpound 10 in CD3OD  
 
1
H NMR spectrum (500 MHz) of coumpound 11 in CD3OD 
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COSY 2D NMR spectrum (500 MHz) of coumpound 11 in CD3OD  
 
 
HSQC 2D NMR spectrum (500 MHz) of coumpound 11 in CD3OD 
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HMBC 2D NMR spectrum (500 MHz) of coumpound 11 in CD3OD 
 
 
1
H NMR spectrum (500 MHz) of coumpound 12 in CD3OD  
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COSY 2D NMR spectrum (500 MHz) of coumpound 12 in CD3OD 
 
HSQC 2D NMR spectrum (500 MHz) of coumpound 12 in CD3OD 
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HMBC 2D NMR spectrum (500 MHz) of coumpound 12 in CD3OD 
 
1
H NMR spectrum (700 MHz) of phallusiasterol A (15) in C5D5N 
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13
C NMR spectrum (125 MHz) of phallusiasterol A (15) in C5D5N 
 
 
COSY 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in C5D5N 
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HSQC 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in C5D5N 
 
 
HMBC 2D NMR spectrum (700 MHz) of  phallusiasterol A (15) in C5D5N 
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ROESY 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in C5D5N
 
 
 
1
H NMR spectrum (700 MHz) of phallusiasterol B (16) in C5D5N 
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COSY 2D NMR spectrum (700 MHz) of phallusiasterol B (16) in C5D5N 
 
HSQC 2D NMR spectrum (700 MHz) of phallusiasterol B (16) in C5D5N 
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HMBC 2D NMR spectrum (700 MHz) of phallusiasterol B (16) in C5D5N 
 
 
TOCSY 2D NMR spectrum (700 MHz) of phallusiasterol B (16) in C5D5N 
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ROESY 2D NMR spectrum (700 MHz) of phallusiasterol B (16) in C5D5N 
 
 
1
H NMR spectrum (700 MHz) of phallusiasterol A (15) in CDCl3 
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13
C NMR spectrum (125 MHz) of phallusiasterol A (15) in CDCl3 
 
 
 
COSY 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in CDCl3 
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HSQC 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in CDCl3 
 
HMBC 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in CDCl3 
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ROESY 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in CDCl3 
 
TOCSY 2D NMR spectrum (700 MHz) of phallusiasterol A (15) in CDCl3
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1
H NMR spectrum (700 MHz) of phallusiasterol B (16) in CDCl3 
 
COSY 2D NMR spectrum (700 MHz) of phallusiasterol B (16) in CDCl3 
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1
H NMR spectrum (700 MHz) of compound 17 in C6D6 
 
 
1
H NMR spectrum (700 MHz) of phallusiasterol C (18) in CD3OD 
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13
C NMR spectrum (700 MHz) of phallusiasterol C (18) in CD3OD 
 
 
 
COSY 2D NMR spectrum (700 MHz) of phallusiasterol C (18) in CD3OD 
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HSQC 2D NMR spectrum (700 MHz) of phallusiasterol C (18) in CD3OD 
 
 
 
HMBC 2D NMR spectrum (700 MHz) of  phallusiasterol C (18) in CD3OD 
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ROESY 2D NMR spectrum (700 MHz) of phallusiasterol C (18) in CD3OD
 
 
 
1
H NMR spectrum (700 MHz) of phosphoeleganin (19) in CD3OD 
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COSY 2D NMR spectrum (700 MHz) of phosphoeleganin (19) in CD3OD 
 
HSQC 2D NMR spectrum (700 MHz) of phosphoeleganin (19) in CD3OD 
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HMBC 2D NMR spectrum (700 MHz) of phosphoeleganin (19) in CD3OD 
 
TOCSY 2D NMR spectrum (700 MHz) of phosphoeleganin (19) in CD3OD 
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1
H NMR spectrum (700 MHz) of betaine (28) in CD3OD 
 
 
COSY 2D NMR spectrum (700 MHz) of betaine (28) in CD3OD 
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HSQC 2D NMR spectrum (700 MHz) of betaine (28) in CD3OD 
 
HMBC 2D NMR spectrum (700 MHz) of betaine (28) in CD3OD 
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13
C NMR spectrum (125 MHz) of betaine (28) in CD3OD 
 
 
 
 
1
H NMR spectrum (700 MHz) of cyclonucleoside (31) in d6-DMSO 
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COSY 2D NMR spectrum (700 MHz) of cyclonucleoside (31) in d6-DMSO 
 
 
HSQC 2D NMR spectrum (700 MHz) of cyclonucleoside (31) in d6-DMSO 
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HMBC 2D NMR spectrum (700 MHz) of cyclonucleoside (31) in d6-DMSO 
 
 
13
C NMR spectrum (125 MHz) of cyclonucleoside (31) in d6-DMSO 
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5.4. Computational details of conithiaquinones A and B 
Optimized Z-Matrixes of model A1 
 
C 0   -5.134261    0.668195   -0.229577 
C 0   -6.451732   -0.056444    0.063127 
S 0   -7.761221    0.658546   -0.934958 
C 0   -7.541432    2.435388   -0.813438 
C 0   -6.350786    2.924993   -0.374273 
N 0   -5.248754    2.129205   -0.062811 
C 0   -8.636026    3.361870   -1.174684 
C 0   -8.380528    4.836797   -1.223085 
C 0   -7.174315    5.318555   -0.824545 
C 0   -6.168579    4.395413   -0.226923 
C 0   -9.496744    5.744554   -1.761876 
C 0   -9.162400    7.214921   -1.420029 
C 0   -7.728990    7.583253   -1.805752 
C 0   -6.764473    6.790802   -0.917971 
C 0  -10.034368    8.327546   -2.022691 
C 0   -9.112806    9.548027   -2.176181 
C 0   -7.708774    9.116607   -1.731712 
O 0   -7.525879    0.261173   -2.310539 
O 0   -9.014940    0.242383   -0.335817 
O 0   -9.703809    2.863566   -1.516374 
O 0   -5.171043    4.794779    0.363793 
C 0   -9.622497    5.476618   -3.278319 
C 0  -10.861744    5.466744   -1.086920 
O 0   -5.468006    6.920107   -1.472543 
C 0   -4.543912    7.589326   -0.638052 
O 0   -7.533507    9.512225   -0.397400 
C 0   -6.636450    9.791985   -2.585606 
 
H 0   -4.780889    0.456603   -1.265746 
H 0   -4.344676    0.299345    0.466515 
H 0   -6.366772   -1.147227   -0.148100 
H 0   -6.717143    0.071071    1.138902 
H 0   -4.403243    2.659707    0.266965 
H 0   -9.227163    7.335088   -0.307723 
H 0   -7.567622    7.303691   -2.873556 
H 0   -6.785594    7.172959    0.127984 
H 0  -10.426665    8.048904   -3.024866 
H 0  -10.913972    8.557174   -1.378134 
H 0   -9.477587   10.422486   -1.590193 
H 0   -9.100971    9.862351   -3.246568 
H 0   -8.682798    5.700367   -3.828337 
H 0   -9.860413    4.411957   -3.493715 
H 0  -10.442153    6.058931   -3.750033 
H 0  -10.778320    5.487839    0.023487 
H 0  -11.317700    4.496375   -1.372715 
H 0  -11.619336    6.226589   -1.381227 
H 0   -4.344017    7.012733    0.288490 
H 0   -4.910879    8.601461   -0.366483 
H 0   -3.590009    7.693907   -1.201571 
H 0   -7.596043   10.467812   -0.333453 
H 0   -5.606271    9.538219   -2.260592 
H 0   -6.732133   10.900443   -2.530979 
H 0   -6.721620    9.496465   -3.655643 
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Optimized Z-Matrixes of model A2 
C 0    1.287443    5.880124   -0.581787 
N 0    0.321030    6.885015   -0.624545 
C 0   -1.104018    6.728220   -0.971656 
C 0   -1.312572    5.710731   -2.097508 
S 0   -0.540273    4.154768   -1.644408 
C 0    1.055641    4.589930   -0.948583 
C 0    2.122255    3.572242   -0.823461 
C 0    3.475209    3.964539   -0.320932 
C 0    3.689373    5.243240    0.080502 
C 0    2.632692    6.279404   -0.085539 
C 0    4.572509    2.898935   -0.212733 
C 0    4.303423    2.090984    1.073411 
C 0    4.607441    1.927982   -1.417056 
C 0    5.931019    3.635060   -0.232830 
C 0    6.057022    4.680204    0.875446 
C 0    4.972684    5.748503    0.741098 
O 0    4.638814    6.225641    2.033881 
C 0    5.168473    7.496794    2.338210 
C 0    7.226962    2.813254   -0.113384 
C 0    8.239513    3.725452    0.604145 
C 0    7.541233    5.076923    0.812041 
C 0    7.923621    6.070428   -0.286395 
O 0    7.953558    5.615851    2.038739 
O 0   -0.375469    3.401123   -2.873054 
O 0   -1.355388    3.552819   -0.605957 
O 0    2.846988    7.466128    0.144044 
O 0    1.829803    2.411350   -1.090828 
 
H 0    0.655365    7.831093   -0.310881 
H 0   -1.664839    6.434911   -0.053694 
H 0   -1.495897    7.722207   -1.291579 
H 0   -0.833555    6.085808   -3.032472 
H 0   -2.396423    5.550312   -2.300956 
H 0    3.340639    1.536295    1.005233 
H 0    5.091134    1.332175    1.270113 
H 0    4.221741    2.738765    1.973681 
H 0    5.501351    1.267238   -1.382863 
H 0    3.753592    1.219889   -1.447504 
H 0    4.634083    2.478965   -2.384331 
H 0    5.986080    4.184210   -1.206995 
H 0    5.912329    4.135759    1.840456 
H 0    5.330643    6.575498    0.089906 
H 0    6.275589    7.488593    2.270925 
H 0    4.748548    8.270483    1.659881 
H 0    4.875909    7.745848    3.382878 
H 0    7.603569    2.503058   -1.115777 
H 0    7.073558    1.888508    0.486636 
H 0    8.495377    3.276541    1.593874 
H 0    9.193681    3.822677    0.039071 
H 0    7.631359    5.717236   -1.299468 
H 0    7.466006    7.071014   -0.124646 
H 0    9.025357    6.233187   -0.303374 
H 0    8.912501    5.608193    2.084469 
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Optimized Z-Matrixes of model A3 
C 0    1.305856    6.152216   -0.267925 
S 0   -0.027974    7.285001   -0.662370 
C 0   -1.472506    6.247475   -0.903548 
C 0   -1.538311    5.196412    0.209123 
N 0   -0.289159    4.418527    0.321790 
C 0    1.012744    4.886155    0.136620 
C 0    2.114211    3.922485    0.433152 
C 0    3.504883    4.435164    0.614124 
C 0    3.777358    5.701741    0.220565 
C 0    2.715887    6.579417   -0.361462 
C 0    4.573104    3.497692    1.187543 
C 0    4.810586    2.368696    0.158226 
C 0    4.059563    2.820168    2.487274 
C 0    5.858683    4.262909    1.611827 
C 0    6.273529    5.473771    0.767910 
C 0    5.120535    6.388534    0.373584 
O 0    4.959629    7.397066    1.356451 
C 0    5.693861    8.570593    1.076747 
C 0    7.172462    3.458452    1.610810 
C 0    7.776437    3.644536    0.207028 
C 0    7.205971    4.962576   -0.337760 
C 0    8.304482    5.964864   -0.696368 
O 0    6.465701    4.722938   -1.503405 
O 0    2.985442    7.677531   -0.840900 
O 0    1.794749    2.751347    0.609417 
O 0    0.210979    7.964295   -1.921481 
O 0   -0.279631    8.120227    0.497208 
H 0   -1.379308    5.736622   -1.890694 
H 0   -2.391898    6.876904   -0.921366 
H 0   -1.755134    5.667898    1.196144 
H 0   -2.372289    4.486187   -0.001520 
H 0   -0.354663    3.416451    0.632918 
H 0    5.559123    1.622583    0.499338 
H 0    5.125299    2.754661   -0.832051 
H 0    3.894334    1.772452   -0.039387 
H 0    4.870718    2.246549    2.990172 
H 0    3.248494    2.081036    2.319024 
H 0    3.672627    3.568916    3.215566 
H 0    5.666663    4.661904    2.640982 
H 0    6.963476    6.070428    1.420729 
H 0    5.368155    6.863541   -0.603616 
H 0    6.776996    8.342446    0.973118 
H 0    5.307525    9.055807    0.152939 
H 0    5.555154    9.273601    1.927857 
H 0    7.065492    2.396541    1.917639 
H 0    7.870339    3.919247    2.352755 
H 0    8.889275    3.656320    0.261358 
H 0    7.509826    2.790834   -0.455520 
H 0    8.957846    6.189902    0.177008 
H 0    7.870979    6.927250   -1.051068 
H 0    8.955736    5.567439   -1.507724 
H 0    7.016575    4.285087   -2.155702 
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Optimized Z-Matrixes of model A4 
C 0    1.025298    6.169174   -0.026752 
S 0   -0.245605    7.247838   -0.690894 
C 0   -1.715905    6.226890   -0.819057 
C 0   -1.870613    5.399690    0.461152 
N 0   -0.659573    4.616282    0.773177 
C 0    0.666590    5.000603    0.572493 
C 0    1.710693    4.050922    1.057117 
C 0    3.151951    4.359116    0.835954 
C 0    3.496937    5.562717    0.313503 
C 0    2.452603    6.521432   -0.160245 
C 0    4.215347    3.339243    1.257466 
C 0    3.821670    1.875099    0.947619 
C 0    4.414953    3.485901    2.779942 
C 0    5.477605    3.622455    0.410664 
C 0    5.997661    5.050313    0.579573 
C 0    4.932959    6.067460    0.167082 
O 0    5.073501    7.230082    0.965718 
C 0    5.703606    8.308396    0.310411 
C 0    6.730087    2.762739    0.644194 
C 0    7.915895    3.630264    0.185512 
C 0    7.354848    5.023128   -0.144470 
C 0    7.304706    5.249180   -1.656991 
O 0    8.208002    5.993540    0.401826 
O 0    2.756424    7.576708   -0.709609 
O 0    1.324267    3.040422    1.634987 
O 0    0.085968    7.668192   -2.039158 
O 0   -0.524520    8.293547    0.275343 
 
H 0   -1.598360    5.544423   -1.693620 
H 0   -2.609133    6.869392   -0.995673 
H 0   -2.110035    6.050622    1.334012 
H 0   -2.722163    4.689525    0.340268 
H 0   -0.777867    3.685725    1.247899 
H 0    3.004984    1.485061    1.589889 
H 0    4.665530    1.176186    1.138271 
H 0    3.515094    1.751341   -0.115850 
H 0    4.673599    4.525641    3.077620 
H 0    5.206992    2.810278    3.169042 
H 0    3.483009    3.230522    3.332793 
H 0    5.194986    3.496508   -0.665441 
H 0    6.220007    5.174975    1.667621 
H 0    5.036287    6.311414   -0.912433 
H 0    6.717068    8.021304   -0.037364 
H 0    5.088682    8.659091   -0.546425 
H 0    5.800545    9.141576    1.041829 
H 0    6.688891    1.800815    0.083219 
H 0    6.849946    2.522359    1.724698 
H 0    8.671227    3.688561    1.004607 
H 0    8.431069    3.175523   -0.690909 
H 0    6.615526    4.538554   -2.164750 
H 0    6.989505    6.283721   -1.916326 
H 0    8.313119    5.113703   -2.110111 
H 0    9.101257    5.848981    0.080785 
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Optimized Z-Matrixes of model B1 
C 0   -5.769599    1.391478   -0.221508 
C 0   -6.163454   -0.088296   -0.260604 
S 0   -4.988290   -0.988847   -1.275137 
C 0   -3.370554   -0.401318   -0.767235 
C 0   -3.275758    0.774822   -0.089795 
N 0   -4.369157    1.593005    0.198079 
C 0   -2.153771   -1.182924   -1.073602 
C 0   -0.811600   -0.695420   -0.621726 
C 0   -0.726955    0.440600    0.118465 
C 0   -1.946302    1.258923    0.375644 
C 0    0.418350   -1.529005   -1.010276 
C 0    1.701245   -0.704779   -0.764074 
C 0    1.723686   -0.017194    0.600713 
C 0    0.575433    0.989055    0.708410 
C 0    3.046715   -1.444688   -0.754453 
C 0    4.006717   -0.379169   -0.209546 
C 0    3.182210    0.484941    0.768952 
O 0   -5.160838   -2.394520   -0.961300 
O 0   -5.210256   -0.591327   -2.653045 
O 0   -2.303940   -2.233390   -1.689470 
O 0   -1.899789    2.355231    0.924745 
C 0    0.393249   -2.852656   -0.216720 
C 0    0.426730   -1.856385   -2.524689 
O 0    0.400728    1.293118    2.082033 
C 0    0.713501    2.624721    2.435158 
O 0    3.228908    1.823441    0.368443 
C 0    4.455644    2.485543    0.589261 
C 0    3.651022    0.291659    2.217024 
 
H 0   -5.915142    1.872972   -1.216478 
H 0   -6.428241    1.928716    0.500571 
H 0   -6.135538   -0.511274    0.771076 
H 0   -7.193046   -0.221880   -0.665204 
H 0   -4.131220    2.468080    0.730359 
H 0    1.756081    0.106408   -1.533442 
H 0    1.540353   -0.817054    1.358738 
H 0    0.798105    1.907160    0.118778 
H 0    3.033446   -2.301214   -0.041941 
H 0    3.356633   -1.821205   -1.754628 
H 0    4.364341    0.221974   -1.078987 
H 0    4.904841   -0.838389    0.261772 
H 0    1.226130   -3.528607   -0.509427 
H 0    0.449600   -2.686931    0.881189 
H 0   -0.536885   -3.433449   -0.399324 
H 0   -0.343997   -2.593430   -2.830955 
H 0    1.389282   -2.317647   -2.836736 
H 0    0.279537   -0.939694   -3.139797 
H 0    0.121195    3.352685    1.842021 
H 0    1.796973    2.823930    2.303191 
H 0    0.464881    2.757979    3.511444 
H 0    4.432199    3.439615    0.016087 
H 0    5.317850    1.881980    0.234265 
H 0    4.567166    2.742738    1.665335 
H 0    3.525885   -0.766081    2.541619 
H 0    4.731433    0.519455    2.351628 
H 0    3.076291    0.926199    2.926754 
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Optimized Z-Matrixes of model B2 
C 0    1.691375    6.065476   -0.339936 
N 0    0.587819    6.880371   -0.594731 
C 0   -0.835051    6.491804   -0.551741 
C 0   -1.119475    5.459454    0.544105 
S 0   -0.022550    4.054486    0.333983 
C 0    1.600415    4.763442    0.045063 
C 0    2.825027    3.959016    0.251466 
C 0    4.169878    4.613279    0.183794 
C 0    4.250459    5.935631   -0.116772 
C 0    3.030016    6.692749   -0.513422 
C 0    5.412017    3.756320    0.475571 
C 0    5.403696    2.427861   -0.320468 
C 0    5.440135    3.435131    1.984857 
C 0    6.659231    4.520054   -0.022649 
C 0    6.704214    5.958181    0.492441 
C 0    5.542173    6.757332   -0.093579 
O 0    5.347460    7.909754    0.708856 
C 0    5.694635    9.125239    0.080342 
C 0    8.060549    3.955941    0.274701 
C 0    8.930575    5.163621    0.668937 
C 0    8.154732    6.421915    0.243390 
C 0    8.441585    6.777073   -1.221109 
O 0    8.406584    7.497461    1.100624 
C 0    9.713907    8.024650    1.049042 
O 0   -0.053199    3.312198    1.579748 
O 0   -0.443427    3.351184   -0.863270 
O 0    3.090221    7.824072   -0.984572 
O 0    2.681467    2.770994    0.521257 
 
H 0    0.825454    7.861940   -0.887095 
H 0   -1.132408    6.108502   -1.555228 
H 0   -1.439031    7.409669   -0.359897 
H 0   -2.180620    5.120907    0.514922 
H 0   -0.924824    5.912811    1.544690 
H 0    4.667658    1.685634    0.053354 
H 0    6.384881    1.907178   -0.253388 
H 0    5.191960    2.601461   -1.400339 
H 0    6.303407    2.794923    2.267373 
H 0    4.532911    2.874303    2.301744 
H 0    5.474765    4.349257    2.616249 
H 0    6.566157    4.587956   -1.136804 
H 0    6.565063    5.912220    1.600701 
H 0    5.751404    7.033528   -1.150760 
H 0    5.460519    9.952687    0.786782 
H 0    5.107199    9.277811   -0.850239 
H 0    6.780292    9.156254   -0.147098 
H 0    8.475034    3.452969   -0.630840 
H 0    8.067050    3.202362    1.091536 
H 0    9.947021    5.105128    0.218730 
H 0    9.056964    5.161156    1.778784 
H 0    8.093444    5.988991   -1.922863 
H 0    9.530925    6.884540   -1.419056 
H 0    7.955565    7.729428   -1.525368 
H 0    9.885912    8.560734    0.090915 
H 0   10.474883    7.231651    1.209553 
H 0    9.807819    8.770345    1.870232 
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Optimized Z-Matrixes of model B3 
C 0    1.507815    6.107003   -0.075037 
S 0    0.024804    6.973224   -0.595343 
C 0   -1.169694    5.683828   -0.959284 
C 0   -1.149107    4.643803    0.165852 
N 0    0.205577    4.114761    0.414116 
C 0    1.412300    4.809175    0.321515 
C 0    2.642805    4.046883    0.675696 
C 0    3.983087    4.657166    0.437948 
C 0    4.072073    5.974647    0.110582 
C 0    2.827195    6.770437   -0.126170 
C 0    5.212001    3.746230    0.590790 
C 0    5.047570    2.428435   -0.205746 
C 0    5.408827    3.415266    2.086453 
C 0    6.428269    4.457469   -0.038770 
C 0    6.567399    5.891116    0.481834 
C 0    5.404993    6.711220   -0.083638 
O 0    5.419054    7.970542    0.560908 
C 0    5.633752    9.059573   -0.315822 
C 0    7.824266    3.823270    0.086492 
C 0    8.751793    4.974491    0.501441 
C 0    8.021452    6.280011    0.140600 
C 0    8.556138    7.443593    0.981680 
O 0    8.070783    6.526935   -1.234498 
C 0    9.286834    7.040137   -1.731700 
O 0    2.853831    7.954865   -0.443563 
O 0    2.491593    2.911456    1.115295 
O 0    0.250632    7.690773   -1.835534 
O 0   -0.492254    7.737658    0.524104 
 
H 0   -0.885444    5.200465   -1.923811 
H 0   -2.183704    6.130262   -1.078196 
H 0   -1.808534    3.788103   -0.112166 
H 0   -1.547668    5.069273    1.116022 
H 0    0.298310    3.117501    0.733957 
H 0    5.993496    1.842775   -0.223290 
H 0    4.758051    2.626369   -1.262976 
H 0    4.292228    1.737156    0.222654 
H 0    4.547446    2.850492    2.504798 
H 0    5.514200    4.325288    2.715640 
H 0    6.299509    2.776555    2.267552 
H 0    6.229375    4.540228   -1.139242 
H 0    6.482985    5.882379    1.594223 
H 0    5.518000    6.836473   -1.184801 
H 0    6.599719    8.950652   -0.853989 
H 0    5.666106    9.989251    0.294827 
H 0    4.813519    9.150745   -1.057941 
H 0    8.149697    3.406794   -0.896498 
H 0    7.880919    2.990822    0.819943 
H 0    9.768009    4.877120    0.063133 
H 0    8.882809    4.932381    1.609969 
H 0    9.664569    7.521091    0.914652 
H 0    8.320654    7.307520    2.061116 
H 0    8.132192    8.424454    0.681876 
H 0    9.433974    8.091205   -1.401806 
H 0    9.219525    7.043936   -2.842907 
H 0   10.148736    6.405147   -1.439357 
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Optimized Z-Matrixes of model B4 
 
C 0    1.418371    6.123099   -0.053290 
S 0   -0.049951    6.998227   -0.598557 
C 0   -1.262440    5.715305   -0.925376 
C 0   -1.263516    4.715090    0.235266 
N 0    0.081997    4.171092    0.502070 
C 0    1.301394    4.839930    0.385285 
C 0    2.517579    4.063601    0.761185 
C 0    3.868953    4.653254    0.538200 
C 0    3.974447    5.960106    0.181450 
C 0    2.749003    6.761564   -0.123132 
C 0    5.092138    3.747331    0.738694 
C 0    4.921308    2.385385    0.020797 
C 0    5.285332    3.500923    2.249766 
C 0    6.302321    4.419367    0.053716 
C 0    6.488427    5.867797    0.503203 
C 0    5.302167    6.713881    0.042397 
O 0    5.266575    7.891884    0.830037 
C 0    5.607152    9.070861    0.131522 
C 0    7.695510    3.780995    0.191958 
C 0    8.673494    4.946736    0.423403 
C 0    7.919037    6.235806    0.055360 
C 0    8.033096    6.532407   -1.445267 
O 0    8.341613    7.317188    0.834331 
C 0    9.661135    7.757608    0.600808 
O 0    2.818937    7.921965   -0.516824 
O 0    2.346985    2.939943    1.223142 
O 0    0.184339    7.677361   -1.858753 
O 0   -0.554469    7.802865    0.498266 
 
H 0   -0.976211    5.192575   -1.868625 
H 0   -2.269374    6.170172   -1.070209 
H 0   -1.937902    3.862112   -0.014348 
H 0   -1.656231    5.179338    1.169653 
H 0    0.157484    3.183568    0.855144 
H 0    5.869881    1.803846    0.020561 
H 0    4.612663    2.520400   -1.041036 
H 0    4.179594    1.714647    0.502566 
H 0    4.410112    2.979968    2.696744 
H 0    5.409326    4.444073    2.824526 
H 0    6.162888    2.854350    2.465006 
H 0    6.069540    4.455873   -1.041100 
H 0    6.493258    5.863121    1.620776 
H 0    5.397687    6.958409   -1.038998 
H 0    6.657255    9.028665   -0.224372 
H 0    5.510354    9.925627    0.837501 
H 0    4.922855    9.240216   -0.727044 
H 0    7.959975    3.224405   -0.738104 
H 0    7.765431    3.055163    1.030965 
H 0    9.616841    4.813955   -0.152901 
H 0    8.944448    4.969452    1.506897 
H 0    7.567325    7.504459   -1.718054 
H 0    7.551556    5.748279   -2.068052 
H 0    9.091965    6.565941   -1.784758 
H 0   10.387071    6.922466    0.695532 
H 0    9.902627    8.519315    1.375746 
H 0    9.742006    8.253004   -0.390496 
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5.5. Computational details of compound 28  
 
Minimum Energy Conformations for S-28 
 
S-5a S-5b S-5c
S-5d S-5e
S-5f
S-5g
S-5h S-5i
S-5l S-5m S-5n
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Conformational Analysis of S-28 conformers in methanol 
 
 Ea Gb P%
c
 
S-28a 0.00 0.00 45.75 
S-28b 0.25 0.52 18.91 
S-28c 0.79 0.69 14.29 
S-28d 0.91 1.01 8.32 
S-28e 1.05 1.25 5.55 
S-28f 1.24 1.57 3.23 
S-28g 1.26 1.62 2.97 
S-28h 1.47 3.08 0.25 
S-28i 1.47 3.08 0.25 
S-28l 1.81 3.25 0.19 
S-28m 1.81 3.25 0.19 
S-28n 1.94 3.69 0.09 
a
Relative energy (kcal/mol). 
b
Relative Gibbs free energy (kcal/mol). 
c
Conformational distribution calculated at the at the B3LYP/6-
31G(d) level in methanol. 
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Calculated ECD of S-28 at the B3LYP/6-31G** 
 
 
 
 
